P-value | ln(P) | Term | GO Tree | GO ID | # of Genes in Term | # of Target Genes in Term | # of Total Genes | # of Target Genes | Common Genes |
4.641e-07 | -14.58 | cytoplasm | cellular component | GO:0005737 | 12081 | 47 | 19108 | 50 |
FNIP1,MEF2C,SH2B3,STAB1,DOCK4,ADGRG3,FMNL1,RBM47,DAB2,DISC1,TFEB,BLNK,GLDC,RXRA,CD68,MYO1F,ETS1,FLRT2,ARHGAP45,MICAL2,CSF3R,MARK4,ARHGEF1,ABCC5,MAN1A1,CERT1,FCHO2,RHBDF1,MLKL,SRGN,RGL1,AOX1,ARAP1,SGMS1,SH3KBP1,CD53,HCK,ABCA1,FERMT3,CTSV,DIAPH2,CEBPB,ATP8A1,ETV6,MFSD1,PLEK,ARAP3 |
9.747e-07 | -13.84 | INPP5D (inositol polyphosphate-5-phosphatase D) | protein interactions | 3635 | 70 | 5 | 19454 | 50 |
CSF3R,ARAP1,DAB2,HCK,SH3KBP1 |
3.398e-06 | -12.59 | lysosome | cellular component | GO:0005764 | 762 | 11 | 19108 | 50 |
ARHGAP45,SRGN,CSF3R,TFEB,DAB2,CTSV,CD68,ATP8A1,MFSD1,HCK,FNIP1 |
3.398e-06 | -12.59 | lytic vacuole | cellular component | GO:0000323 | 762 | 11 | 19108 | 50 |
FNIP1,HCK,MFSD1,ATP8A1,CD68,CTSV,DAB2,TFEB,CSF3R,SRGN,ARHGAP45 |
4.793e-06 | -12.25 | signaling | biological process | GO:0023052 | 4968 | 29 | 18204 | 50 |
MARK4,CERT1,SH2B3,FNIP1,BLNK,HCK,CSF3R,ARAP3,STAB1,ABCA1,SH3KBP1,ARHGEF1,MEF2C,DOCK4,ARAP1,ADGRG3,RGL1,SRGN,FERMT3,CD276,CD53,MLKL,RXRA,CEBPB,ARHGAP45,PLEK,DAB2,FLRT2,DISC1 |
5.749e-06 | -12.07 | cell communication | biological process | GO:0007154 | 5010 | 29 | 18204 | 50 |
FNIP1,SH2B3,BLNK,CERT1,MARK4,ABCA1,SH3KBP1,HCK,ARAP3,CSF3R,STAB1,ARHGEF1,MEF2C,RGL1,ADGRG3,FERMT3,SRGN,CD276,DOCK4,ARAP1,MLKL,CD53,RXRA,CEBPB,ARHGAP45,PLEK,FLRT2,DISC1,DAB2 |
5.833e-06 | -12.05 | lymph_node | COSMIC cancer mutations | lymph_node | 1703 | 16 | 16828 | 46 |
MARK4,FLRT2,HCK,ABCA1,ETV6,MEF2C,GLDC,FNIP1,ATP8A1,AOX1,ELF4,MLKL,ARAP3,ETS1,BLNK,SH3KBP1 |
6.001e-06 | -12.02 | cellular response to stimulus | biological process | GO:0051716 | 6307 | 33 | 18204 | 50 |
RGL1,ADGRG3,SRGN,FERMT3,CD276,ABCC5,DOCK4,ARAP1,TFEB,MAN1A1,MEF2C,ARHGEF1,CD68,ABCA1,HCK,AOX1,ARAP3,CSF3R,SH2B3,FNIP1,BLNK,CERT1,MARK4,FLRT2,DISC1,DAB2,GLDC,PLEK,CEBPB,ARHGAP45,CD53,MLKL,RXRA |
6.474e-06 | -11.95 | Inppl1 (inositol polyphosphate phosphatase-like 1) | protein interactions | 16332 | 2 | 2 | 19454 | 50 |
SH3KBP1,ARAP3 |
6.866e-06 | -11.89 | PH_domain | interpro domains | IPR001849 | 266 | 7 | 18521 | 50 |
SH2B3,CERT1,PLEK,ARAP1,ARAP3,FERMT3,ARHGEF1 |
7.027e-06 | -11.87 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-angioimmunoblastic_T_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-angioimmunoblastic_T_cell_lymphoma | 265 | 7 | 16828 | 46 |
SH2B3,ETS1,HCK,ETV6,MICAL2,MEF2C,BLNK |
7.750e-06 | -11.77 | angioimmunoblastic_T_cell_lymphoma | COSMIC cancer mutations | angioimmunoblastic_T_cell_lymphoma | 269 | 7 | 16828 | 46 |
SH2B3,ETS1,HCK,MICAL2,ETV6,BLNK,MEF2C |
9.204e-06 | -11.60 | cytoplasmic vesicle | cellular component | GO:0031410 | 2521 | 19 | 19108 | 50 |
ADGRG3,MAN1A1,ABCC5,STAB1,FCHO2,FMNL1,DAB2,SRGN,DISC1,FERMT3,ABCA1,CD53,HCK,SH3KBP1,ATP8A1,CD68,DIAPH2,CSF3R,ARHGAP45 |
9.531e-06 | -11.56 | intracellular vesicle | cellular component | GO:0097708 | 2527 | 19 | 19108 | 50 |
CSF3R,ARHGAP45,ABCA1,FERMT3,SH3KBP1,HCK,CD53,ATP8A1,DIAPH2,CD68,DAB2,DISC1,SRGN,STAB1,MAN1A1,ABCC5,ADGRG3,FCHO2,FMNL1 |
1.039e-05 | -11.47 | vacuole | cellular component | GO:0005773 | 857 | 11 | 19108 | 50 |
CSF3R,TFEB,ARHGAP45,SRGN,DAB2,ATP8A1,MFSD1,CTSV,CD68,HCK,FNIP1 |
1.193e-05 | -11.34 | SH3KBP1 (SH3 domain containing kinase binding protein 1) | protein interactions | 30011 | 304 | 7 | 19454 | 50 |
HCK,ARAP1,BLNK,SH3KBP1,DAB2,ARAP3,ARHGEF1 |
1.194e-05 | -11.34 | PH | pfam domains | PF00169 | 187 | 6 | 17795 | 49 |
ARAP3,PLEK,FERMT3,SH2B3,CERT1,ARAP1 |
1.538e-05 | -11.08 | signal transduction | biological process | GO:0007165 | 4637 | 27 | 18204 | 50 |
ARHGAP45,CEBPB,RXRA,CD53,MLKL,DAB2,DISC1,FLRT2,PLEK,CSF3R,ARAP3,HCK,ABCA1,MARK4,CERT1,BLNK,SH2B3,FNIP1,ARAP1,DOCK4,CD276,SRGN,FERMT3,RGL1,ADGRG3,MEF2C,ARHGEF1 |
1.732e-05 | -10.96 | plasma membrane | cellular component | GO:0005886 | 5538 | 29 | 19108 | 50 |
FLRT2,CD276,ARHGAP45,CSF3R,CD68,MYO1F,DAB2,GLDC,BLNK,SH2B3,ADGRG3,STAB1,DOCK4,FMNL1,ARAP3,PLEK,HCK,CD53,ARAP1,SH3KBP1,SGMS1,ABCA1,ETV6,ATP8A1,MLKL,RGL1,ARHGEF1,ABCC5,FCHO2 |
1.762e-05 | -10.95 | SAM/pointed_sf | interpro domains | IPR013761 | 120 | 5 | 18521 | 50 |
ETV6,ARAP1,SGMS1,ETS1,ARAP3 |
1.837e-05 | -10.90 | PH-like_dom_sf | interpro domains | IPR011993 | 431 | 8 | 18521 | 50 |
ARAP3,DAB2,ARHGEF1,FERMT3,SH2B3,CERT1,ARAP1,PLEK |
2.139e-05 | -10.75 | RhoGAP_ARAP | interpro domains | IPR037858 | 3 | 2 | 18521 | 50 |
ARAP3,ARAP1 |
2.783e-05 | -10.49 | skin-trunk-malignant_melanoma-nodular | COSMIC cancer mutations | skin-trunk-malignant_melanoma-nodular | 1291 | 13 | 16828 | 46 |
BLNK,DISC1,ATP8A1,MICAL2,PLEK,ARAP3,FMNL1,CSF3R,TFEB,RBM47,STAB1,MAN1A1,SRGN |
2.839e-05 | -10.47 | response to stimulus | biological process | GO:0050896 | 7803 | 36 | 18204 | 50 |
CD68,MEF2C,ARHGEF1,MAN1A1,DOCK4,TFEB,ARAP1,ABCC5,CD276,ADGRG3,RGL1,SRGN,FERMT3,CERT1,MARK4,BLNK,SH2B3,FNIP1,CSF3R,ARAP3,STAB1,HCK,AOX1,ABCA1,PLEK,CTSV,GLDC,DAB2,DISC1,FLRT2,ETS1,RXRA,MLKL,CD53,ARHGAP45,CEBPB |
3.415e-05 | -10.28 | Transcription Factor, Ets-1 | gene3d domains | 1.10.150.50 | 115 | 5 | 14470 | 47 |
ARAP3,SGMS1,ARAP1,ETS1,ETV6 |
4.348e-05 | -10.04 | NHLRC2 (NHL repeat containing 2) | protein interactions | 374354 | 372 | 7 | 19454 | 50 |
PLEK,ARHGEF1,FERMT3,SH3KBP1,FMNL1,TFEB,MYO1F |
4.939e-05 | -9.92 | trunk | COSMIC cancer mutations | trunk | 3554 | 22 | 16828 | 46 |
TFEB,RBM47,SRGN,AOX1,CSF3R,FMNL1,ARAP3,DAB2,MYO1F,MICAL2,ABCC5,BLNK,SH3KBP1,MAN1A1,STAB1,HCK,FLRT2,PLEK,ABCA1,GLDC,ATP8A1,DISC1 |
5.483e-05 | -9.81 | PH | smart domains | SM00233 | 259 | 7 | 9717 | 38 |
ARAP1,FERMT3,CERT1,ARHGEF1,PLEK,ARAP3,SH2B3 |
5.783e-05 | -9.76 | Ets_dom | interpro domains | IPR000418 | 28 | 3 | 18521 | 50 |
ETS1,ETV6,ELF4 |
5.783e-05 | -9.76 | ETS_fam | interpro domains | IPR046328 | 28 | 3 | 18521 | 50 |
ETS1,ELF4,ETV6 |
6.084e-05 | -9.71 | cellular process | biological process | GO:0009987 | 14996 | 50 | 18204 | 50 |
BAZ2B,GLDC,CTSV,ELF4,DIAPH2,DISC1,RXRA,ARHGAP45,ETV6,CD68,MAN1A1,RHBDF1,DOCK4,FCHO2,ABCC5,CD276,RGL1,FMNL1,SRGN,FERMT3,RBM47,MARK4,BLNK,SH2B3,STAB1,HCK,AOX1,SH3KBP1,PLEK,MICAL2,DAB2,SGMS1,FLRT2,ETS1,MLKL,CD53,CEBPB,ATP8A1,MEF2C,MYO1F,ARHGEF1,ARAP1,TFEB,MFSD1,ADGRG3,CERT1,FNIP1,CSF3R,ARAP3,ABCA1 |
6.124e-05 | -9.70 | Ets | pfam domains | PF00178 | 28 | 3 | 17795 | 49 |
ETV6,ELF4,ETS1 |
6.583e-05 | -9.63 | Pleckstrin-homology domain (PH domain)/Phosphotyrosine-binding domain (PTB) | gene3d domains | 2.30.29.30 | 431 | 8 | 14470 | 47 |
DAB2,CERT1,PLEK,ARHGEF1,FERMT3,SH2B3,ARAP3,ARAP1 |
6.876e-05 | -9.58 | oesophagus-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | oesophagus-carcinoma-squamous_cell_carcinoma | 6486 | 31 | 16828 | 46 |
FNIP1,GLDC,DISC1,RHBDF1,HCK,FLRT2,ABCA1,BAZ2B,CD53,ARHGEF1,MYO1F,ARAP3,ELF4,RXRA,CD276,MFSD1,ATP8A1,FERMT3,ETV6,MAN1A1,ARAP1,SH3KBP1,DIAPH2,DAB2,MICAL2,ABCC5,CSF3R,ETS1,DOCK4,TFEB,AOX1 |
9.059e-05 | -9.31 | positive regulation of lipid transport | biological process | GO:0032370 | 86 | 4 | 18204 | 50 |
RXRA,ABCA1,DAB2,ATP8A1 |
9.321e-05 | -9.28 | hemopoiesis | biological process | GO:0030097 | 688 | 9 | 18204 | 50 |
ADGRG3,ETV6,CEBPB,BLNK,SH2B3,FNIP1,PLEK,RBM47,MEF2C |
9.616e-05 | -9.25 | cell periphery | cellular component | GO:0071944 | 6020 | 29 | 19108 | 50 |
ARHGEF1,ABCC5,FCHO2,MLKL,RGL1,HCK,CD53,SGMS1,SH3KBP1,ARAP1,ABCA1,ETV6,ATP8A1,ARAP3,PLEK,SH2B3,ADGRG3,STAB1,DOCK4,FMNL1,DAB2,BLNK,GLDC,CD68,MYO1F,FLRT2,ARHGAP45,CD276,CSF3R |
9.715e-05 | -9.24 | enzyme binding | molecular function | GO:0019899 | 2086 | 16 | 18094 | 50 |
RXRA,MLKL,RBM47,CEBPB,MICAL2,MEF2C,BLNK,SH3KBP1,DIAPH2,FMNL1,FNIP1,TFEB,PLEK,DOCK4,SH2B3,ABCA1 |
1.106e-04 | -9.11 | RA | pfam domains | PF00788 | 34 | 3 | 17795 | 49 |
ARAP3,RGL1,ARAP1 |
1.153e-04 | -9.07 | ETS_DOMAIN_2 | prosite domains | PS00346 | 26 | 3 | 12186 | 45 |
ETS1,ETV6,ELF4 |
1.389e-04 | -8.88 | integrin-mediated signaling pathway | biological process | GO:0007229 | 96 | 4 | 18204 | 50 |
PLEK,DAB2,HCK,FERMT3 |
1.445e-04 | -8.84 | ETS_DOMAIN_3 | prosite domains | PS50061 | 28 | 3 | 12186 | 45 |
ELF4,ETV6,ETS1 |
1.455e-04 | -8.84 | nodular | COSMIC cancer mutations | nodular | 1515 | 13 | 16828 | 46 |
STAB1,MAN1A1,PLEK,DISC1,ATP8A1,SRGN,TFEB,RBM47,FMNL1,ARAP3,CSF3R,MICAL2,BLNK |
1.455e-04 | -8.84 | cytosol | cellular component | GO:0005829 | 5475 | 27 | 19108 | 50 |
FCHO2,CERT1,ARHGEF1,MAN1A1,MLKL,AOX1,RGL1,DIAPH2,ETV6,ATP8A1,HCK,ARAP1,SH3KBP1,PLEK,FMNL1,FNIP1,SH2B3,MEF2C,DOCK4,DISC1,BLNK,TFEB,DAB2,RXRA,MYO1F,ARHGAP45,MARK4 |
1.492e-04 | -8.81 | intracellular anatomical structure | cellular component | GO:0005622 | 15205 | 49 | 19108 | 50 |
MYO1F,MICAL2,CSF3R,ETS1,RBM47,FNIP1,STAB1,DOCK4,DISC1,GLDC,BLNK,DAB2,DIAPH2,BAZ2B,HCK,ARAP1,SGMS1,ABCA1,ARAP3,PLEK,CERT1,ARHGEF1,ABCC5,MLKL,RHBDF1,CD68,RXRA,ARHGAP45,FLRT2,MARK4,FMNL1,MEF2C,SH2B3,ADGRG3,TFEB,CEBPB,CTSV,MFSD1,ETV6,ATP8A1,CD53,SH3KBP1,FERMT3,FCHO2,ELF4,MAN1A1,SRGN,AOX1,RGL1 |
1.511e-04 | -8.80 | lytic vacuole membrane | cellular component | GO:0098852 | 446 | 7 | 19108 | 50 |
CSF3R,TFEB,DAB2,CD68,ATP8A1,MFSD1,FNIP1 |
1.511e-04 | -8.80 | lysosomal membrane | cellular component | GO:0005765 | 446 | 7 | 19108 | 50 |
CSF3R,TFEB,DAB2,CD68,ATP8A1,MFSD1,FNIP1 |
1.580e-04 | -8.75 | RA_dom | interpro domains | IPR000159 | 39 | 3 | 18521 | 50 |
ARAP3,RGL1,ARAP1 |
1.690e-04 | -8.69 | ETS | smart domains | SM00413 | 28 | 3 | 9717 | 38 |
ETS1,ELF4,ETV6 |
1.823e-04 | -8.61 | regulation of biomineral tissue development | biological process | GO:0070167 | 103 | 4 | 18204 | 50 |
RXRA,SRGN,CEBPB,MEF2C |
1.824e-04 | -8.61 | KIT (KIT proto-oncogene, receptor tyrosine kinase) | protein interactions | 3815 | 110 | 4 | 19454 | 50 |
SH3KBP1,HCK,BLNK,SH2B3 |
1.858e-04 | -8.59 | skin-mucosal-malignant_melanoma | COSMIC cancer mutations | skin-mucosal-malignant_melanoma | 2009 | 15 | 16828 | 46 |
HCK,GLDC,ATP8A1,ETV6,MLKL,CSF3R,ARAP3,TFEB,RBM47,ELF4,RXRA,AOX1,SH3KBP1,DAB2,MICAL2 |
1.858e-04 | -8.59 | mucosal | COSMIC cancer mutations | mucosal | 2009 | 15 | 16828 | 46 |
HCK,ETV6,GLDC,ATP8A1,TFEB,RBM47,ELF4,RXRA,AOX1,MLKL,CSF3R,ARAP3,DAB2,MICAL2,SH3KBP1 |
1.873e-04 | -8.58 | positive regulation of cellular component organization | biological process | GO:0051130 | 1122 | 11 | 18204 | 50 |
CD53,FNIP1,MARK4,ATP8A1,PLEK,FLRT2,ABCA1,DISC1,HCK,DAB2,ARAP1 |
1.978e-04 | -8.53 | immune system process | biological process | GO:0002376 | 1991 | 15 | 18204 | 50 |
CEBPB,HCK,CSF3R,ETS1,CERT1,FNIP1,SH2B3,BLNK,TFEB,ADGRG3,CD276,MEF2C,CTSV,CD68,ELF4 |
1.979e-04 | -8.53 | DAD_dom | interpro domains | IPR014767 | 8 | 2 | 18521 | 50 |
DIAPH2,FMNL1 |
2.039e-04 | -8.50 | CRKL (CRK like proto-oncogene, adaptor protein) | protein interactions | 1399 | 211 | 5 | 19454 | 50 |
AOX1,BLNK,ETV6,SH3KBP1,HCK |
2.062e-04 | -8.49 | regulation of response to stimulus | biological process | GO:0048583 | 4104 | 23 | 18204 | 50 |
MARK4,ETS1,RBM47,FNIP1,SH2B3,RXRA,BLNK,HCK,CEBPB,ARHGAP45,ABCA1,CTSV,MEF2C,ARHGEF1,PLEK,ELF4,RHBDF1,DAB2,ARAP1,SGMS1,ADGRG3,DISC1,CD276 |
2.110e-04 | -8.46 | positive regulation of protein-containing complex assembly | biological process | GO:0031334 | 199 | 5 | 18204 | 50 |
HCK,MARK4,PLEK,ABCA1,FNIP1 |
2.161e-04 | -8.44 | CAPZA1 (capping actin protein of muscle Z-line subunit alpha 1) | protein interactions | 829 | 337 | 6 | 19454 | 50 |
BLNK,ARAP1,DISC1,SH3KBP1,ARHGEF1,RXRA |
2.204e-04 | -8.42 | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma | COSMIC cancer mutations | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma | 7205 | 32 | 16828 | 46 |
SRGN,AOX1,ETS1,CSF3R,DOCK4,DIAPH2,DAB2,RGL1,MICAL2,ABCC5,SH3KBP1,MARK4,MAN1A1,ARAP1,STAB1,SGMS1,ETV6,MFSD1,ATP8A1,SH2B3,ELF4,RXRA,MLKL,ARAP3,MYO1F,CD53,BLNK,BAZ2B,PLEK,ABCA1,FNIP1,GLDC |
2.270e-04 | -8.39 | ETSDOMAIN | prints domains | PR00454 | 28 | 3 | 5227 | 23 |
ETV6,ELF4,ETS1 |
2.429e-04 | -8.32 | positive regulation of lipid localization | biological process | GO:1905954 | 111 | 4 | 18204 | 50 |
ATP8A1,DAB2,ABCA1,RXRA |
2.540e-04 | -8.28 | GTPase-bd | interpro domains | IPR010473 | 9 | 2 | 18521 | 50 |
FMNL1,DIAPH2 |
2.540e-04 | -8.28 | FH3_dom | interpro domains | IPR010472 | 9 | 2 | 18521 | 50 |
DIAPH2,FMNL1 |
2.641e-04 | -8.24 | Drf_FH3 | pfam domains | PF06367 | 9 | 2 | 17795 | 49 |
DIAPH2,FMNL1 |
2.641e-04 | -8.24 | Drf_GBD | pfam domains | PF06371 | 9 | 2 | 17795 | 49 |
DIAPH2,FMNL1 |
2.661e-04 | -8.23 | phosphatidylserine floppase activity | molecular function | GO:0090556 | 9 | 2 | 18094 | 50 |
ABCA1,ATP8A1 |
2.681e-04 | -8.22 | PH_DOMAIN | prosite domains | PS50003 | 246 | 6 | 12186 | 45 |
ARHGEF1,PLEK,CERT1,ARAP1,FERMT3,ARAP3 |
2.687e-04 | -8.22 | vacuolar membrane | cellular component | GO:0005774 | 490 | 7 | 19108 | 50 |
ATP8A1,MFSD1,CD68,FNIP1,CSF3R,TFEB,DAB2 |
2.736e-04 | -8.20 | regulation of developmental process | biological process | GO:0050793 | 2540 | 17 | 18204 | 50 |
MEF2C,ARAP1,DAB2,DISC1,FMNL1,SRGN,FLRT2,ETS1,RXRA,FNIP1,CD53,STAB1,CSF3R,CEBPB,HCK,SH3KBP1,ABCA1 |
3.349e-04 | -8.00 | RA | prosite domains | PS50200 | 37 | 3 | 12186 | 45 |
RGL1,ARAP1,ARAP3 |
3.456e-04 | -7.97 | ARHGEF1 (Rho guanine nucleotide exchange factor 1) | protein interactions | 9138 | 130 | 4 | 19454 | 50 |
PLEK,DOCK4,ARHGEF1,SH3KBP1 |
3.508e-04 | -7.96 | PLEK (pleckstrin) | protein interactions | 5341 | 11 | 2 | 19454 | 50 |
ARHGEF1,PLEK |
3.681e-04 | -7.91 | DAD | prosite domains | PS51231 | 8 | 2 | 12186 | 45 |
DIAPH2,FMNL1 |
3.737e-04 | -7.89 | oesophagus-lower_third-carcinoma-adenocarcinoma | COSMIC cancer mutations | oesophagus-lower_third-carcinoma-adenocarcinoma | 6302 | 29 | 16828 | 46 |
MYO1F,RXRA,ELF4,SH2B3,MLKL,DISC1,FCHO2,GLDC,BAZ2B,ABCA1,FLRT2,ABCC5,MICAL2,RGL1,DIAPH2,DAB2,AOX1,SRGN,TFEB,DOCK4,FMNL1,ETS1,CSF3R,ATP8A1,CD276,SGMS1,STAB1,ARAP1,MAN1A1 |
3.868e-04 | -7.86 | GBD/FH3_dom | interpro domains | IPR014768 | 11 | 2 | 18521 | 50 |
FMNL1,DIAPH2 |
3.868e-04 | -7.86 | Pointed_dom | interpro domains | IPR003118 | 11 | 2 | 18521 | 50 |
ETV6,ETS1 |
4.013e-04 | -7.82 | endocytosis | biological process | GO:0006897 | 499 | 7 | 18204 | 50 |
FCHO2,DAB2,STAB1,HCK,MYO1F,SH3KBP1,ABCA1 |
4.021e-04 | -7.82 | SAM_PNT | pfam domains | PF02198 | 11 | 2 | 17795 | 49 |
ETV6,ETS1 |
4.059e-04 | -7.81 | ITSN1 (intersectin 1) | protein interactions | 6453 | 245 | 5 | 19454 | 50 |
DOCK4,SH3KBP1,DISC1,DAB2,FCHO2 |
4.382e-04 | -7.73 | positive regulation of biomineral tissue development | biological process | GO:0070169 | 54 | 3 | 18204 | 50 |
RXRA,CEBPB,MEF2C |
4.848e-04 | -7.63 | positive regulation of cellular component biogenesis | biological process | GO:0044089 | 515 | 7 | 18204 | 50 |
MARK4,PLEK,FNIP1,HCK,ARAP1,ABCA1,FLRT2 |
4.982e-04 | -7.60 | acute_lymphoblastic_leukaemia | COSMIC cancer mutations | acute_lymphoblastic_leukaemia | 2197 | 15 | 16828 | 46 |
DAB2,BLNK,ARHGEF1,TFEB,AOX1,MLKL,CSF3R,FMNL1,ETV6,MEF2C,MAN1A1,MARK4,STAB1,BAZ2B,HCK |
4.990e-04 | -7.60 | thyroid-carcinoma | COSMIC cancer mutations | thyroid-carcinoma | 4126 | 22 | 16828 | 46 |
STAB1,ARAP1,MAN1A1,ABCC5,RGL1,SH3KBP1,AOX1,FMNL1,DOCK4,ETS1,CSF3R,MEF2C,FNIP1,BAZ2B,ABCA1,PLEK,FLRT2,RXRA,ELF4,SH2B3,RBM47,ARAP3 |
5.179e-04 | -7.57 | lipid binding | molecular function | GO:0008289 | 861 | 9 | 18094 | 50 |
ABCA1,ARAP1,BLNK,RXRA,HCK,ARAP3,FERMT3,CERT1,FCHO2 |
5.269e-04 | -7.55 | Drf_GBD | smart domains | SM01140 | 9 | 2 | 9717 | 38 |
FMNL1,DIAPH2 |
5.269e-04 | -7.55 | Drf_FH3 | smart domains | SM01139 | 9 | 2 | 9717 | 38 |
DIAPH2,FMNL1 |
5.273e-04 | -7.55 | anion binding | molecular function | GO:0043168 | 2412 | 16 | 18094 | 50 |
MYO1F,MICAL2,RXRA,GLDC,AOX1,ARAP3,ATP8A1,HCK,MLKL,ABCC5,CERT1,PLEK,MARK4,ABCA1,ARAP1,FCHO2 |
5.563e-04 | -7.49 | membrane | cellular component | GO:0016020 | 9220 | 36 | 19108 | 50 |
RGL1,MLKL,RHBDF1,CERT1,FCHO2,MAN1A1,ABCC5,ARHGEF1,PLEK,ARAP3,ATP8A1,MFSD1,ETV6,ABCA1,FERMT3,SH3KBP1,ARAP1,SGMS1,HCK,CD53,BLNK,TFEB,GLDC,DAB2,FMNL1,DOCK4,STAB1,ADGRG3,FNIP1,SH2B3,CSF3R,CD276,FLRT2,ARHGAP45,MYO1F,CD68 |
5.709e-04 | -7.47 | regulation of cell shape | biological process | GO:0008360 | 139 | 4 | 18204 | 50 |
ARAP1,HCK,SH3KBP1,FMNL1 |
6.026e-04 | -7.41 | signaling receptor binding | molecular function | GO:0005102 | 1493 | 12 | 18094 | 50 |
DAB2,DOCK4,SH2B3,ABCA1,ARAP1,ARHGEF1,FLRT2,DIAPH2,FERMT3,BLNK,HCK,CD276 |
6.132e-04 | -7.40 | intracellular signal transduction | biological process | GO:0035556 | 1505 | 12 | 18204 | 50 |
MARK4,ARHGEF1,MEF2C,PLEK,FNIP1,SH2B3,BLNK,HCK,CEBPB,DOCK4,RGL1,DISC1 |
6.362e-04 | -7.36 | programmed cell death | biological process | GO:0012501 | 1087 | 10 | 18204 | 50 |
MEF2C,CTSV,FNIP1,MLKL,CEBPB,ETV6,DAB2,SRGN,SGMS1,SH3KBP1 |
6.547e-04 | -7.33 | cell death | biological process | GO:0008219 | 1091 | 10 | 18204 | 50 |
SH3KBP1,SRGN,SGMS1,DAB2,CEBPB,ETV6,FNIP1,MLKL,MEF2C,CTSV |
6.816e-04 | -7.29 | ASAP1 (ArfGAP with SH3 domain, ankyrin repeat and PH domain 1) | protein interactions | 50807 | 67 | 3 | 19454 | 50 |
SH3KBP1,HCK,ARAP3 |
6.933e-04 | -7.27 | actin cytoskeleton organization | biological process | GO:0030036 | 547 | 7 | 18204 | 50 |
SH3KBP1,FMNL1,ARAP1,DIAPH2,PLEK,MICAL2,MYO1F |
7.006e-04 | -7.26 | cell surface receptor signaling pathway | biological process | GO:0007166 | 1992 | 14 | 18204 | 50 |
MEF2C,PLEK,ADGRG3,FLRT2,FERMT3,CD276,DISC1,DAB2,MLKL,SH2B3,BLNK,ABCA1,HCK,CSF3R |
7.082e-04 | -7.25 | GRB2 (growth factor receptor bound protein 2) | protein interactions | 2885 | 769 | 8 | 19454 | 50 |
SH2B3,CSF3R,SH3KBP1,DAB2,DOCK4,ETV6,BLNK,ARAP1 |
7.180e-04 | -7.24 | PNT | prosite domains | PS51433 | 11 | 2 | 12186 | 45 |
ETV6,ETS1 |
7.180e-04 | -7.24 | GBD_FH3 | prosite domains | PS51232 | 11 | 2 | 12186 | 45 |
DIAPH2,FMNL1 |
7.188e-04 | -7.24 | RhoGAP_dom | interpro domains | IPR000198 | 65 | 3 | 18521 | 50 |
ARAP3,ARHGAP45,ARAP1 |
7.333e-04 | -7.22 | FH2_Formin_sf | interpro domains | IPR042201 | 15 | 2 | 18521 | 50 |
DIAPH2,FMNL1 |
7.333e-04 | -7.22 | FH2_Formin | interpro domains | IPR015425 | 15 | 2 | 18521 | 50 |
DIAPH2,FMNL1 |
7.347e-04 | -7.22 | phospholipid transporter activity | molecular function | GO:0005548 | 64 | 3 | 18094 | 50 |
CERT1,ABCA1,ATP8A1 |
7.426e-04 | -7.21 | cell activation | biological process | GO:0001775 | 725 | 8 | 18204 | 50 |
MEF2C,PLEK,FNIP1,BLNK,ELF4,FERMT3,ADGRG3,CD276 |
7.601e-04 | -7.18 | RhoGAP | pfam domains | PF00620 | 65 | 3 | 17795 | 49 |
ARAP1,ARHGAP45,ARAP3 |
7.623e-04 | -7.18 | FH2 | pfam domains | PF02181 | 15 | 2 | 17795 | 49 |
DIAPH2,FMNL1 |
7.983e-04 | -7.13 | regulation of lipid transport | biological process | GO:0032368 | 152 | 4 | 18204 | 50 |
ABCA1,RXRA,DAB2,ATP8A1 |
8.011e-04 | -7.13 | SAM_PNT | smart domains | SM00251 | 11 | 2 | 9717 | 38 |
ETS1,ETV6 |
8.181e-04 | -7.11 | organophosphate ester transport | biological process | GO:0015748 | 153 | 4 | 18204 | 50 |
ABCA1,ABCC5,CERT1,ATP8A1 |
8.563e-04 | -7.06 | serous_carcinoma | COSMIC cancer mutations | serous_carcinoma | 10987 | 40 | 16828 | 46 |
TFEB,AOX1,CD68,DOCK4,CSF3R,ETS1,RGL1,DAB2,DIAPH2,ABCC5,MICAL2,SH3KBP1,STAB1,ARAP1,MAN1A1,MARK4,SGMS1,FERMT3,ETV6,CD276,MFSD1,ATP8A1,SH2B3,RBM47,RXRA,ELF4,MLKL,ARAP3,MYO1F,ARHGEF1,BAZ2B,PLEK,FLRT2,HCK,ABCA1,RHBDF1,MEF2C,GLDC,FNIP1,FCHO2 |
8.566e-04 | -7.06 | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-acute_lymphoblastic_leukaemia | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-acute_lymphoblastic_leukaemia | 156 | 4 | 16828 | 46 |
HCK,BLNK,MEF2C,ETV6 |
8.761e-04 | -7.04 | floppase activity | molecular function | GO:0140328 | 16 | 2 | 18094 | 50 |
ABCA1,ATP8A1 |
9.171e-04 | -6.99 | GTPase activator activity | molecular function | GO:0005096 | 273 | 5 | 18094 | 50 |
ARAP3,ARHGAP45,DOCK4,ARHGEF1,ARAP1 |
9.470e-04 | -6.96 | HDAC9 (histone deacetylase 9) | protein interactions | 9734 | 75 | 3 | 19454 | 50 |
CEBPB,MEF2C,ETV6 |
9.477e-04 | -6.96 | LMO7 (LIM domain 7) | protein interactions | 4008 | 170 | 4 | 19454 | 50 |
RBM47,GLDC,FMNL1,ABCA1 |
9.511e-04 | -6.96 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_leukaemia | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_leukaemia | 2081 | 14 | 16828 | 46 |
TFEB,AOX1,MLKL,FMNL1,CSF3R,DAB2,BLNK,ARHGEF1,BAZ2B,STAB1,MAN1A1,MARK4,HCK,ETV6 |
9.682e-04 | -6.94 | actin filament organization | biological process | GO:0007015 | 278 | 5 | 18204 | 50 |
DIAPH2,SH3KBP1,MYO1F,MICAL2,ARAP1 |
9.685e-04 | -6.94 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-chronic_eosinophilic_leukaemia-hypereosinophilic_syndrome | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-chronic_eosinophilic_leukaemia-hypereosinophilic_syndrome | 17 | 2 | 16828 | 46 |
SH2B3,ETV6 |
9.685e-04 | -6.94 | chronic_eosinophilic_leukaemia-hypereosinophilic_syndrome | COSMIC cancer mutations | chronic_eosinophilic_leukaemia-hypereosinophilic_syndrome | 17 | 2 | 16828 | 46 |
SH2B3,ETV6 |
9.694e-04 | -6.94 | vesicle | cellular component | GO:0031982 | 4141 | 21 | 19108 | 50 |
ARHGAP45,FLRT2,CSF3R,CD68,DIAPH2,ATP8A1,HCK,CD53,SH3KBP1,FERMT3,ABCA1,SRGN,DISC1,AOX1,DAB2,FCHO2,FMNL1,MAN1A1,ADGRG3,ABCC5,STAB1 |
9.912e-04 | -6.92 | transmembrane receptor protein tyrosine kinase adaptor activity | molecular function | GO:0005068 | 17 | 2 | 18094 | 50 |
SH2B3,BLNK |
1.033e-03 | -6.88 | regulation of multicellular organismal process | biological process | GO:0051239 | 3113 | 18 | 18204 | 50 |
ETS1,RBM47,SH2B3,RXRA,CEBPB,CSF3R,STAB1,ABCA1,SH3KBP1,MEF2C,PLEK,ELF4,DOCK4,DAB2,FLRT2,SRGN,DISC1,CD276 |
1.055e-03 | -6.85 | Formin, FH2 domain | gene3d domains | 1.20.58.2220 | 15 | 2 | 14470 | 47 |
FMNL1,DIAPH2 |
1.061e-03 | -6.85 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-myelodysplastic_syndrome | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-myelodysplastic_syndrome | 1174 | 10 | 16828 | 46 |
MARK4,SH2B3,HCK,MLKL,CSF3R,DIAPH2,ETV6,MICAL2,FNIP1,BLNK |
1.061e-03 | -6.85 | myelodysplastic_syndrome | COSMIC cancer mutations | myelodysplastic_syndrome | 1174 | 10 | 16828 | 46 |
SH2B3,MARK4,MLKL,HCK,CSF3R,DIAPH2,ETV6,MICAL2,BLNK,FNIP1 |
1.078e-03 | -6.83 | cargo receptor activity | molecular function | GO:0038024 | 73 | 3 | 18094 | 50 |
STAB1,ABCA1,DAB2 |
1.100e-03 | -6.81 | clathrin coat assembly | biological process | GO:0048268 | 18 | 2 | 18204 | 50 |
FCHO2,DAB2 |
1.100e-03 | -6.81 | Mercaptopurine Metabolism Pathway | SMPDB pathways | SMP0000609 | 15 | 2 | 1369 | 5 |
ABCC5,AOX1 |
1.107e-03 | -6.81 | positive regulation of defense response | biological process | GO:0031349 | 430 | 6 | 18204 | 50 |
CEBPB,HCK,RBM47,MEF2C,ETS1,MARK4 |
1.152e-03 | -6.77 | bounding membrane of organelle | cellular component | GO:0098588 | 2198 | 14 | 19108 | 50 |
CSF3R,TFEB,RHBDF1,DAB2,CD68,ATP8A1,MFSD1,SGMS1,FNIP1,CD53,STAB1,ABCC5,MAN1A1,ADGRG3 |
1.221e-03 | -6.71 | enzyme activator activity | molecular function | GO:0008047 | 599 | 7 | 18094 | 50 |
DOCK4,ARHGAP45,ARAP3,FNIP1,CTSV,ARAP1,ARHGEF1 |
1.273e-03 | -6.67 | Rho GTPase activation protein | gene3d domains | 1.10.555.10 | 66 | 3 | 14470 | 47 |
ARAP3,ARHGAP45,ARAP1 |
1.358e-03 | -6.60 | FH2 | prosite domains | PS51444 | 15 | 2 | 12186 | 45 |
FMNL1,DIAPH2 |
1.368e-03 | -6.59 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia_associated_with_MDS | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia_associated_with_MDS | 177 | 4 | 16828 | 46 |
CSF3R,DOCK4,ETV6,SH2B3 |
1.368e-03 | -6.59 | acute_myeloid_leukaemia_associated_with_MDS | COSMIC cancer mutations | acute_myeloid_leukaemia_associated_with_MDS | 177 | 4 | 16828 | 46 |
DOCK4,CSF3R,ETV6,SH2B3 |
1.377e-03 | -6.59 | sphingolipid transporter activity | molecular function | GO:0046624 | 20 | 2 | 18094 | 50 |
ABCA1,CERT1 |
1.384e-03 | -6.58 | ovary-carcinoma-serous_carcinoma | COSMIC cancer mutations | ovary-carcinoma-serous_carcinoma | 10710 | 39 | 16828 | 46 |
FCHO2,MEF2C,GLDC,FNIP1,RHBDF1,ABCA1,PLEK,FLRT2,HCK,BAZ2B,ARHGEF1,MYO1F,ARAP3,MLKL,RXRA,ELF4,SH2B3,RBM47,ATP8A1,CD276,ETV6,FERMT3,SGMS1,STAB1,ARAP1,MARK4,MAN1A1,SH3KBP1,ABCC5,MICAL2,RGL1,DAB2,DIAPH2,DOCK4,ETS1,CSF3R,AOX1,CD68,TFEB |
1.385e-03 | -6.58 | actin filament-based process | biological process | GO:0030029 | 616 | 7 | 18204 | 50 |
DIAPH2,PLEK,MICAL2,MYO1F,SH3KBP1,FMNL1,ARAP1 |
1.444e-03 | -6.54 | pharynx | COSMIC cancer mutations | pharynx | 2696 | 16 | 16828 | 46 |
MEF2C,FNIP1,RHBDF1,FLRT2,SGMS1,STAB1,MARK4,ARHGEF1,ABCC5,MICAL2,DIAPH2,DAB2,DOCK4,ETS1,MLKL,SH2B3 |
1.455e-03 | -6.53 | FGR (FGR proto-oncogene, Src family tyrosine kinase) | protein interactions | 2268 | 87 | 3 | 19454 | 50 |
HCK,SH3KBP1,DAB2 |
1.482e-03 | -6.51 | regulation of bone mineralization | biological process | GO:0030500 | 82 | 3 | 18204 | 50 |
SRGN,RXRA,MEF2C |
1.491e-03 | -6.51 | thyroid | COSMIC cancer mutations | thyroid | 9867 | 37 | 16828 | 46 |
ARHGEF1,MYO1F,ARAP3,RXRA,ELF4,RBM47,SH2B3,FCHO2,MEF2C,GLDC,FNIP1,RHBDF1,ABCA1,FLRT2,PLEK,BAZ2B,SH3KBP1,ABCC5,MICAL2,RGL1,DAB2,DIAPH2,DOCK4,FMNL1,CSF3R,ETS1,CEBPB,AOX1,TFEB,ATP8A1,MFSD1,CD276,ETV6,STAB1,ARAP1,MAN1A1,MARK4 |
1.508e-03 | -6.50 | receptor tyrosine kinase binding | molecular function | GO:0030971 | 82 | 3 | 18094 | 50 |
BLNK,DOCK4,SH2B3 |
1.514e-03 | -6.49 | FH2 | smart domains | SM00498 | 15 | 2 | 9717 | 38 |
DIAPH2,FMNL1 |
1.551e-03 | -6.47 | protein binding | molecular function | GO:0005515 | 13983 | 47 | 18094 | 50 |
MFSD1,CEBPB,SH3KBP1,DISC1,CD276,GLDC,HCK,SH2B3,PLEK,MARK4,STAB1,FNIP1,MYO1F,RGL1,MEF2C,ARAP3,RHBDF1,RBM47,CD53,MLKL,DAB2,CTSV,ARAP1,TFEB,ELF4,ARHGAP45,BLNK,ETS1,AOX1,ADGRG3,RXRA,ETV6,DOCK4,CD68,DIAPH2,FCHO2,MICAL2,BAZ2B,ATP8A1,CSF3R,CERT1,ABCA1,FLRT2,ARHGEF1,FERMT3,SRGN,FMNL1 |
1.572e-03 | -6.46 | CD2AP (CD2 associated protein) | protein interactions | 23607 | 195 | 4 | 19454 | 50 |
ARAP3,BLNK,SH3KBP1,HCK |
1.582e-03 | -6.45 | CD2 (CD2 molecule) | protein interactions | 914 | 23 | 2 | 19454 | 50 |
SH3KBP1,CD53 |
1.587e-03 | -6.45 | regulation of lipid localization | biological process | GO:1905952 | 183 | 4 | 18204 | 50 |
RXRA,ABCA1,ATP8A1,DAB2 |
1.705e-03 | -6.37 | positive regulation of multicellular organismal process | biological process | GO:0051240 | 1691 | 12 | 18204 | 50 |
DAB2,FLRT2,DISC1,CD276,MEF2C,PLEK,CEBPB,ABCA1,SH3KBP1,ETS1,RBM47,RXRA |
1.742e-03 | -6.35 | specific granule membrane | cellular component | GO:0035579 | 91 | 3 | 19108 | 50 |
CD53,ADGRG3,ATP8A1 |
1.743e-03 | -6.35 | FCH_dom | interpro domains | IPR001060 | 23 | 2 | 18521 | 50 |
ARHGAP45,FCHO2 |
1.752e-03 | -6.35 | RHOGAP | prosite domains | PS50238 | 65 | 3 | 12186 | 45 |
ARAP1,ARAP3,ARHGAP45 |
1.775e-03 | -6.33 | lymphoid_neoplasm | COSMIC cancer mutations | lymphoid_neoplasm | 12233 | 42 | 16828 | 46 |
SH3KBP1,MICAL2,ABCC5,DIAPH2,DAB2,RGL1,CSF3R,ETS1,FMNL1,DOCK4,SRGN,AOX1,TFEB,ATP8A1,CD276,MFSD1,ETV6,FERMT3,SGMS1,MARK4,MAN1A1,STAB1,ARAP1,ARHGEF1,CD53,BLNK,MYO1F,ARAP3,MLKL,ELF4,RXRA,RBM47,SH2B3,FNIP1,MEF2C,GLDC,RHBDF1,ABCA1,HCK,FLRT2,PLEK,BAZ2B |
1.781e-03 | -6.33 | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-mantle_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-mantle_cell_lymphoma | 476 | 6 | 16828 | 46 |
ATP8A1,FNIP1,GLDC,ETV6,ELF4,AOX1 |
1.783e-03 | -6.33 | biphasic | COSMIC cancer mutations | biphasic | 88 | 3 | 16828 | 46 |
ETV6,SH2B3,FNIP1 |
1.785e-03 | -6.33 | B cell activation | biological process | GO:0042113 | 189 | 4 | 18204 | 50 |
MEF2C,FNIP1,ADGRG3,BLNK |
1.786e-03 | -6.33 | Rho GTPase cycle | REACTOME pathways | R-HSA-194840 | 142 | 4 | 10285 | 38 |
ARAP3,ARAP1,ARHGAP45,ARHGEF1 |
1.829e-03 | -6.30 | RHOU (ras homolog family member U) | protein interactions | 58480 | 507 | 6 | 19454 | 50 |
PLEK,ABCC5,FMNL1,DAB2,FCHO2,FLRT2 |
1.844e-03 | -6.30 | Rho_GTPase_activation_prot | interpro domains | IPR008936 | 90 | 3 | 18521 | 50 |
ARAP3,ARAP1,ARHGAP45 |
1.857e-03 | -6.29 | cytoskeleton organization | biological process | GO:0007010 | 1251 | 10 | 18204 | 50 |
DIAPH2,MYO1F,MARK4,MICAL2,PLEK,FMNL1,SH3KBP1,DISC1,ARAP1,ARAP3 |
1.857e-03 | -6.29 | lymphocyte activation | biological process | GO:0046649 | 476 | 6 | 18204 | 50 |
FNIP1,ADGRG3,BLNK,ELF4,CD276,MEF2C |
1.859e-03 | -6.29 | apoptotic process | biological process | GO:0006915 | 1038 | 9 | 18204 | 50 |
SH3KBP1,SGMS1,SRGN,DAB2,ETV6,CEBPB,FNIP1,CTSV,MEF2C |
1.870e-03 | -6.28 | lower_third | COSMIC cancer mutations | lower_third | 7961 | 32 | 16828 | 46 |
FCHO2,DISC1,MEF2C,GLDC,RHBDF1,ABCA1,FLRT2,BAZ2B,MYO1F,ARAP3,MLKL,ELF4,RXRA,SH2B3,ATP8A1,CD276,SGMS1,MAN1A1,ARAP1,STAB1,MICAL2,ABCC5,DIAPH2,DAB2,RGL1,ETS1,CSF3R,DOCK4,FMNL1,SRGN,AOX1,TFEB |
1.893e-03 | -6.27 | stomach-carcinoma-intestinal_adenocarcinoma | COSMIC cancer mutations | stomach-carcinoma-intestinal_adenocarcinoma | 7225 | 30 | 16828 | 46 |
MLKL,ARAP3,RBM47,RXRA,ELF4,BLNK,CD53,ARHGEF1,MYO1F,PLEK,FLRT2,ABCA1,BAZ2B,GLDC,FNIP1,RHBDF1,FMNL1,DOCK4,AOX1,SH3KBP1,DAB2,ABCC5,MICAL2,STAB1,ARAP1,MARK4,SGMS1,ATP8A1,FERMT3,ETV6 |
1.893e-03 | -6.27 | intestinal_adenocarcinoma | COSMIC cancer mutations | intestinal_adenocarcinoma | 7225 | 30 | 16828 | 46 |
SGMS1,STAB1,ARAP1,MARK4,ETV6,FERMT3,ATP8A1,AOX1,FMNL1,DOCK4,ABCC5,MICAL2,DAB2,SH3KBP1,BAZ2B,ABCA1,PLEK,FLRT2,RHBDF1,GLDC,FNIP1,RXRA,ELF4,RBM47,ARAP3,MLKL,MYO1F,ARHGEF1,BLNK,CD53 |
1.923e-03 | -6.25 | organelle membrane | cellular component | GO:0031090 | 3742 | 19 | 19108 | 50 |
ARAP1,SGMS1,SH3KBP1,CD53,ABCA1,CD68,ATP8A1,MFSD1,FLRT2,CSF3R,FNIP1,STAB1,ADGRG3,ABCC5,MAN1A1,CERT1,RHBDF1,DAB2,TFEB |
1.927e-03 | -6.25 | cellular response to xenobiotic stimulus | biological process | GO:0071466 | 193 | 4 | 18204 | 50 |
ABCA1,AOX1,MEF2C,ABCC5 |
1.943e-03 | -6.24 | positive regulation of cellular process | biological process | GO:0048522 | 5719 | 26 | 18204 | 50 |
ETV6,CEBPB,CD53,RXRA,ETS1,FLRT2,DISC1,DAB2,ELF4,CTSV,PLEK,MICAL2,ABCA1,SH3KBP1,HCK,FNIP1,BLNK,MARK4,RBM47,FERMT3,CD276,DOCK4,TFEB,ARAP1,MEF2C,ATP8A1 |
1.950e-03 | -6.24 | RhoGAP | smart domains | SM00324 | 64 | 3 | 9717 | 38 |
ARAP1,ARHGAP45,ARAP3 |
1.959e-03 | -6.24 | Regulation of signaling by CBL | REACTOME pathways | R-HSA-912631 | 18 | 2 | 10285 | 38 |
BLNK,HCK |
1.964e-03 | -6.23 | SAM | interpro domains | IPR001660 | 92 | 3 | 18521 | 50 |
ARAP1,SGMS1,ARAP3 |
2.059e-03 | -6.19 | F_BAR | interpro domains | IPR031160 | 25 | 2 | 18521 | 50 |
ARHGAP45,FCHO2 |
2.133e-03 | -6.15 | endocytic vesicle | cellular component | GO:0030139 | 349 | 5 | 19108 | 50 |
CSF3R,FMNL1,ABCA1,STAB1,SH3KBP1 |
2.146e-03 | -6.14 | response to lipopolysaccharide | biological process | GO:0032496 | 333 | 5 | 18204 | 50 |
CD68,CEBPB,MEF2C,HCK,ABCA1 |
2.237e-03 | -6.10 | nucleoside-triphosphatase regulator activity | molecular function | GO:0060589 | 491 | 6 | 18094 | 50 |
RGL1,ARHGAP45,DOCK4,ARAP3,ARAP1,ARHGEF1 |
2.237e-03 | -6.10 | GTPase regulator activity | molecular function | GO:0030695 | 491 | 6 | 18094 | 50 |
ARAP3,ARHGAP45,RGL1,DOCK4,ARHGEF1,ARAP1 |
2.243e-03 | -6.10 | response to lipid | biological process | GO:0033993 | 862 | 8 | 18204 | 50 |
RXRA,CD68,GLDC,MEF2C,ABCA1,DAB2,HCK,CEBPB |
2.368e-03 | -6.05 | ATPase-coupled transmembrane transporter activity | molecular function | GO:0042626 | 96 | 3 | 18094 | 50 |
ABCC5,ATP8A1,ABCA1 |
2.401e-03 | -6.03 | ArfGAP_dom | interpro domains | IPR001164 | 27 | 2 | 18521 | 50 |
ARAP1,ARAP3 |
2.401e-03 | -6.03 | ArfGAP_dom_sf | interpro domains | IPR038508 | 27 | 2 | 18521 | 50 |
ARAP1,ARAP3 |
2.401e-03 | -6.03 | ARFGAP/RecO | interpro domains | IPR037278 | 27 | 2 | 18521 | 50 |
ARAP1,ARAP3 |
2.409e-03 | -6.03 | Transcription factor regulation in adipogenesis | WikiPathways | WP3599 | 22 | 2 | 5310 | 18 |
RXRA,CEBPB |
2.450e-03 | -6.01 | response to bacterium | biological process | GO:0009617 | 681 | 7 | 18204 | 50 |
ABCA1,STAB1,TFEB,CEBPB,HCK,CD68,MEF2C |
2.479e-03 | -6.00 | central_nervous_system-medulla-primitive_neuroectodermal_tumour-medulloblastoma-classic | COSMIC cancer mutations | central_nervous_system-medulla-primitive_neuroectodermal_tumour-medulloblastoma-classic | 14773 | 46 | 16828 | 46 |
SH3KBP1,RGL1,FMNL1,CEBPB,CSF3R,TFEB,CD68,SRGN,MFSD1,FERMT3,ARAP1,BLNK,ARHGEF1,MYO1F,MLKL,SH2B3,FNIP1,DISC1,FCHO2,RHBDF1,DIAPH2,DAB2,ABCC5,MICAL2,DOCK4,ETS1,AOX1,CD276,ATP8A1,ETV6,STAB1,MAN1A1,MARK4,SGMS1,CD53,ARAP3,RBM47,RXRA,ELF4,MEF2C,GLDC,FLRT2,PLEK,HCK,ABCA1,BAZ2B |
2.479e-03 | -6.00 | central_nervous_system-medulla-primitive_neuroectodermal_tumour-medulloblastoma-large_cell | COSMIC cancer mutations | central_nervous_system-medulla-primitive_neuroectodermal_tumour-medulloblastoma-large_cell | 14773 | 46 | 16828 | 46 |
ABCC5,MICAL2,DIAPH2,DAB2,AOX1,DOCK4,ETS1,ETV6,ATP8A1,CD276,SGMS1,STAB1,MAN1A1,MARK4,CD53,RXRA,ELF4,RBM47,ARAP3,MEF2C,GLDC,BAZ2B,ABCA1,PLEK,FLRT2,HCK,RGL1,SH3KBP1,CD68,SRGN,TFEB,FMNL1,CEBPB,CSF3R,FERMT3,MFSD1,ARAP1,MYO1F,ARHGEF1,BLNK,SH2B3,MLKL,RHBDF1,DISC1,FCHO2,FNIP1 |
2.479e-03 | -6.00 | central_nervous_system-medulla-primitive_neuroectodermal_tumour-medulloblastoma | COSMIC cancer mutations | central_nervous_system-medulla-primitive_neuroectodermal_tumour-medulloblastoma | 14773 | 46 | 16828 | 46 |
CD276,ATP8A1,ETV6,MARK4,MAN1A1,STAB1,SGMS1,DIAPH2,DAB2,MICAL2,ABCC5,ETS1,DOCK4,AOX1,GLDC,MEF2C,HCK,FLRT2,PLEK,ABCA1,BAZ2B,CD53,ARAP3,RBM47,ELF4,RXRA,MFSD1,FERMT3,ARAP1,SH3KBP1,RGL1,CEBPB,CSF3R,FMNL1,TFEB,SRGN,CD68,FNIP1,FCHO2,DISC1,RHBDF1,BLNK,ARHGEF1,MYO1F,MLKL,SH2B3 |
2.479e-03 | -6.00 | central_nervous_system-medulla-primitive_neuroectodermal_tumour-medulloblastoma-desmoplastic | COSMIC cancer mutations | central_nervous_system-medulla-primitive_neuroectodermal_tumour-medulloblastoma-desmoplastic | 14773 | 46 | 16828 | 46 |
CD53,ARAP3,RXRA,ELF4,RBM47,MEF2C,GLDC,ABCA1,FLRT2,PLEK,HCK,BAZ2B,ABCC5,MICAL2,DIAPH2,DAB2,DOCK4,ETS1,AOX1,ATP8A1,CD276,ETV6,SGMS1,STAB1,MAN1A1,MARK4,ARHGEF1,BLNK,MYO1F,MLKL,SH2B3,DISC1,FCHO2,FNIP1,RHBDF1,SH3KBP1,RGL1,FMNL1,CSF3R,CEBPB,CD68,SRGN,TFEB,MFSD1,FERMT3,ARAP1 |
2.484e-03 | -6.00 | positive regulation of leukocyte apoptotic process | biological process | GO:2000108 | 27 | 2 | 18204 | 50 |
FNIP1,MEF2C |
2.484e-03 | -6.00 | positive regulation of cholesterol efflux | biological process | GO:0010875 | 27 | 2 | 18204 | 50 |
ABCA1,RXRA |
2.487e-03 | -6.00 | classic | COSMIC cancer mutations | classic | 14774 | 46 | 16828 | 46 |
GLDC,MEF2C,ABCA1,PLEK,FLRT2,HCK,BAZ2B,CD53,ARAP3,RXRA,ELF4,RBM47,ATP8A1,CD276,ETV6,SGMS1,STAB1,MAN1A1,MARK4,ABCC5,MICAL2,DIAPH2,DAB2,DOCK4,ETS1,AOX1,DISC1,FCHO2,FNIP1,RHBDF1,ARHGEF1,BLNK,MYO1F,MLKL,SH2B3,MFSD1,FERMT3,ARAP1,SH3KBP1,RGL1,FMNL1,CSF3R,CEBPB,CD68,SRGN,TFEB |
2.495e-03 | -5.99 | ArfGap | pfam domains | PF01412 | 27 | 2 | 17795 | 49 |
ARAP1,ARAP3 |
2.503e-03 | -5.99 | WH_DNA-bd_sf | interpro domains | IPR036390 | 211 | 4 | 18521 | 50 |
PLEK,ETV6,ELF4,ETS1 |
2.513e-03 | -5.99 | ATPase-coupled intramembrane lipid transporter activity | molecular function | GO:0140326 | 27 | 2 | 18094 | 50 |
ATP8A1,ABCA1 |
2.518e-03 | -5.98 | medulla | COSMIC cancer mutations | medulla | 14778 | 46 | 16828 | 46 |
GLDC,MEF2C,PLEK,FLRT2,HCK,ABCA1,BAZ2B,CD53,ARAP3,RBM47,RXRA,ELF4,CD276,ATP8A1,ETV6,STAB1,MARK4,MAN1A1,SGMS1,DAB2,DIAPH2,ABCC5,MICAL2,DOCK4,ETS1,AOX1,FNIP1,DISC1,FCHO2,RHBDF1,BLNK,ARHGEF1,MYO1F,MLKL,SH2B3,MFSD1,FERMT3,ARAP1,SH3KBP1,RGL1,FMNL1,CSF3R,CEBPB,TFEB,CD68,SRGN |
2.526e-03 | -5.98 | desmoplastic | COSMIC cancer mutations | desmoplastic | 14779 | 46 | 16828 | 46 |
FMNL1,CEBPB,CSF3R,CD68,SRGN,TFEB,SH3KBP1,RGL1,ARAP1,MFSD1,FERMT3,MLKL,SH2B3,ARHGEF1,BLNK,MYO1F,DISC1,FCHO2,FNIP1,RHBDF1,DOCK4,ETS1,AOX1,ABCC5,MICAL2,DIAPH2,DAB2,SGMS1,STAB1,MARK4,MAN1A1,ATP8A1,CD276,ETV6,ARAP3,RXRA,ELF4,RBM47,CD53,ABCA1,PLEK,FLRT2,HCK,BAZ2B,MEF2C,GLDC |
2.529e-03 | -5.98 | cellular response to lipopolysaccharide | biological process | GO:0071222 | 208 | 4 | 18204 | 50 |
ABCA1,MEF2C,HCK,CD68 |
2.541e-03 | -5.98 | phospholipid transport | biological process | GO:0015914 | 99 | 3 | 18204 | 50 |
ATP8A1,CERT1,ABCA1 |
2.546e-03 | -5.97 | SH3-like_dom_sf | interpro domains | IPR036028 | 212 | 4 | 18521 | 50 |
DOCK4,MYO1F,HCK,SH3KBP1 |
2.570e-03 | -5.96 | Irf2bp1 (interferon regulatory factor 2 binding protein 1) | protein interactions | 272359 | 1 | 1 | 19454 | 50 |
SH3KBP1 |
2.570e-03 | -5.96 | Blnk (B cell linker) | protein interactions | 17060 | 1 | 1 | 19454 | 50 |
SH3KBP1 |
2.570e-03 | -5.96 | CBP (sarcoplasmic calcium-binding protein) | protein interactions | 31669 | 1 | 1 | 19454 | 50 |
SH3KBP1 |
2.570e-03 | -5.96 | Parp1 (poly (ADP-ribose) polymerase 1) | protein interactions | 25591 | 1 | 1 | 19454 | 50 |
RXRA |
2.570e-03 | -5.96 | Arap1 (ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 1) | protein interactions | 69710 | 1 | 1 | 19454 | 50 |
SH3KBP1 |
2.570e-03 | -5.96 | Pik3cd (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta) | protein interactions | 18707 | 1 | 1 | 19454 | 50 |
SH3KBP1 |
2.570e-03 | -5.96 | Rtkn2 (rhotekin 2) | protein interactions | 170799 | 1 | 1 | 19454 | 50 |
SH3KBP1 |
2.570e-03 | -5.96 | Chtf8 (CTF8, chromosome transmission fidelity factor 8) | protein interactions | 214987 | 1 | 1 | 19454 | 50 |
SH3KBP1 |
2.570e-03 | -5.96 | Wipf1 (WAS/WASL interacting protein family, member 1) | protein interactions | 215280 | 1 | 1 | 19454 | 50 |
SH3KBP1 |
2.570e-03 | -5.96 | Pdcd6ip (programmed cell death 6 interacting protein) | protein interactions | 18571 | 1 | 1 | 19454 | 50 |
SH3KBP1 |
2.570e-03 | -5.96 | Pik3ap1 (phosphoinositide-3-kinase adaptor protein 1) | protein interactions | 83490 | 1 | 1 | 19454 | 50 |
SH3KBP1 |
2.570e-03 | -5.96 | pparg.L (peroxisome proliferator activated receptor gamma L homeolog) | protein interactions | 397769 | 1 | 1 | 19454 | 50 |
RXRA |
2.570e-03 | -5.96 | Gtse1 (G two S phase expressed protein 1) | protein interactions | 29870 | 1 | 1 | 19454 | 50 |
SH3KBP1 |
2.570e-03 | -5.96 | Was (Wiskott-Aldrich syndrome) | protein interactions | 22376 | 1 | 1 | 19454 | 50 |
SH3KBP1 |
2.570e-03 | -5.96 | Sh3bp1 (SH3-domain binding protein 1) | protein interactions | 20401 | 1 | 1 | 19454 | 50 |
SH3KBP1 |
2.570e-03 | -5.96 | Map4k1 (mitogen-activated protein kinase kinase kinase kinase 1) | protein interactions | 26411 | 1 | 1 | 19454 | 50 |
SH3KBP1 |
2.570e-03 | -5.96 | Inpp5d (inositol polyphosphate-5-phosphatase D) | protein interactions | 16331 | 1 | 1 | 19454 | 50 |
SH3KBP1 |
2.570e-03 | -5.96 | LINC00473 (long intergenic non-protein coding RNA 473) | protein interactions | 90632 | 1 | 1 | 19454 | 50 |
CEBPB |
2.570e-03 | -5.96 | Impdh1 (inosine monophosphate dehydrogenase 1) | protein interactions | 23917 | 1 | 1 | 19454 | 50 |
SH3KBP1 |
2.570e-03 | -5.96 | Hectd1 (HECT domain E3 ubiquitin protein ligase 1) | protein interactions | 100762999 | 1 | 1 | 19454 | 50 |
ABCA1 |
2.570e-03 | -5.96 | Stap1 (signal transducing adaptor family member 1) | protein interactions | 56792 | 1 | 1 | 19454 | 50 |
SH3KBP1 |
2.570e-03 | -5.96 | Shkbp1 (Sh3kbp1 binding protein 1) | protein interactions | 192192 | 1 | 1 | 19454 | 50 |
SH3KBP1 |
2.570e-03 | -5.96 | Tfap2a (transcription factor AP-2 alpha) | protein interactions | 306862 | 1 | 1 | 19454 | 50 |
DAB2 |
2.573e-03 | -5.96 | import into cell | biological process | GO:0098657 | 687 | 7 | 18204 | 50 |
STAB1,DAB2,FCHO2,MYO1F,HCK,SH3KBP1,ABCA1 |
2.614e-03 | -5.95 | hematopoietic progenitor cell differentiation | biological process | GO:0002244 | 100 | 3 | 18204 | 50 |
RBM47,PLEK,SH2B3 |
2.628e-03 | -5.94 | APLP2 (amyloid beta precursor like protein 2) | protein interactions | 334 | 107 | 3 | 19454 | 50 |
DAB2,DISC1,ETS1 |
2.630e-03 | -5.94 | SH2 | pfam domains | PF00017 | 100 | 3 | 17795 | 49 |
HCK,BLNK,SH2B3 |
2.639e-03 | -5.94 | SAM_DOMAIN | prosite domains | PS50105 | 75 | 3 | 12186 | 45 |
ARAP1,ARAP3,SGMS1 |
2.670e-03 | -5.93 | positive regulation of phosphatase activity | biological process | GO:0010922 | 28 | 2 | 18204 | 50 |
PLEK,MEF2C |
2.690e-03 | -5.92 | CSF3R (colony stimulating factor 3 receptor) | protein interactions | 1441 | 30 | 2 | 19454 | 50 |
CSF3R,HCK |
2.697e-03 | -5.92 | liver-carcinoma-hepatocellular_carcinoma | COSMIC cancer mutations | liver-carcinoma-hepatocellular_carcinoma | 14800 | 46 | 16828 | 46 |
MEF2C,GLDC,FNIP1,DISC1,FCHO2,RHBDF1,PLEK,FLRT2,HCK,ABCA1,BAZ2B,BLNK,CD53,ARHGEF1,MYO1F,MLKL,ARAP3,SH2B3,RBM47,RXRA,ELF4,MFSD1,CD276,ATP8A1,FERMT3,ETV6,ARAP1,STAB1,MARK4,MAN1A1,SGMS1,SH3KBP1,RGL1,DAB2,DIAPH2,ABCC5,MICAL2,FMNL1,DOCK4,ETS1,CEBPB,CSF3R,TFEB,AOX1,CD68,SRGN |
2.697e-03 | -5.92 | hepatocellular_carcinoma | COSMIC cancer mutations | hepatocellular_carcinoma | 14800 | 46 | 16828 | 46 |
SH3KBP1,RGL1,CEBPB,CSF3R,FMNL1,TFEB,SRGN,CD68,MFSD1,FERMT3,ARAP1,BLNK,ARHGEF1,MYO1F,MLKL,SH2B3,FNIP1,FCHO2,DISC1,RHBDF1,DAB2,DIAPH2,MICAL2,ABCC5,ETS1,DOCK4,AOX1,CD276,ATP8A1,ETV6,MAN1A1,MARK4,STAB1,SGMS1,CD53,ARAP3,RBM47,ELF4,RXRA,MEF2C,GLDC,HCK,PLEK,FLRT2,ABCA1,BAZ2B |
2.700e-03 | -5.91 | CIN85_SH3_1 | interpro domains | IPR035770 | 1 | 1 | 18521 | 50 |
SH3KBP1 |
2.700e-03 | -5.91 | GDC-P_C | interpro domains | IPR049316 | 1 | 1 | 18521 | 50 |
GLDC |
2.700e-03 | -5.91 | Serglycin | interpro domains | IPR007455 | 1 | 1 | 18521 | 50 |
SRGN |
2.700e-03 | -5.91 | SAM_PNT-ETS-1 | interpro domains | IPR041886 | 1 | 1 | 18521 | 50 |
ETS1 |
2.700e-03 | -5.91 | GDC-P_N | interpro domains | IPR049315 | 1 | 1 | 18521 | 50 |
GLDC |
2.700e-03 | -5.91 | CD276_IgV | interpro domains | IPR047318 | 1 | 1 | 18521 | 50 |
CD276 |
2.700e-03 | -5.91 | ProQ/FinO | interpro domains | IPR016103 | 1 | 1 | 18521 | 50 |
MICAL2 |
2.700e-03 | -5.91 | RBM47_RRM1 | interpro domains | IPR047044 | 1 | 1 | 18521 | 50 |
RBM47 |
2.700e-03 | -5.91 | p115RhoGEF_RGS | interpro domains | IPR037887 | 1 | 1 | 18521 | 50 |
ARHGEF1 |
2.700e-03 | -5.91 | ArAA_b-elim_lyase/Thr_aldolase | interpro domains | IPR001597 | 1 | 1 | 18521 | 50 |
GLDC |
2.700e-03 | -5.91 | CIN85_SH3_3 | interpro domains | IPR035772 | 1 | 1 | 18521 | 50 |
SH3KBP1 |
2.700e-03 | -5.91 | CIN85_SH3_2 | interpro domains | IPR035771 | 1 | 1 | 18521 | 50 |
SH3KBP1 |
2.700e-03 | -5.91 | RBM47_RRM2 | interpro domains | IPR034440 | 1 | 1 | 18521 | 50 |
RBM47 |
2.700e-03 | -5.91 | GDC_P | interpro domains | IPR020581 | 1 | 1 | 18521 | 50 |
GLDC |
2.700e-03 | -5.91 | DISC1 | interpro domains | IPR026081 | 1 | 1 | 18521 | 50 |
DISC1 |
2.700e-03 | -5.91 | HCK_SH2 | interpro domains | IPR035851 | 1 | 1 | 18521 | 50 |
HCK |
2.700e-03 | -5.91 | RGL1_RA | interpro domains | IPR030748 | 1 | 1 | 18521 | 50 |
RGL1 |
2.700e-03 | -5.91 | DOCK4_SH3 | interpro domains | IPR035769 | 1 | 1 | 18521 | 50 |
DOCK4 |
2.700e-03 | -5.91 | DHR2_DOCK4 | interpro domains | IPR037014 | 1 | 1 | 18521 | 50 |
DOCK4 |
2.700e-03 | -5.91 | Aldehyde_oxidase | interpro domains | IPR014313 | 1 | 1 | 18521 | 50 |
AOX1 |
2.700e-03 | -5.91 | PLEK_DEP | interpro domains | IPR037371 | 1 | 1 | 18521 | 50 |
PLEK |
2.700e-03 | -5.91 | FCHo2_F-BAR | interpro domains | IPR030122 | 1 | 1 | 18521 | 50 |
FCHO2 |
2.700e-03 | -5.91 | RBM47_RRM3 | interpro domains | IPR034445 | 1 | 1 | 18521 | 50 |
RBM47 |
2.700e-03 | -5.91 | GcvP | interpro domains | IPR003437 | 1 | 1 | 18521 | 50 |
GLDC |
2.700e-03 | -5.91 | bHLHzip_TFEB | interpro domains | IPR024098 | 1 | 1 | 18521 | 50 |
TFEB |
2.700e-03 | -5.91 | SH2B3_SH2 | interpro domains | IPR035059 | 1 | 1 | 18521 | 50 |
SH2B3 |
2.700e-03 | -5.91 | STARD11_START | interpro domains | IPR041952 | 1 | 1 | 18521 | 50 |
CERT1 |
2.747e-03 | -5.90 | protease localization to T cell secretory granule | biological process | GO:0033375 | 1 | 1 | 18204 | 50 |
SRGN |
2.747e-03 | -5.90 | sinoatrial valve morphogenesis | biological process | GO:0003185 | 1 | 1 | 18204 | 50 |
MEF2C |
2.747e-03 | -5.90 | intermembrane sphingolipid transfer | biological process | GO:0120012 | 1 | 1 | 18204 | 50 |
CERT1 |
2.747e-03 | -5.90 | regulation of cell diameter | biological process | GO:0060305 | 1 | 1 | 18204 | 50 |
PLEK |
2.747e-03 | -5.90 | protein localization to mast cell secretory granule | biological process | GO:0033367 | 1 | 1 | 18204 | 50 |
SRGN |
2.747e-03 | -5.90 | maintenance of protease location in mast cell secretory granule | biological process | GO:0033373 | 1 | 1 | 18204 | 50 |
SRGN |
2.747e-03 | -5.90 | protein secretion by platelet | biological process | GO:0070560 | 1 | 1 | 18204 | 50 |
PLEK |
2.747e-03 | -5.90 | regulation of inositol-polyphosphate 5-phosphatase activity | biological process | GO:0010924 | 1 | 1 | 18204 | 50 |
PLEK |
2.747e-03 | -5.90 | cGMP transport | biological process | GO:0070731 | 1 | 1 | 18204 | 50 |
ABCC5 |
2.747e-03 | -5.90 | protease localization to mast cell secretory granule | biological process | GO:0033368 | 1 | 1 | 18204 | 50 |
SRGN |
2.747e-03 | -5.90 | leading edge cell differentiation | biological process | GO:0035026 | 1 | 1 | 18204 | 50 |
DAB2 |
2.747e-03 | -5.90 | granzyme B localization to T cell secretory granule | biological process | GO:0033380 | 1 | 1 | 18204 | 50 |
SRGN |
2.747e-03 | -5.90 | maintenance of granzyme B location in T cell secretory granule | biological process | GO:0033382 | 1 | 1 | 18204 | 50 |
SRGN |
2.747e-03 | -5.90 | protein localization to T cell secretory granule | biological process | GO:0033374 | 1 | 1 | 18204 | 50 |
SRGN |
2.747e-03 | -5.90 | response to lipoic acid | biological process | GO:1903442 | 1 | 1 | 18204 | 50 |
GLDC |
2.747e-03 | -5.90 | phospholipase C-inhibiting G protein-coupled receptor signaling pathway | biological process | GO:0030845 | 1 | 1 | 18204 | 50 |
PLEK |
2.747e-03 | -5.90 | T cell secretory granule organization | biological process | GO:0033371 | 1 | 1 | 18204 | 50 |
SRGN |
2.747e-03 | -5.90 | maintenance of protease location in T cell secretory granule | biological process | GO:0033379 | 1 | 1 | 18204 | 50 |
SRGN |
2.747e-03 | -5.90 | response to methylamine | biological process | GO:0036255 | 1 | 1 | 18204 | 50 |
GLDC |
2.747e-03 | -5.90 | maintenance of protein location in mast cell secretory granule | biological process | GO:0033370 | 1 | 1 | 18204 | 50 |
SRGN |
2.747e-03 | -5.90 | positive regulation of inositol-polyphosphate 5-phosphatase activity | biological process | GO:0010925 | 1 | 1 | 18204 | 50 |
PLEK |
2.747e-03 | -5.90 | maintenance of protein location in T cell secretory granule | biological process | GO:0033377 | 1 | 1 | 18204 | 50 |
SRGN |
2.754e-03 | -5.89 | GcvP2_C | pfam domains | PF21478 | 1 | 1 | 17795 | 49 |
GLDC |
2.754e-03 | -5.89 | GDC-P | pfam domains | PF02347 | 1 | 1 | 17795 | 49 |
GLDC |
2.754e-03 | -5.89 | Serglycin | pfam domains | PF04360 | 1 | 1 | 17795 | 49 |
SRGN |
2.754e-03 | -5.89 | Beta_elim_lyase | pfam domains | PF01212 | 1 | 1 | 17795 | 49 |
GLDC |
2.763e-03 | -5.89 | glycine dehydrogenase (decarboxylating) activity | molecular function | GO:0004375 | 1 | 1 | 18094 | 50 |
GLDC |
2.763e-03 | -5.89 | granulocyte colony-stimulating factor binding | molecular function | GO:0051916 | 1 | 1 | 18094 | 50 |
CSF3R |
2.763e-03 | -5.89 | pyridoxal binding | molecular function | GO:0070280 | 1 | 1 | 18094 | 50 |
GLDC |
2.763e-03 | -5.89 | oxidoreductase activity, acting on the CH-NH2 group of donors, disulfide as acceptor | molecular function | GO:0016642 | 1 | 1 | 18094 | 50 |
GLDC |
2.777e-03 | -5.89 | cell motility | biological process | GO:0048870 | 1101 | 9 | 18204 | 50 |
DISC1,SH3KBP1,FMNL1,DOCK4,CSF3R,HCK,RHBDF1,ETS1,MEF2C |
2.795e-03 | -5.88 | response to molecule of bacterial origin | biological process | GO:0002237 | 354 | 5 | 18204 | 50 |
ABCA1,HCK,CEBPB,MEF2C,CD68 |
2.812e-03 | -5.87 | regulation of anatomical structure morphogenesis | biological process | GO:0022603 | 894 | 8 | 18204 | 50 |
ETS1,MEF2C,DISC1,SH3KBP1,FMNL1,STAB1,ARAP1,HCK |
2.870e-03 | -5.85 | regulation of signal transduction | biological process | GO:0009966 | 3114 | 17 | 18204 | 50 |
ADGRG3,SGMS1,DISC1,ARAP1,DAB2,RHBDF1,ARHGEF1,MEF2C,CTSV,PLEK,ABCA1,ARHGAP45,FNIP1,SH2B3,RXRA,MARK4,RBM47 |
2.870e-03 | -5.85 | PSRC1 (proline and serine rich coiled-coil 1) | protein interactions | 84722 | 31 | 2 | 19454 | 50 |
SRGN,SH3KBP1 |
2.897e-03 | -5.84 | regulation of myeloid cell differentiation | biological process | GO:0045637 | 216 | 4 | 18204 | 50 |
CSF3R,CEBPB,ETS1,MEF2C |
2.897e-03 | -5.84 | phosphatidylinositol-3,4-bisphosphate binding | molecular function | GO:0043325 | 29 | 2 | 18094 | 50 |
ARAP3,PLEK |
2.939e-03 | -5.83 | ETS_DOMAIN_1 | prosite domains | PS00345 | 22 | 2 | 12186 | 45 |
ETS1,ELF4 |
2.991e-03 | -5.81 | GGA3 (golgi associated, gamma adaptin ear containing, ARF binding protein 3) | protein interactions | 23163 | 112 | 3 | 19454 | 50 |
ETS1,STAB1,ARAP3 |
3.003e-03 | -5.81 | Golgi apparatus | cellular component | GO:0005794 | 1645 | 11 | 19108 | 50 |
ATP8A1,CERT1,MAN1A1,ABCC5,DOCK4,ABCA1,HCK,SGMS1,ARAP1,SRGN,RHBDF1 |
3.005e-03 | -5.81 | SH3_domain | interpro domains | IPR001452 | 222 | 4 | 18521 | 50 |
DOCK4,MYO1F,HCK,SH3KBP1 |
3.102e-03 | -5.78 | large_cell | COSMIC cancer mutations | large_cell | 14845 | 46 | 16828 | 46 |
SGMS1,MARK4,MAN1A1,STAB1,ARAP1,ATP8A1,MFSD1,CD276,ETV6,FERMT3,CSF3R,ETS1,CEBPB,DOCK4,FMNL1,SRGN,CD68,AOX1,TFEB,SH3KBP1,MICAL2,ABCC5,DAB2,DIAPH2,RGL1,ABCA1,HCK,FLRT2,PLEK,BAZ2B,FCHO2,DISC1,FNIP1,GLDC,MEF2C,RHBDF1,ARAP3,MLKL,ELF4,RXRA,RBM47,SH2B3,ARHGEF1,CD53,BLNK,MYO1F |
3.145e-03 | -5.76 | cellular response to molecule of bacterial origin | biological process | GO:0071219 | 221 | 4 | 18204 | 50 |
ABCA1,CD68,MEF2C,HCK |
3.159e-03 | -5.76 | Regulation of RhoA activity | Pathway Interaction DB | rhoa_reg_pathway | 46 | 3 | 2226 | 15 |
ARHGEF1,ARAP3,ARAP1 |
3.179e-03 | -5.75 | SH2 | interpro domains | IPR000980 | 109 | 3 | 18521 | 50 |
HCK,SH2B3,BLNK |
3.222e-03 | -5.74 | PPARD (peroxisome proliferator activated receptor delta) | protein interactions | 5467 | 115 | 3 | 19454 | 50 |
ARAP3,RXRA,ARHGEF1 |
3.249e-03 | -5.73 | RARB (retinoic acid receptor beta) | protein interactions | 5915 | 33 | 2 | 19454 | 50 |
RXRA,CEBPB |
3.261e-03 | -5.73 | regulation of immune system process | biological process | GO:0002682 | 1584 | 11 | 18204 | 50 |
MEF2C,CD68,CD276,MARK4,ETS1,RBM47,BLNK,HCK,CEBPB,CSF3R,SH3KBP1 |
3.274e-03 | -5.72 | FCH | smart domains | SM00055 | 22 | 2 | 9717 | 38 |
ARHGAP45,FCHO2 |
3.279e-03 | -5.72 | RHOD (ras homolog family member D) | protein interactions | 29984 | 570 | 6 | 19454 | 50 |
FMNL1,FCHO2,DAB2,DIAPH2,ABCC5,FLRT2 |
3.301e-03 | -5.71 | right_lower_lobe | COSMIC cancer mutations | right_lower_lobe | 5692 | 25 | 16828 | 46 |
MYO1F,ARAP3,RHBDF1,DISC1,FCHO2,GLDC,FNIP1,BAZ2B,ABCA1,PLEK,FLRT2,MICAL2,RGL1,DIAPH2,DAB2,SH3KBP1,AOX1,TFEB,FMNL1,DOCK4,ETV6,FERMT3,MFSD1,CD276,MARK4 |
3.301e-03 | -5.71 | lung-right_lower_lobe-carcinoma-adenocarcinoma | COSMIC cancer mutations | lung-right_lower_lobe-carcinoma-adenocarcinoma | 5692 | 25 | 16828 | 46 |
MICAL2,RGL1,DIAPH2,DAB2,SH3KBP1,AOX1,TFEB,DOCK4,FMNL1,ETV6,FERMT3,CD276,MFSD1,MARK4,MYO1F,ARAP3,RHBDF1,DISC1,FCHO2,GLDC,FNIP1,BAZ2B,ABCA1,PLEK,FLRT2 |
3.306e-03 | -5.71 | lipoprotein particle binding | molecular function | GO:0071813 | 31 | 2 | 18094 | 50 |
STAB1,ABCA1 |
3.306e-03 | -5.71 | protein-lipid complex binding | molecular function | GO:0071814 | 31 | 2 | 18094 | 50 |
STAB1,ABCA1 |
3.375e-03 | -5.69 | cell migration | biological process | GO:0016477 | 921 | 8 | 18204 | 50 |
RHBDF1,MEF2C,FMNL1,DISC1,SH3KBP1,HCK,CSF3R,DOCK4 |
3.387e-03 | -5.69 | urinary_tract-bladder-carcinoma-transitional_cell_carcinoma | COSMIC cancer mutations | urinary_tract-bladder-carcinoma-transitional_cell_carcinoma | 6040 | 26 | 16828 | 46 |
BLNK,ARHGEF1,MYO1F,ARAP3,RBM47,RXRA,ELF4,GLDC,FLRT2,HCK,ABCA1,BAZ2B,SH3KBP1,DAB2,DIAPH2,ABCC5,FMNL1,CSF3R,AOX1,CD276,ATP8A1,FERMT3,STAB1,ARAP1,MARK4,SGMS1 |
3.405e-03 | -5.68 | transitional_cell_carcinoma | COSMIC cancer mutations | transitional_cell_carcinoma | 6042 | 26 | 16828 | 46 |
SH3KBP1,ABCC5,DAB2,DIAPH2,CSF3R,FMNL1,AOX1,ATP8A1,CD276,FERMT3,SGMS1,MARK4,ARAP1,STAB1,ARHGEF1,BLNK,MYO1F,ARAP3,ELF4,RXRA,RBM47,GLDC,ABCA1,HCK,FLRT2,BAZ2B |
3.426e-03 | -5.68 | skin-trunk-malignant_melanoma | COSMIC cancer mutations | skin-trunk-malignant_melanoma | 2647 | 15 | 16828 | 46 |
STAB1,MAN1A1,FLRT2,HCK,ABCA1,GLDC,ATP8A1,AOX1,SRGN,FMNL1,MYO1F,DAB2,ABCC5,MICAL2,SH3KBP1 |
3.442e-03 | -5.67 | Arf GTPase activating protein | gene3d domains | 1.10.220.150 | 27 | 2 | 14470 | 47 |
ARAP3,ARAP1 |
3.446e-03 | -5.67 | ELMO1 (engulfment and cell motility 1) | protein interactions | 9844 | 34 | 2 | 19454 | 50 |
DOCK4,HCK |
3.498e-03 | -5.66 | cell population proliferation | biological process | GO:0008283 | 726 | 7 | 18204 | 50 |
MEF2C,CERT1,RHBDF1,ELF4,CEBPB,ETV6,DISC1 |
3.516e-03 | -5.65 | immune response-activating cell surface receptor signaling pathway | biological process | GO:0002429 | 228 | 4 | 18204 | 50 |
CD276,BLNK,HCK,MEF2C |
3.519e-03 | -5.65 | SH2_dom_sf | interpro domains | IPR036860 | 113 | 3 | 18521 | 50 |
BLNK,SH2B3,HCK |
3.519e-03 | -5.65 | WH-like_DNA-bd_sf | interpro domains | IPR036388 | 232 | 4 | 18521 | 50 |
ETS1,ELF4,ETV6,PLEK |
3.520e-03 | -5.65 | macromolecule transmembrane transporter activity | molecular function | GO:0022884 | 32 | 2 | 18094 | 50 |
ABCA1,ABCC5 |
3.538e-03 | -5.64 | myelodysplastic-myeloproliferative_neoplasm-unclassifiable | COSMIC cancer mutations | myelodysplastic-myeloproliferative_neoplasm-unclassifiable | 112 | 3 | 16828 | 46 |
SH2B3,ETV6,CSF3R |
3.538e-03 | -5.64 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-myelodysplastic-myeloproliferative_neoplasm-unclassifiable | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-myelodysplastic-myeloproliferative_neoplasm-unclassifiable | 112 | 3 | 16828 | 46 |
CSF3R,ETV6,SH2B3 |
3.629e-03 | -5.62 | TOP3B (DNA topoisomerase III beta) | protein interactions | 8940 | 1465 | 10 | 19454 | 50 |
SH2B3,RBM47,RHBDF1,ARAP3,TFEB,MARK4,CEBPB,ARAP1,DIAPH2,CD276 |
3.668e-03 | -5.61 | CAPZA2 (capping actin protein of muscle Z-line subunit alpha 2) | protein interactions | 830 | 403 | 5 | 19454 | 50 |
ARAP1,BLNK,FCHO2,DAB2,SH3KBP1 |
3.682e-03 | -5.60 | RXR and RAR heterodimerization with other nuclear receptor | Pathway Interaction DB | rxr_vdr_pathway | 14 | 2 | 2226 | 15 |
RXRA,ABCA1 |
3.751e-03 | -5.59 | cellular component organization | biological process | GO:0016043 | 5636 | 25 | 18204 | 50 |
TFEB,ARAP1,FCHO2,SRGN,FERMT3,FMNL1,MYO1F,ATP8A1,HCK,ARAP3,ABCA1,SH3KBP1,CERT1,MARK4,DAB2,FLRT2,DISC1,CTSV,MICAL2,BAZ2B,PLEK,DIAPH2,ETV6,ETS1,MLKL |
3.767e-03 | -5.58 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_B_cell_leukaemia | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_B_cell_leukaemia | 3828 | 19 | 16828 | 46 |
ETV6,ATP8A1,MEF2C,GLDC,MAN1A1,ARAP1,STAB1,ABCA1,FLRT2,MICAL2,ABCC5,DAB2,DIAPH2,SH3KBP1,BLNK,SH2B3,CSF3R,FMNL1,MLKL |
3.767e-03 | -5.58 | acute_lymphoblastic_B_cell_leukaemia | COSMIC cancer mutations | acute_lymphoblastic_B_cell_leukaemia | 3828 | 19 | 16828 | 46 |
MAN1A1,ARAP1,STAB1,ABCA1,FLRT2,ETV6,ATP8A1,GLDC,MEF2C,SH2B3,CSF3R,FMNL1,MLKL,MICAL2,ABCC5,DIAPH2,DAB2,SH3KBP1,BLNK |
3.790e-03 | -5.58 | F_BAR | prosite domains | PS51741 | 25 | 2 | 12186 | 45 |
FCHO2,ARHGAP45 |
3.819e-03 | -5.57 | actin filament | cellular component | GO:0005884 | 120 | 3 | 19108 | 50 |
HCK,DIAPH2,MICAL2 |
3.825e-03 | -5.57 | SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4) | protein interactions | 6597 | 407 | 5 | 19454 | 50 |
CEBPB,ETS1,MARK4,RXRA,GLDC |
3.836e-03 | -5.56 | RAC1 (Rac family small GTPase 1) | protein interactions | 5879 | 1005 | 8 | 19454 | 50 |
DIAPH2,ARAP1,DOCK4,FLRT2,FMNL1,DAB2,FCHO2,ABCC5 |
3.905e-03 | -5.55 | LIMA1 (LIM domain and actin binding 1) | protein interactions | 51474 | 409 | 5 | 19454 | 50 |
FCHO2,DAB2,DISC1,FMNL1,GLDC |
3.911e-03 | -5.54 | ProQ | smart domains | SM00945 | 1 | 1 | 9717 | 38 |
MICAL2 |
4.068e-03 | -5.50 | B Cell Receptor Signaling Pathway | WikiPathways | WP23 | 98 | 3 | 5310 | 18 |
BLNK,ETS1,MEF2C |
4.077e-03 | -5.50 | intracellular organelle | cellular component | GO:0043229 | 13594 | 44 | 19108 | 50 |
MYO1F,CD68,RXRA,ETS1,CSF3R,MARK4,MICAL2,ARHGAP45,FLRT2,ADGRG3,DOCK4,STAB1,MEF2C,FNIP1,RBM47,FMNL1,DAB2,GLDC,BLNK,TFEB,DISC1,FERMT3,ABCA1,HCK,CD53,ARAP1,SH3KBP1,SGMS1,MFSD1,ETV6,ATP8A1,DIAPH2,CEBPB,CTSV,BAZ2B,ARAP3,ABCC5,MAN1A1,ELF4,FCHO2,CERT1,RHBDF1,SRGN,MLKL |
4.079e-03 | -5.50 | regulation of biological quality | biological process | GO:0065008 | 2936 | 16 | 18204 | 50 |
HCK,ABCA1,SH3KBP1,RBM47,SH2B3,ARAP1,DAB2,DOCK4,FERMT3,FMNL1,FLRT2,MFSD1,DISC1,MEF2C,ATP8A1,PLEK |
4.152e-03 | -5.48 | response to fluid shear stress | biological process | GO:0034405 | 35 | 2 | 18204 | 50 |
ABCA1,MEF2C |
4.155e-03 | -5.48 | biological regulation | biological process | GO:0065007 | 12501 | 43 | 18204 | 50 |
SGMS1,FLRT2,DISC1,DAB2,ELF4,CTSV,BAZ2B,PLEK,MICAL2,ETV6,CEBPB,ARHGAP45,CD53,MLKL,RXRA,ETS1,RGL1,ADGRG3,FMNL1,SRGN,FERMT3,MFSD1,CD276,DOCK4,ARAP1,TFEB,RHBDF1,MEF2C,ARHGEF1,ATP8A1,CD68,ABCA1,SH3KBP1,HCK,ARAP3,CSF3R,STAB1,FNIP1,SH2B3,BLNK,MARK4,CERT1,RBM47 |
4.175e-03 | -5.48 | response to external stimulus | biological process | GO:0009605 | 1882 | 12 | 18204 | 50 |
MLKL,ABCA1,CEBPB,HCK,STAB1,CSF3R,MEF2C,CD68,FLRT2,DISC1,TFEB,DOCK4 |
4.200e-03 | -5.47 | nef (Nef) | protein interactions | 156110 | 802 | 7 | 19454 | 50 |
CD53,RXRA,SH3KBP1,DAB2,TFEB,HCK,ABCA1 |
4.209e-03 | -5.47 | cytoplasmic vesicle membrane | cellular component | GO:0030659 | 1230 | 9 | 19108 | 50 |
CSF3R,DAB2,CD68,ATP8A1,CD53,SH3KBP1,ADGRG3,ABCC5,STAB1 |
4.228e-03 | -5.47 | essential_thrombocythaemia | COSMIC cancer mutations | essential_thrombocythaemia | 393 | 5 | 16828 | 46 |
FLRT2,CSF3R,STAB1,SH2B3,RHBDF1 |
4.228e-03 | -5.47 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-essential_thrombocythaemia | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-essential_thrombocythaemia | 393 | 5 | 16828 | 46 |
RHBDF1,SH2B3,STAB1,CSF3R,FLRT2 |
4.233e-03 | -5.46 | large_intestine-caecum-carcinoma-adenocarcinoma | COSMIC cancer mutations | large_intestine-caecum-carcinoma-adenocarcinoma | 14236 | 45 | 16828 | 46 |
FNIP1,FCHO2,DISC1,RHBDF1,MLKL,SH2B3,ARHGEF1,MYO1F,ARAP1,MFSD1,FERMT3,CEBPB,CSF3R,FMNL1,TFEB,SRGN,CD68,SH3KBP1,RGL1,HCK,FLRT2,PLEK,ABCA1,BAZ2B,MEF2C,GLDC,ARAP3,RBM47,ELF4,RXRA,CD53,MAN1A1,MARK4,STAB1,SGMS1,CD276,ATP8A1,ETV6,ETS1,DOCK4,AOX1,DIAPH2,DAB2,MICAL2,ABCC5 |
4.290e-03 | -5.45 | BHLHE41 (basic helix-loop-helix family member e41) | protein interactions | 79365 | 38 | 2 | 19454 | 50 |
RXRA,CEBPB |
4.290e-03 | -5.45 | NT5C (5', 3'-nucleotidase, cytosolic) | protein interactions | 30833 | 38 | 2 | 19454 | 50 |
ARHGEF1,ARAP3 |
4.314e-03 | -5.45 | PLCG1 (phospholipase C gamma 1) | protein interactions | 5335 | 258 | 4 | 19454 | 50 |
SH2B3,DISC1,BLNK,HCK |
4.363e-03 | -5.43 | Signaling by Rho GTPases | REACTOME pathways | R-HSA-194315 | 426 | 6 | 10285 | 38 |
ARHGAP45,ARHGEF1,FMNL1,ARAP3,DIAPH2,ARAP1 |
4.378e-03 | -5.43 | regulation of biological process | biological process | GO:0050789 | 12079 | 42 | 18204 | 50 |
DAB2,DISC1,SGMS1,FLRT2,BAZ2B,PLEK,MICAL2,CTSV,ELF4,ARHGAP45,ETV6,CEBPB,ETS1,RXRA,CD53,MLKL,DOCK4,TFEB,ARAP1,CD276,RGL1,ADGRG3,FERMT3,SRGN,FMNL1,ATP8A1,CD68,ARHGEF1,MEF2C,RHBDF1,CSF3R,ARAP3,STAB1,HCK,SH3KBP1,ABCA1,RBM47,CERT1,MARK4,BLNK,SH2B3,FNIP1 |
4.380e-03 | -5.43 | caecum | COSMIC cancer mutations | caecum | 14248 | 45 | 16828 | 46 |
ETS1,DOCK4,AOX1,DAB2,DIAPH2,MICAL2,ABCC5,MAN1A1,MARK4,STAB1,SGMS1,CD276,ATP8A1,ETV6,ARAP3,RBM47,ELF4,RXRA,CD53,HCK,FLRT2,PLEK,ABCA1,BAZ2B,GLDC,MEF2C,CSF3R,CEBPB,FMNL1,TFEB,SRGN,CD68,SH3KBP1,RGL1,ARAP1,MFSD1,FERMT3,MLKL,SH2B3,ARHGEF1,MYO1F,FNIP1,FCHO2,DISC1,RHBDF1 |
4.388e-03 | -5.43 | TOR signaling | biological process | GO:0031929 | 36 | 2 | 18204 | 50 |
DISC1,FNIP1 |
4.388e-03 | -5.43 | positive regulation of cholesterol transport | biological process | GO:0032376 | 36 | 2 | 18204 | 50 |
ABCA1,RXRA |
4.388e-03 | -5.43 | positive regulation of sterol transport | biological process | GO:0032373 | 36 | 2 | 18204 | 50 |
ABCA1,RXRA |
4.413e-03 | -5.42 | ARFGAP | prosite domains | PS50115 | 27 | 2 | 12186 | 45 |
ARAP3,ARAP1 |
4.542e-03 | -5.39 | femur | COSMIC cancer mutations | femur | 1197 | 9 | 16828 | 46 |
CSF3R,ABCA1,STAB1,BAZ2B,RBM47,ELF4,GLDC,BLNK,DAB2 |
4.577e-03 | -5.39 | lung-carcinoma-small_cell_carcinoma | COSMIC cancer mutations | lung-carcinoma-small_cell_carcinoma | 9908 | 36 | 16828 | 46 |
TFEB,AOX1,FMNL1,DOCK4,CEBPB,ETS1,CSF3R,RGL1,DAB2,DIAPH2,MICAL2,SH3KBP1,ARAP1,STAB1,MARK4,MAN1A1,SGMS1,ETV6,CD276,MFSD1,RBM47,SH2B3,ELF4,MLKL,ARAP3,MYO1F,CD53,ARHGEF1,BAZ2B,FLRT2,HCK,ABCA1,GLDC,MEF2C,FNIP1,DISC1 |
4.605e-03 | -5.38 | regulation of cell morphogenesis | biological process | GO:0022604 | 246 | 4 | 18204 | 50 |
ARAP1,HCK,SH3KBP1,FMNL1 |
4.631e-03 | -5.38 | small_cell_carcinoma | COSMIC cancer mutations | small_cell_carcinoma | 9913 | 36 | 16828 | 46 |
DAB2,DIAPH2,RGL1,MICAL2,SH3KBP1,TFEB,AOX1,CSF3R,ETS1,CEBPB,FMNL1,DOCK4,ETV6,MFSD1,CD276,MARK4,MAN1A1,ARAP1,STAB1,SGMS1,MYO1F,CD53,ARHGEF1,SH2B3,RBM47,ELF4,MLKL,ARAP3,FNIP1,GLDC,MEF2C,DISC1,BAZ2B,HCK,FLRT2,ABCA1 |
4.631e-03 | -5.38 | cellular response to low-density lipoprotein particle stimulus | biological process | GO:0071404 | 37 | 2 | 18204 | 50 |
ABCA1,CD68 |
4.631e-03 | -5.38 | response to lipoprotein particle | biological process | GO:0055094 | 37 | 2 | 18204 | 50 |
ABCA1,CD68 |
4.672e-03 | -5.37 | cellular response to biotic stimulus | biological process | GO:0071216 | 247 | 4 | 18204 | 50 |
CD68,MEF2C,HCK,ABCA1 |
4.684e-03 | -5.36 | STAT3 (signal transducer and activator of transcription 3) | protein interactions | 6774 | 427 | 5 | 19454 | 50 |
HCK,SH3KBP1,CEBPB,RXRA,CSF3R |
4.703e-03 | -5.36 | vesicle membrane | cellular component | GO:0012506 | 1251 | 9 | 19108 | 50 |
DAB2,CSF3R,STAB1,ABCC5,ADGRG3,SH3KBP1,CD53,ATP8A1,CD68 |
4.742e-03 | -5.35 | TXNDC12 (thioredoxin domain containing 12) | protein interactions | 51060 | 132 | 3 | 19454 | 50 |
ARHGEF1,HCK,DIAPH2 |
4.788e-03 | -5.34 | regulation of ossification | biological process | GO:0030278 | 124 | 3 | 18204 | 50 |
SRGN,RXRA,MEF2C |
4.915e-03 | -5.32 | ArfGap | smart domains | SM00105 | 27 | 2 | 9717 | 38 |
ARAP1,ARAP3 |
4.979e-03 | -5.30 | protein tyrosine kinase binding | molecular function | GO:1990782 | 125 | 3 | 18094 | 50 |
DOCK4,SH2B3,BLNK |
4.980e-03 | -5.30 | RASSF7 (Ras association domain family member 7) | protein interactions | 8045 | 41 | 2 | 19454 | 50 |
DISC1,CEBPB |
4.994e-03 | -5.30 | pancreas-carcinoid-endocrine_tumour | COSMIC cancer mutations | pancreas-carcinoid-endocrine_tumour | 7250 | 29 | 16828 | 46 |
SH3KBP1,ABCC5,MICAL2,RGL1,DIAPH2,FMNL1,CSF3R,AOX1,SRGN,ATP8A1,CD276,ETV6,SGMS1,STAB1,MAN1A1,MARK4,ARHGEF1,BLNK,MYO1F,MLKL,RXRA,ELF4,SH2B3,FCHO2,GLDC,FNIP1,ABCA1,PLEK,BAZ2B |
5.094e-03 | -5.28 | SRC (SRC proto-oncogene, non-receptor tyrosine kinase) | protein interactions | 6714 | 624 | 6 | 19454 | 50 |
ETS1,RXRA,CTSV,DAB2,HCK,SH3KBP1 |
5.127e-03 | -5.27 | RHOB (ras homolog family member B) | protein interactions | 388 | 832 | 7 | 19454 | 50 |
FLRT2,DIAPH2,ABCC5,ARHGEF1,DAB2,FCHO2,FMNL1 |
5.134e-03 | -5.27 | Atf2 (activating transcription factor 2) | protein interactions | 81647 | 2 | 1 | 19454 | 50 |
CEBPB |
5.134e-03 | -5.27 | Cbl (Cbl proto-oncogene) | protein interactions | 500985 | 2 | 1 | 19454 | 50 |
SH3KBP1 |
5.134e-03 | -5.27 | Micall1 (microtubule associated monooxygenase, calponin and LIM domain containing -like 1) | protein interactions | 27008 | 2 | 1 | 19454 | 50 |
SH3KBP1 |
5.134e-03 | -5.27 | Idh3b (isocitrate dehydrogenase 3 (NAD+) beta) | protein interactions | 170718 | 2 | 1 | 19454 | 50 |
SH3KBP1 |
5.134e-03 | -5.27 | Ap2a1 (adaptor-related protein complex 2, alpha 1 subunit) | protein interactions | 11771 | 2 | 1 | 19454 | 50 |
SH3KBP1 |
5.134e-03 | -5.27 | Flcn (folliculin) | protein interactions | 303185 | 2 | 1 | 19454 | 50 |
FNIP1 |
5.134e-03 | -5.27 | Sh3kbp1 (SH3-domain kinase binding protein 1) | protein interactions | 58194 | 2 | 1 | 19454 | 50 |
SH3KBP1 |
5.134e-03 | -5.27 | Gcdh (glutaryl-Coenzyme A dehydrogenase) | protein interactions | 270076 | 2 | 1 | 19454 | 50 |
SH3KBP1 |
5.134e-03 | -5.27 | Timm50 (translocase of inner mitochondrial membrane 50) | protein interactions | 66525 | 2 | 1 | 19454 | 50 |
SH3KBP1 |
5.134e-03 | -5.27 | Wasl (WASP like actin nucleation promoting factor) | protein interactions | 73178 | 2 | 1 | 19454 | 50 |
SH3KBP1 |
5.134e-03 | -5.27 | Arhgap17 (Rho GTPase activating protein 17) | protein interactions | 70497 | 2 | 1 | 19454 | 50 |
SH3KBP1 |
5.134e-03 | -5.27 | Dbt (dihydrolipoamide branched chain transacylase E2) | protein interactions | 13171 | 2 | 1 | 19454 | 50 |
SH3KBP1 |
5.153e-03 | -5.27 | EMSY (EMSY transcriptional repressor, BRCA2 interacting) | protein interactions | 56946 | 136 | 3 | 19454 | 50 |
ETS1,ELF4,DISC1 |
5.227e-03 | -5.25 | C/EBP complex | cellular component | GO:1990647 | 2 | 1 | 19108 | 50 |
CEBPB |
5.227e-03 | -5.25 | glycine cleavage complex | cellular component | GO:0005960 | 2 | 1 | 19108 | 50 |
GLDC |
5.319e-03 | -5.24 | soft_tissue-striated_muscle-rhabdomyosarcoma | COSMIC cancer mutations | soft_tissue-striated_muscle-rhabdomyosarcoma | 594 | 6 | 16828 | 46 |
DOCK4,FNIP1,ABCC5,RGL1,DIAPH2,DAB2 |
5.346e-03 | -5.23 | kinase binding | molecular function | GO:0019900 | 780 | 7 | 18094 | 50 |
MLKL,PLEK,CEBPB,DOCK4,MICAL2,SH2B3,BLNK |
5.392e-03 | -5.22 | Ald_Oxase/xanthine_DH-like | interpro domains | IPR016208 | 2 | 1 | 18521 | 50 |
AOX1 |
5.392e-03 | -5.22 | DAB1/2_SBM | interpro domains | IPR048559 | 2 | 1 | 18521 | 50 |
DAB2 |
5.392e-03 | -5.22 | FNIP_N_dom | interpro domains | IPR028084 | 2 | 1 | 18521 | 50 |
FNIP1 |
5.392e-03 | -5.22 | Mopterin_DH_FAD-bd | interpro domains | IPR002346 | 2 | 1 | 18521 | 50 |
AOX1 |
5.392e-03 | -5.22 | Ald_Oxase/Xan_DH_a/b_sf | interpro domains | IPR036856 | 2 | 1 | 18521 | 50 |
AOX1 |
5.392e-03 | -5.22 | DENN_FNIP1/2 | interpro domains | IPR037545 | 2 | 1 | 18521 | 50 |
FNIP1 |
5.392e-03 | -5.22 | 2Fe-2S-bd | interpro domains | IPR002888 | 2 | 1 | 18521 | 50 |
AOX1 |
5.392e-03 | -5.22 | Nuc_recep-AF1 | interpro domains | IPR021780 | 2 | 1 | 18521 | 50 |
RXRA |
5.392e-03 | -5.22 | Dab_PTB | interpro domains | IPR048561 | 2 | 1 | 18521 | 50 |
DAB2 |
5.392e-03 | -5.22 | Ie/If_SH3 | interpro domains | IPR035507 | 2 | 1 | 18521 | 50 |
MYO1F |
5.392e-03 | -5.22 | Ets1_N_flank | interpro domains | IPR045688 | 2 | 1 | 18521 | 50 |
ETS1 |
5.392e-03 | -5.22 | Transform_prot_C-ets | interpro domains | IPR016311 | 2 | 1 | 18521 | 50 |
ETS1 |
5.392e-03 | -5.22 | FNIP_fam | interpro domains | IPR026156 | 2 | 1 | 18521 | 50 |
FNIP1 |
5.392e-03 | -5.22 | BAZ2A/B_Bromo | interpro domains | IPR037374 | 2 | 1 | 18521 | 50 |
BAZ2B |
5.392e-03 | -5.22 | CO_DH_flav_C | interpro domains | IPR005107 | 2 | 1 | 18521 | 50 |
AOX1 |
5.392e-03 | -5.22 | C2_Dock-B | interpro domains | IPR037811 | 2 | 1 | 18521 | 50 |
DOCK4 |
5.392e-03 | -5.22 | CO_DH_flav_C_dom_sf | interpro domains | IPR036683 | 2 | 1 | 18521 | 50 |
AOX1 |
5.392e-03 | -5.22 | FNIP_mid_dom | interpro domains | IPR028085 | 2 | 1 | 18521 | 50 |
FNIP1 |
5.392e-03 | -5.22 | AldOxase/xan_DH_MoCoBD1 | interpro domains | IPR008274 | 2 | 1 | 18521 | 50 |
AOX1 |
5.392e-03 | -5.22 | Ald_Oxase/Xan_DH_a/b | interpro domains | IPR000674 | 2 | 1 | 18521 | 50 |
AOX1 |
5.392e-03 | -5.22 | iRhom1_2_N | interpro domains | IPR022241 | 2 | 1 | 18521 | 50 |
RHBDF1 |
5.392e-03 | -5.22 | 2Fe-2S-bd_dom_sf | interpro domains | IPR036884 | 2 | 1 | 18521 | 50 |
AOX1 |
5.392e-03 | -5.22 | Pleckstrin | interpro domains | IPR037370 | 2 | 1 | 18521 | 50 |
PLEK |
5.392e-03 | -5.22 | AldOxase/xan_DH_Mopterin-bd_sf | interpro domains | IPR037165 | 2 | 1 | 18521 | 50 |
AOX1 |
5.392e-03 | -5.22 | AldOxase/xan_DH_MoCoBD2 | interpro domains | IPR046867 | 2 | 1 | 18521 | 50 |
AOX1 |
5.392e-03 | -5.22 | FNIP_C_dom | interpro domains | IPR028086 | 2 | 1 | 18521 | 50 |
FNIP1 |
5.395e-03 | -5.22 | cellular response to lipoprotein particle stimulus | biological process | GO:0071402 | 40 | 2 | 18204 | 50 |
ABCA1,CD68 |
5.419e-03 | -5.22 | upper_aerodigestive_tract | COSMIC cancer mutations | upper_aerodigestive_tract | 13181 | 43 | 16828 | 46 |
FNIP1,DISC1,FCHO2,RHBDF1,MLKL,SH2B3,BLNK,ARHGEF1,MYO1F,ARAP1,MFSD1,FERMT3,FMNL1,CEBPB,CSF3R,TFEB,SRGN,SH3KBP1,RGL1,FLRT2,PLEK,HCK,ABCA1,BAZ2B,GLDC,MEF2C,ARAP3,RBM47,RXRA,ELF4,STAB1,MAN1A1,MARK4,SGMS1,ATP8A1,ETV6,DOCK4,ETS1,AOX1,DIAPH2,DAB2,ABCC5,MICAL2 |
5.437e-03 | -5.21 | SH3DOMAIN | prints domains | PR00452 | 83 | 3 | 5227 | 23 |
HCK,SH3KBP1,MYO1F |
5.459e-03 | -5.21 | phosphatidylinositol-3,4,5-trisphosphate binding | molecular function | GO:0005547 | 40 | 2 | 18094 | 50 |
ARAP3,ARAP1 |
5.459e-03 | -5.21 | FAD binding | molecular function | GO:0071949 | 40 | 2 | 18094 | 50 |
AOX1,MICAL2 |
5.461e-03 | -5.21 | B cell differentiation | biological process | GO:0030183 | 130 | 3 | 18204 | 50 |
ADGRG3,FNIP1,BLNK |
5.471e-03 | -5.21 | RBBP5 (RB binding protein 5, histone lysine methyltransferase complex subunit) | protein interactions | 5929 | 276 | 4 | 19454 | 50 |
FERMT3,BAZ2B,DISC1,ELF4 |
5.486e-03 | -5.21 | positive regulation of high-density lipoprotein particle assembly | biological process | GO:0090108 | 2 | 1 | 18204 | 50 |
ABCA1 |
5.486e-03 | -5.21 | nephron tubule epithelial cell differentiation | biological process | GO:0072160 | 2 | 1 | 18204 | 50 |
MEF2C |
5.486e-03 | -5.21 | negative regulation of inositol phosphate biosynthetic process | biological process | GO:0010920 | 2 | 1 | 18204 | 50 |
PLEK |
5.486e-03 | -5.21 | negative regulation of Kit signaling pathway | biological process | GO:1900235 | 2 | 1 | 18204 | 50 |
SH2B3 |
5.486e-03 | -5.21 | positive regulation of alkaline phosphatase activity | biological process | GO:0010694 | 2 | 1 | 18204 | 50 |
MEF2C |
5.486e-03 | -5.21 | NK T cell activation | biological process | GO:0051132 | 2 | 1 | 18204 | 50 |
ELF4 |
5.486e-03 | -5.21 | cAMP transport | biological process | GO:0070730 | 2 | 1 | 18204 | 50 |
ABCC5 |
5.486e-03 | -5.21 | cellular response to trichostatin A | biological process | GO:0035984 | 2 | 1 | 18204 | 50 |
MEF2C |
5.486e-03 | -5.21 | sulfur oxidation | biological process | GO:0019417 | 2 | 1 | 18204 | 50 |
MICAL2 |
5.486e-03 | -5.21 | NMDA selective glutamate receptor signaling pathway | biological process | GO:0098989 | 2 | 1 | 18204 | 50 |
MEF2C |
5.486e-03 | -5.21 | mast cell secretory granule organization | biological process | GO:0033364 | 2 | 1 | 18204 | 50 |
SRGN |
5.486e-03 | -5.21 | positive regulation of thyroid hormone mediated signaling pathway | biological process | GO:0002157 | 2 | 1 | 18204 | 50 |
RXRA |
5.486e-03 | -5.21 | muscle cell fate determination | biological process | GO:0007521 | 2 | 1 | 18204 | 50 |
MEF2C |
5.486e-03 | -5.21 | AMPA selective glutamate receptor signaling pathway | biological process | GO:0098990 | 2 | 1 | 18204 | 50 |
MEF2C |
5.486e-03 | -5.21 | regulation of Kit signaling pathway | biological process | GO:1900234 | 2 | 1 | 18204 | 50 |
SH2B3 |
5.486e-03 | -5.21 | sinoatrial valve development | biological process | GO:0003172 | 2 | 1 | 18204 | 50 |
MEF2C |
5.486e-03 | -5.21 | execution phase of necroptosis | biological process | GO:0097528 | 2 | 1 | 18204 | 50 |
MLKL |
5.486e-03 | -5.21 | regulation of alkaline phosphatase activity | biological process | GO:0010692 | 2 | 1 | 18204 | 50 |
MEF2C |
5.486e-03 | -5.21 | response to trichostatin A | biological process | GO:0035983 | 2 | 1 | 18204 | 50 |
MEF2C |
5.486e-03 | -5.21 | NK T cell proliferation | biological process | GO:0001866 | 2 | 1 | 18204 | 50 |
ELF4 |
5.500e-03 | -5.20 | Ets1_N_flank | pfam domains | PF19525 | 2 | 1 | 17795 | 49 |
ETS1 |
5.500e-03 | -5.20 | FNIP_M | pfam domains | PF14637 | 2 | 1 | 17795 | 49 |
FNIP1 |
5.500e-03 | -5.20 | Ald_Xan_dh_C | pfam domains | PF01315 | 2 | 1 | 17795 | 49 |
AOX1 |
5.500e-03 | -5.20 | FAD_binding_5 | pfam domains | PF00941 | 2 | 1 | 17795 | 49 |
AOX1 |
5.500e-03 | -5.20 | Fer2_2 | pfam domains | PF01799 | 2 | 1 | 17795 | 49 |
AOX1 |
5.500e-03 | -5.20 | FNIP_C | pfam domains | PF14638 | 2 | 1 | 17795 | 49 |
FNIP1 |
5.500e-03 | -5.20 | CO_deh_flav_C | pfam domains | PF03450 | 2 | 1 | 17795 | 49 |
AOX1 |
5.500e-03 | -5.20 | MoCoBD_1 | pfam domains | PF02738 | 2 | 1 | 17795 | 49 |
AOX1 |
5.500e-03 | -5.20 | FNIP_N | pfam domains | PF14636 | 2 | 1 | 17795 | 49 |
FNIP1 |
5.500e-03 | -5.20 | DAB2_SBM | pfam domains | PF21792 | 2 | 1 | 17795 | 49 |
DAB2 |
5.500e-03 | -5.20 | MoCoBD_2 | pfam domains | PF20256 | 2 | 1 | 17795 | 49 |
AOX1 |
5.500e-03 | -5.20 | iRhom1-2_N | pfam domains | PF12595 | 2 | 1 | 17795 | 49 |
RHBDF1 |
5.500e-03 | -5.20 | Nuc_recep-AF1 | pfam domains | PF11825 | 2 | 1 | 17795 | 49 |
RXRA |
5.519e-03 | -5.20 | apolipoprotein A-I receptor activity | molecular function | GO:0034188 | 2 | 1 | 18094 | 50 |
ABCA1 |
5.535e-03 | -5.20 | bone-femur-chondrosarcoma | COSMIC cancer mutations | bone-femur-chondrosarcoma | 419 | 5 | 16828 | 46 |
BLNK,CSF3R,ABCA1,RBM47,DAB2 |
5.563e-03 | -5.19 | cell-substrate junction | cellular component | GO:0030055 | 437 | 5 | 19108 | 50 |
FLRT2,FERMT3,SH3KBP1,HCK,DAB2 |
5.575e-03 | -5.19 | SH2 domain | gene3d domains | 3.30.505.10 | 111 | 3 | 14470 | 47 |
BLNK,HCK,SH2B3 |
5.662e-03 | -5.17 | intracellular lipid transport | biological process | GO:0032365 | 41 | 2 | 18204 | 50 |
ABCA1,CERT1 |
5.662e-03 | -5.17 | cortical actin cytoskeleton organization | biological process | GO:0030866 | 41 | 2 | 18204 | 50 |
PLEK,FMNL1 |
5.662e-03 | -5.17 | negative regulation of ossification | biological process | GO:0030279 | 41 | 2 | 18204 | 50 |
SRGN,MEF2C |
5.696e-03 | -5.17 | MAPK7 (mitogen-activated protein kinase 7) | protein interactions | 5598 | 141 | 3 | 19454 | 50 |
RXRA,ETS1,MEF2C |
5.709e-03 | -5.17 | regulation of protein-containing complex assembly | biological process | GO:0043254 | 419 | 5 | 18204 | 50 |
ABCA1,FNIP1,PLEK,HCK,MARK4 |
5.717e-03 | -5.16 | CCDC88B (coiled-coil domain containing 88B) | protein interactions | 283234 | 44 | 2 | 19454 | 50 |
SH3KBP1,HCK |
5.717e-03 | -5.16 | Cargo recognition for clathrin-mediated endocytosis | REACTOME pathways | R-HSA-8856825 | 99 | 3 | 10285 | 38 |
SH3KBP1,DAB2,FCHO2 |
5.747e-03 | -5.16 | immune response-regulating cell surface receptor signaling pathway | biological process | GO:0002768 | 262 | 4 | 18204 | 50 |
BLNK,CD276,MEF2C,HCK |
5.753e-03 | -5.16 | leukocyte activation | biological process | GO:0045321 | 599 | 6 | 18204 | 50 |
CD276,ADGRG3,ELF4,BLNK,FNIP1,MEF2C |
5.824e-03 | -5.15 | heart morphogenesis | biological process | GO:0003007 | 263 | 4 | 18204 | 50 |
FLRT2,MICAL2,CERT1,MEF2C |
5.832e-03 | -5.14 | SH3 Domains | gene3d domains | 2.30.30.40 | 223 | 4 | 14470 | 47 |
DOCK4,MYO1F,SH3KBP1,HCK |
5.973e-03 | -5.12 | SH3BP2 (SH3 domain binding protein 2) | protein interactions | 6452 | 45 | 2 | 19454 | 50 |
SH3KBP1,MYO1F |
5.973e-03 | -5.12 | WIPF1 (WAS/WASL interacting protein family member 1) | protein interactions | 7456 | 45 | 2 | 19454 | 50 |
HCK,SH3KBP1 |
5.973e-03 | -5.12 | SPTBN4 (spectrin beta, non-erythrocytic 4) | protein interactions | 57731 | 45 | 2 | 19454 | 50 |
ETS1,DISC1 |
5.986e-03 | -5.12 | positive regulation of transcription by RNA polymerase II | biological process | GO:0045944 | 1237 | 9 | 18204 | 50 |
TFEB,DAB2,ETV6,CEBPB,ELF4,RXRA,MICAL2,MEF2C,ETS1 |
5.994e-03 | -5.12 | Dorso-ventral axis formation | KEGG pathways | ko04320 | 28 | 2 | 7161 | 30 |
ETV6,ETS1 |
5.994e-03 | -5.12 | Dorso-ventral axis formation | KEGG pathways | hsa04320 | 28 | 2 | 7161 | 30 |
ETV6,ETS1 |
5.997e-03 | -5.12 | endomembrane system | cellular component | GO:0012505 | 4764 | 21 | 19108 | 50 |
ARHGAP45,FLRT2,DIAPH2,CD68,ATP8A1,ARAP1,SGMS1,CD53,HCK,ABCA1,FERMT3,DISC1,SRGN,RHBDF1,DAB2,CERT1,FCHO2,DOCK4,MAN1A1,ABCC5,ADGRG3 |
6.005e-03 | -5.12 | intramembrane lipid transporter activity | molecular function | GO:0140303 | 42 | 2 | 18094 | 50 |
ATP8A1,ABCA1 |
6.010e-03 | -5.11 | ABC_transporter-like_CS | interpro domains | IPR017871 | 43 | 2 | 18521 | 50 |
ABCC5,ABCA1 |
6.081e-03 | -5.10 | REVINTRACTNG | prints domains | PR00405 | 27 | 2 | 5227 | 23 |
ARAP3,ARAP1 |
6.087e-03 | -5.10 | regulation of cellular component biogenesis | biological process | GO:0044087 | 1016 | 8 | 18204 | 50 |
FNIP1,PLEK,MEF2C,MARK4,ABCA1,FLRT2,ARAP1,HCK |
6.213e-03 | -5.08 | regulation of cell adhesion | biological process | GO:0030155 | 807 | 7 | 18204 | 50 |
ETS1,SH2B3,DAB2,CEBPB,CD276,DISC1,FERMT3 |
6.224e-03 | -5.08 | Transcriptional misregulation in cancer | KEGG pathways | ko05202 | 179 | 4 | 7161 | 30 |
RXRA,MEF2C,ETV6,CEBPB |
6.224e-03 | -5.08 | Transcriptional misregulation in cancer | KEGG pathways | hsa05202 | 179 | 4 | 7161 | 30 |
ETV6,CEBPB,RXRA,MEF2C |
6.420e-03 | -5.05 | secretory vesicle | cellular component | GO:0099503 | 1076 | 8 | 19108 | 50 |
DISC1,ARHGAP45,SRGN,CD53,ADGRG3,FERMT3,CD68,ATP8A1 |
6.440e-03 | -5.05 | cellular component organization or biogenesis | biological process | GO:0071840 | 5850 | 25 | 18204 | 50 |
ABCA1,SH3KBP1,HCK,ARAP3,CERT1,MARK4,FERMT3,FMNL1,SRGN,FCHO2,TFEB,ARAP1,MYO1F,ATP8A1,ETV6,MLKL,ETS1,FLRT2,DISC1,DAB2,DIAPH2,CTSV,BAZ2B,PLEK,MICAL2 |
6.486e-03 | -5.04 | Aldehyde oxidase/xanthine dehydrogenase, a/b hammerhead | gene3d domains | 3.90.1170.50 | 2 | 1 | 14470 | 47 |
AOX1 |
6.486e-03 | -5.04 | Aldehyde oxidase/xanthine dehydrogenase, molybdopterin binding domain | gene3d domains | 3.30.365.10 | 2 | 1 | 14470 | 47 |
AOX1 |
6.486e-03 | -5.04 | [2Fe-2S]-binding domain | gene3d domains | 1.10.150.120 | 2 | 1 | 14470 | 47 |
AOX1 |
6.498e-03 | -5.04 | B cell receptor signaling pathway | biological process | GO:0050853 | 44 | 2 | 18204 | 50 |
MEF2C,BLNK |
6.498e-03 | -5.04 | positive regulation of bone mineralization | biological process | GO:0030501 | 44 | 2 | 18204 | 50 |
RXRA,MEF2C |
6.500e-03 | -5.04 | SH3BP1 (SH3 domain binding protein 1) | protein interactions | 23616 | 47 | 2 | 19454 | 50 |
SH3KBP1,HCK |
6.571e-03 | -5.03 | antigen receptor-mediated signaling pathway | biological process | GO:0050851 | 139 | 3 | 18204 | 50 |
MEF2C,BLNK,CD276 |
6.624e-03 | -5.02 | MCAM (melanoma cell adhesion molecule) | protein interactions | 4162 | 464 | 5 | 19454 | 50 |
ABCC5,FLRT2,FERMT3,RHBDF1,DAB2 |
6.696e-03 | -5.01 | Winged helix-like DNA-binding domain superfamily/Winged helix DNA-binding domain | gene3d domains | 1.10.10.10 | 232 | 4 | 14470 | 47 |
ETV6,ETS1,PLEK,ELF4 |
6.743e-03 | -5.00 | PFN1 (profilin 1) | protein interactions | 5216 | 466 | 5 | 19454 | 50 |
ARHGEF1,DOCK4,FMNL1,FCHO2,DIAPH2 |
6.863e-03 | -4.98 | carcinoid-endocrine_tumour | COSMIC cancer mutations | carcinoid-endocrine_tumour | 7752 | 30 | 16828 | 46 |
BAZ2B,PLEK,HCK,ABCA1,GLDC,FNIP1,FCHO2,SH2B3,RXRA,ELF4,MLKL,MYO1F,BLNK,ARHGEF1,STAB1,MAN1A1,MARK4,SGMS1,ETV6,CD276,ATP8A1,AOX1,SRGN,FMNL1,CSF3R,RGL1,DIAPH2,ABCC5,MICAL2,SH3KBP1 |
6.891e-03 | -4.98 | positive regulation of response to stimulus | biological process | GO:0048584 | 2266 | 13 | 18204 | 50 |
HCK,CEBPB,BLNK,RXRA,FNIP1,RBM47,MARK4,ETS1,DISC1,CD276,DAB2,CTSV,MEF2C |
6.953e-03 | -4.97 | RAC2 (Rac family small GTPase 2) | protein interactions | 5880 | 666 | 6 | 19454 | 50 |
DIAPH2,FLRT2,DAB2,FCHO2,FMNL1,ABCC5 |
7.147e-03 | -4.94 | SH2 | prosite domains | PS50001 | 107 | 3 | 12186 | 45 |
HCK,BLNK,SH2B3 |
7.167e-03 | -4.94 | ABC-type transporter activity | molecular function | GO:0140359 | 46 | 2 | 18094 | 50 |
ABCC5,ABCA1 |
7.203e-03 | -4.93 | RHOF (ras homolog family member F, filopodia associated) | protein interactions | 54509 | 671 | 6 | 19454 | 50 |
DAB2,FCHO2,FMNL1,ABCC5,DIAPH2,FLRT2 |
7.242e-03 | -4.93 | amide transport | biological process | GO:0042886 | 144 | 3 | 18204 | 50 |
ABCC5,CERT1,ABCA1 |
7.263e-03 | -4.92 | RAP1A (RAP1A, member of RAS oncogene family) | protein interactions | 5906 | 154 | 3 | 19454 | 50 |
RGL1,CD53,ARHGEF1 |
7.312e-03 | -4.92 | regulation of cell activation | biological process | GO:0050865 | 630 | 6 | 18204 | 50 |
PLEK,MEF2C,CEBPB,CD276,SH3KBP1,SH2B3 |
7.372e-03 | -4.91 | DENN_FNIP12 | prosite domains | PS51836 | 2 | 1 | 12186 | 45 |
FNIP1 |
7.443e-03 | -4.90 | ABC_transporter-like_ATP-bd | interpro domains | IPR003439 | 48 | 2 | 18521 | 50 |
ABCC5,ABCA1 |
7.456e-03 | -4.90 | SH2 | smart domains | SM00252 | 103 | 3 | 9717 | 38 |
BLNK,SH2B3,HCK |
7.501e-03 | -4.89 | intracellular membrane-bounded organelle | cellular component | GO:0043231 | 12479 | 41 | 19108 | 50 |
CD68,RXRA,CSF3R,MICAL2,FLRT2,ARHGAP45,ETS1,RBM47,FMNL1,ADGRG3,DOCK4,STAB1,MEF2C,FNIP1,TFEB,GLDC,BLNK,DISC1,DAB2,MFSD1,ETV6,ATP8A1,CEBPB,DIAPH2,BAZ2B,CTSV,FERMT3,ABCA1,CD53,HCK,ARAP1,SGMS1,SH3KBP1,ELF4,FCHO2,CERT1,MAN1A1,ABCC5,SRGN,MLKL,RHBDF1 |
7.560e-03 | -4.88 | vesicle-mediated transport | biological process | GO:0016192 | 1283 | 9 | 18204 | 50 |
FCHO2,ARAP3,STAB1,DAB2,HCK,SH3KBP1,ABCA1,PLEK,MYO1F |
7.673e-03 | -4.87 | small GTPase binding | molecular function | GO:0031267 | 283 | 4 | 18094 | 50 |
ABCA1,DIAPH2,DOCK4,FMNL1 |
7.691e-03 | -4.87 | Dnm2 (dynamin 2) | protein interactions | 13430 | 3 | 1 | 19454 | 50 |
SH3KBP1 |
7.691e-03 | -4.87 | Srr (serine racemase) | protein interactions | 27364 | 3 | 1 | 19454 | 50 |
DISC1 |
7.691e-03 | -4.87 | Ppp1cc (protein phosphatase 1 catalytic subunit gamma) | protein interactions | 19047 | 3 | 1 | 19454 | 50 |
SH3KBP1 |
7.691e-03 | -4.87 | Ubtf (upstream binding transcription factor, RNA polymerase I) | protein interactions | 21429 | 3 | 1 | 19454 | 50 |
SH3KBP1 |
7.691e-03 | -4.87 | SPS100 (Sps100p) | protein interactions | 856541 | 3 | 1 | 19454 | 50 |
CERT1 |
7.691e-03 | -4.87 | Pik3r1 (phosphoinositide-3-kinase regulatory subunit 1) | protein interactions | 18708 | 3 | 1 | 19454 | 50 |
SH3KBP1 |
7.691e-03 | -4.87 | Grip1 (glutamate receptor interacting protein 1) | protein interactions | 74053 | 3 | 1 | 19454 | 50 |
RXRA |
7.691e-03 | -4.87 | SEMA3E (semaphorin 3E) | protein interactions | 9723 | 3 | 1 | 19454 | 50 |
GLDC |
7.691e-03 | -4.87 | Myo6 (myosin VI) | protein interactions | 315840 | 3 | 1 | 19454 | 50 |
DAB2 |
7.691e-03 | -4.87 | Rad50 (RAD50 double strand break repair protein) | protein interactions | 19360 | 3 | 1 | 19454 | 50 |
SH3KBP1 |
7.691e-03 | -4.87 | Cbl (Casitas B-lineage lymphoma) | protein interactions | 12402 | 3 | 1 | 19454 | 50 |
SH3KBP1 |
7.691e-03 | -4.87 | HERC2P2 (HERC2 pseudogene 2) | protein interactions | 400322 | 3 | 1 | 19454 | 50 |
DISC1 |
7.700e-03 | -4.87 | SH3 | smart domains | SM00326 | 202 | 4 | 9717 | 38 |
HCK,DOCK4,SH3KBP1,MYO1F |
7.729e-03 | -4.86 | ABC_tran | pfam domains | PF00005 | 48 | 2 | 17795 | 49 |
ABCA1,ABCC5 |
7.806e-03 | -4.85 | Ald_Xan_dh_C | smart domains | SM01008 | 2 | 1 | 9717 | 38 |
AOX1 |
7.806e-03 | -4.85 | CO_deh_flav_C | smart domains | SM01092 | 2 | 1 | 9717 | 38 |
AOX1 |
7.818e-03 | -4.85 | chronic_myelomonocytic_leukaemia | COSMIC cancer mutations | chronic_myelomonocytic_leukaemia | 149 | 3 | 16828 | 46 |
ETV6,SH2B3,CSF3R |
7.818e-03 | -4.85 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-chronic_myelomonocytic_leukaemia | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-chronic_myelomonocytic_leukaemia | 149 | 3 | 16828 | 46 |
CSF3R,SH2B3,ETV6 |
7.830e-03 | -4.85 | CHOP-C/EBP complex | cellular component | GO:0036488 | 3 | 1 | 19108 | 50 |
CEBPB |
7.830e-03 | -4.85 | mast cell granule | cellular component | GO:0042629 | 3 | 1 | 19108 | 50 |
SRGN |
7.832e-03 | -4.85 | regulation of defense response | biological process | GO:0031347 | 843 | 7 | 18204 | 50 |
HCK,CEBPB,RBM47,MARK4,MEF2C,ETS1,ELF4 |
7.847e-03 | -4.85 | regulation of cell migration | biological process | GO:0030334 | 1061 | 8 | 18204 | 50 |
ATP8A1,MEF2C,ETS1,DAB2,DOCK4,FERMT3,ADGRG3,FLRT2 |
7.875e-03 | -4.84 | positive regulation of immune response | biological process | GO:0050778 | 640 | 6 | 18204 | 50 |
CD276,HCK,BLNK,RBM47,MEF2C,MARK4 |
7.902e-03 | -4.84 | azurophil granule | cellular component | GO:0042582 | 156 | 3 | 19108 | 50 |
CD68,ARHGAP45,ATP8A1 |
7.902e-03 | -4.84 | primary lysosome | cellular component | GO:0005766 | 156 | 3 | 19108 | 50 |
ARHGAP45,CD68,ATP8A1 |
7.953e-03 | -4.83 | embryonic organ development | biological process | GO:0048568 | 454 | 5 | 18204 | 50 |
TFEB,MICAL2,MEF2C,CEBPB,SH2B3 |
8.007e-03 | -4.83 | platelet aggregation | biological process | GO:0070527 | 49 | 2 | 18204 | 50 |
PLEK,FERMT3 |
8.078e-03 | -4.82 | Kindlin/fermitin | interpro domains | IPR037843 | 3 | 1 | 18521 | 50 |
FERMT3 |
8.078e-03 | -4.82 | 2Fe2S_fd_BS | interpro domains | IPR006058 | 3 | 1 | 18521 | 50 |
AOX1 |
8.078e-03 | -4.82 | Kindlin_2_N | interpro domains | IPR040790 | 3 | 1 | 18521 | 50 |
FERMT3 |
8.078e-03 | -4.82 | RGS-like_dom | interpro domains | IPR015212 | 3 | 1 | 18521 | 50 |
ARHGEF1 |
8.078e-03 | -4.82 | Sphingomyelin_synth-like_dom | interpro domains | IPR025749 | 3 | 1 | 18521 | 50 |
SGMS1 |
8.078e-03 | -4.82 | Phe_ZIP_sf | interpro domains | IPR036290 | 3 | 1 | 18521 | 50 |
SH2B3 |
8.078e-03 | -4.82 | SH2B | interpro domains | IPR030523 | 3 | 1 | 18521 | 50 |
SH2B3 |
8.078e-03 | -4.82 | FMNL_animal | interpro domains | IPR043592 | 3 | 1 | 18521 | 50 |
FMNL1 |
8.078e-03 | -4.82 | GPR1/GPR3/GPR5 | interpro domains | IPR003910 | 3 | 1 | 18521 | 50 |
ADGRG3 |
8.078e-03 | -4.82 | TF_Elf_N | interpro domains | IPR022084 | 3 | 1 | 18521 | 50 |
ELF4 |
8.078e-03 | -4.82 | DIA_GBD_sf | interpro domains | IPR044933 | 3 | 1 | 18521 | 50 |
DIAPH2 |
8.078e-03 | -4.82 | LAMP_CS | interpro domains | IPR018134 | 3 | 1 | 18521 | 50 |
CD68 |
8.078e-03 | -4.82 | Muniscin_C | interpro domains | IPR018808 | 3 | 1 | 18521 | 50 |
FCHO2 |
8.078e-03 | -4.82 | Phe_ZIP | interpro domains | IPR015012 | 3 | 1 | 18521 | 50 |
SH2B3 |
8.078e-03 | -4.82 | MiT/TFE_N | interpro domains | IPR031867 | 3 | 1 | 18521 | 50 |
TFEB |
8.078e-03 | -4.82 | Sphingomyelin_synth-like | interpro domains | IPR045221 | 3 | 1 | 18521 | 50 |
SGMS1 |
8.078e-03 | -4.82 | PH_Kindlin/fermitin | interpro domains | IPR037837 | 3 | 1 | 18521 | 50 |
FERMT3 |
8.078e-03 | -4.82 | OxRdtase_Mopterin_BS | interpro domains | IPR022407 | 3 | 1 | 18521 | 50 |
AOX1 |
8.179e-03 | -4.81 | congenital_(infantile)_fibrosarcoma | COSMIC cancer mutations | congenital_(infantile)_fibrosarcoma | 3 | 1 | 16828 | 46 |
ETV6 |
8.179e-03 | -4.81 | soft_tissue-fibrous_tissue_and_uncertain_origin-hypertrophic_scar | COSMIC cancer mutations | soft_tissue-fibrous_tissue_and_uncertain_origin-hypertrophic_scar | 3 | 1 | 16828 | 46 |
ETV6 |
8.179e-03 | -4.81 | soft_tissue-fibrous_tissue_and_uncertain_origin | COSMIC cancer mutations | soft_tissue-fibrous_tissue_and_uncertain_origin | 3 | 1 | 16828 | 46 |
BAZ2B |
8.179e-03 | -4.81 | soft_tissue-fibrous_tissue_and_uncertain_origin-congenital_(infantile)_fibrosarcoma | COSMIC cancer mutations | soft_tissue-fibrous_tissue_and_uncertain_origin-congenital_(infantile)_fibrosarcoma | 3 | 1 | 16828 | 46 |
ETV6 |
8.179e-03 | -4.81 | mammary_analogue_secretory_carcinoma_of_salivary_glands | COSMIC cancer mutations | mammary_analogue_secretory_carcinoma_of_salivary_glands | 3 | 1 | 16828 | 46 |
ETV6 |
8.179e-03 | -4.81 | hypertrophic_scar | COSMIC cancer mutations | hypertrophic_scar | 3 | 1 | 16828 | 46 |
ETV6 |
8.179e-03 | -4.81 | salivary_gland-parotid-carcinoma-mammary_analogue_secretory_carcinoma_of_salivary_glands | COSMIC cancer mutations | salivary_gland-parotid-carcinoma-mammary_analogue_secretory_carcinoma_of_salivary_glands | 3 | 1 | 16828 | 46 |
ETV6 |
8.218e-03 | -4.80 | response to vitamin B3 | biological process | GO:0033552 | 3 | 1 | 18204 | 50 |
ABCA1 |
8.218e-03 | -4.80 | positive regulation of macrophage apoptotic process | biological process | GO:2000111 | 3 | 1 | 18204 | 50 |
MEF2C |
8.218e-03 | -4.80 | glycine catabolic process | biological process | GO:0006546 | 3 | 1 | 18204 | 50 |
GLDC |
8.218e-03 | -4.80 | primary heart field specification | biological process | GO:0003138 | 3 | 1 | 18204 | 50 |
MEF2C |
8.218e-03 | -4.80 | positive regulation of mineralocorticoid secretion | biological process | GO:2000857 | 3 | 1 | 18204 | 50 |
DAB2 |
8.218e-03 | -4.80 | positive regulation of aldosterone secretion | biological process | GO:2000860 | 3 | 1 | 18204 | 50 |
DAB2 |
8.218e-03 | -4.80 | positive regulation of aldosterone biosynthetic process | biological process | GO:0032349 | 3 | 1 | 18204 | 50 |
DAB2 |
8.218e-03 | -4.80 | pyramidal neuron migration to cerebral cortex | biological process | GO:0021852 | 3 | 1 | 18204 | 50 |
DISC1 |
8.218e-03 | -4.80 | positive regulation of clathrin-dependent endocytosis | biological process | GO:2000370 | 3 | 1 | 18204 | 50 |
DAB2 |
8.218e-03 | -4.80 | positive regulation of sodium-dependent phosphate transport | biological process | GO:2000120 | 3 | 1 | 18204 | 50 |
CEBPB |
8.218e-03 | -4.80 | positive regulation of B cell apoptotic process | biological process | GO:0002904 | 3 | 1 | 18204 | 50 |
FNIP1 |
8.218e-03 | -4.80 | regulation of synaptic activity | biological process | GO:0060025 | 3 | 1 | 18204 | 50 |
MEF2C |
8.218e-03 | -4.80 | positive regulation of aldosterone metabolic process | biological process | GO:0032346 | 3 | 1 | 18204 | 50 |
DAB2 |
8.218e-03 | -4.80 | heme transmembrane transport | biological process | GO:0035351 | 3 | 1 | 18204 | 50 |
ABCC5 |
8.218e-03 | -4.80 | negative regulation of vascular associated smooth muscle contraction | biological process | GO:1904694 | 3 | 1 | 18204 | 50 |
DOCK4 |
8.218e-03 | -4.80 | leukocyte migration involved in immune response | biological process | GO:0002522 | 3 | 1 | 18204 | 50 |
HCK |
8.218e-03 | -4.80 | ER to Golgi ceramide transport | biological process | GO:0035621 | 3 | 1 | 18204 | 50 |
CERT1 |
8.218e-03 | -4.80 | monocyte homeostasis | biological process | GO:0035702 | 3 | 1 | 18204 | 50 |
SH2B3 |
8.218e-03 | -4.80 | glycine decarboxylation via glycine cleavage system | biological process | GO:0019464 | 3 | 1 | 18204 | 50 |
GLDC |
8.238e-03 | -4.80 | MITF_TFEB_C_3_N | pfam domains | PF15951 | 3 | 1 | 17795 | 49 |
TFEB |
8.238e-03 | -4.80 | Phe_ZIP | pfam domains | PF08916 | 3 | 1 | 17795 | 49 |
SH2B3 |
8.238e-03 | -4.80 | PAP2_C | pfam domains | PF14360 | 3 | 1 | 17795 | 49 |
SGMS1 |
8.238e-03 | -4.80 | Elf-1_N | pfam domains | PF12310 | 3 | 1 | 17795 | 49 |
ELF4 |
8.238e-03 | -4.80 | Kindlin_2_N | pfam domains | PF18124 | 3 | 1 | 17795 | 49 |
FERMT3 |
8.238e-03 | -4.80 | RGS-like | pfam domains | PF09128 | 3 | 1 | 17795 | 49 |
ARHGEF1 |
8.238e-03 | -4.80 | muHD | pfam domains | PF10291 | 3 | 1 | 17795 | 49 |
FCHO2 |
8.268e-03 | -4.80 | sphingomyelin synthase activity | molecular function | GO:0033188 | 3 | 1 | 18094 | 50 |
SGMS1 |
8.268e-03 | -4.80 | aldehyde oxidase activity | molecular function | GO:0004031 | 3 | 1 | 18094 | 50 |
AOX1 |
8.268e-03 | -4.80 | apolipoprotein receptor activity | molecular function | GO:0030226 | 3 | 1 | 18094 | 50 |
ABCA1 |
8.268e-03 | -4.80 | ceramide phosphoethanolamine synthase activity | molecular function | GO:0002950 | 3 | 1 | 18094 | 50 |
SGMS1 |
8.268e-03 | -4.80 | ceramide cholinephosphotransferase activity | molecular function | GO:0047493 | 3 | 1 | 18094 | 50 |
SGMS1 |
8.268e-03 | -4.80 | vitamin D response element binding | molecular function | GO:0070644 | 3 | 1 | 18094 | 50 |
RXRA |
8.268e-03 | -4.80 | DNA binding domain binding | molecular function | GO:0050692 | 3 | 1 | 18094 | 50 |
RXRA |
8.327e-03 | -4.79 | cortical cytoskeleton organization | biological process | GO:0030865 | 50 | 2 | 18204 | 50 |
FMNL1,PLEK |
8.327e-03 | -4.79 | phospholipid translocation | biological process | GO:0045332 | 50 | 2 | 18204 | 50 |
ABCA1,ATP8A1 |
8.384e-03 | -4.78 | primary active transmembrane transporter activity | molecular function | GO:0015399 | 151 | 3 | 18094 | 50 |
ABCA1,ATP8A1,ABCC5 |
8.418e-03 | -4.78 | secretory granule | cellular component | GO:0030141 | 897 | 7 | 19108 | 50 |
SRGN,ARHGAP45,CD53,FERMT3,ADGRG3,CD68,ATP8A1 |
8.468e-03 | -4.77 | specific granule | cellular component | GO:0042581 | 160 | 3 | 19108 | 50 |
ATP8A1,ADGRG3,CD53 |
8.507e-03 | -4.77 | LCP2 (lymphocyte cytosolic protein 2) | protein interactions | 3937 | 54 | 2 | 19454 | 50 |
BLNK,HCK |
8.598e-03 | -4.76 | prostate-carcinoma-adenocarcinoma | COSMIC cancer mutations | prostate-carcinoma-adenocarcinoma | 12379 | 41 | 16828 | 46 |
ARAP3,MLKL,ELF4,RXRA,SH2B3,RBM47,ARHGEF1,CD53,BLNK,MYO1F,ABCA1,PLEK,FLRT2,BAZ2B,FCHO2,DISC1,FNIP1,GLDC,MEF2C,RHBDF1,CSF3R,DOCK4,FMNL1,SRGN,AOX1,TFEB,SH3KBP1,MICAL2,ABCC5,DIAPH2,DAB2,RGL1,SGMS1,MARK4,MAN1A1,ARAP1,STAB1,ATP8A1,CD276,ETV6,FERMT3 |
8.688e-03 | -4.75 | germ_cell_tumour | COSMIC cancer mutations | germ_cell_tumour | 867 | 7 | 16828 | 46 |
HCK,FLRT2,MLKL,MARK4,STAB1,BAZ2B,FNIP1 |
8.752e-03 | -4.74 | signaling receptor complex adaptor activity | molecular function | GO:0030159 | 51 | 2 | 18094 | 50 |
BLNK,SH2B3 |
8.771e-03 | -4.74 | KLC2 (kinesin light chain 2) | protein interactions | 64837 | 165 | 3 | 19454 | 50 |
ARHGEF1,CEBPB,SH3KBP1 |
8.782e-03 | -4.74 | FOLLICULNIP1 | prints domains | PR02073 | 2 | 1 | 5227 | 23 |
FNIP1 |
8.814e-03 | -4.73 | VSTM1 (V-set and transmembrane domain containing 1) | protein interactions | 284415 | 55 | 2 | 19454 | 50 |
CD53,ADGRG3 |
8.846e-03 | -4.73 | positive regulation of hydrolase activity | biological process | GO:0051345 | 466 | 5 | 18204 | 50 |
PLEK,ARAP1,ARHGAP45,CTSV,MEF2C |
8.869e-03 | -4.73 | mouth | COSMIC cancer mutations | mouth | 9004 | 33 | 16828 | 46 |
ATP8A1,ETV6,FERMT3,SGMS1,MAN1A1,MARK4,ARAP1,STAB1,MICAL2,ABCC5,DIAPH2,CSF3R,ETS1,DOCK4,FMNL1,SRGN,AOX1,FCHO2,DISC1,FNIP1,GLDC,MEF2C,RHBDF1,ABCA1,HCK,PLEK,FLRT2,BAZ2B,ARHGEF1,MYO1F,ARAP3,RXRA,RBM47 |
8.907e-03 | -4.72 | SH3 | prosite domains | PS50002 | 222 | 4 | 12186 | 45 |
MYO1F,DOCK4,HCK,SH3KBP1 |
8.926e-03 | -4.72 | CBL (Cbl proto-oncogene) | protein interactions | 867 | 499 | 5 | 19454 | 50 |
ARHGAP45,HCK,SH3KBP1,BLNK,MAN1A1 |
8.982e-03 | -4.71 | regulation of vascular associated smooth muscle cell migration | biological process | GO:1904752 | 52 | 2 | 18204 | 50 |
DOCK4,MEF2C |
8.982e-03 | -4.71 | membrane invagination | biological process | GO:0010324 | 52 | 2 | 18204 | 50 |
FCHO2,ABCA1 |
8.985e-03 | -4.71 | positive regulation of biological process | biological process | GO:0048518 | 6326 | 26 | 18204 | 50 |
DAB2,DISC1,FLRT2,PLEK,MICAL2,CTSV,ELF4,ETV6,CEBPB,ETS1,RXRA,CD53,DOCK4,TFEB,ARAP1,CD276,FERMT3,ATP8A1,MEF2C,HCK,SH3KBP1,ABCA1,RBM47,MARK4,BLNK,FNIP1 |
9.037e-03 | -4.71 | Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | REACTOME pathways | R-HSA-983695 | 39 | 2 | 10285 | 38 |
SH3KBP1,BLNK |
9.130e-03 | -4.70 | Adipogenesis | WikiPathways | WP236 | 131 | 3 | 5310 | 18 |
RXRA,MEF2C,CEBPB |
9.133e-03 | -4.70 | SMARCA2 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2) | protein interactions | 6595 | 320 | 4 | 19454 | 50 |
CEBPB,ETS1,ELF4,AOX1 |
9.318e-03 | -4.68 | regulation of platelet activation | biological process | GO:0010543 | 53 | 2 | 18204 | 50 |
PLEK,SH2B3 |
9.395e-03 | -4.67 | immune response-activating signaling pathway | biological process | GO:0002757 | 302 | 4 | 18204 | 50 |
BLNK,CD276,MEF2C,HCK |
9.401e-03 | -4.67 | secretory granule membrane | cellular component | GO:0030667 | 317 | 4 | 19108 | 50 |
CD53,ADGRG3,CD68,ATP8A1 |
9.442e-03 | -4.66 | SPI1 (Spi-1 proto-oncogene) | protein interactions | 6688 | 57 | 2 | 19454 | 50 |
CEBPB,ETS1 |
9.509e-03 | -4.66 | HRAS (HRas proto-oncogene, GTPase) | protein interactions | 3265 | 712 | 6 | 19454 | 50 |
CD276,SH3KBP1,FCHO2,RGL1,MICAL2,ARHGEF1 |
9.517e-03 | -4.65 | TGF-beta Signaling Pathway | WikiPathways | WP366 | 133 | 3 | 5310 | 18 |
MEF2C,ETS1,DAB2 |
9.530e-03 | -4.65 | human chrXq21.33 | chromosome location | human chrXq21.33 | 5 | 1 | 26134 | 50 |
DIAPH2 |
9.550e-03 | -4.65 | DNA-binding transcription activator activity, RNA polymerase II-specific | molecular function | GO:0001228 | 472 | 5 | 18094 | 50 |
ELF4,ETS1,MEF2C,ETV6,CEBPB |
9.557e-03 | -4.65 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-myeloproliferative_neoplasm | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-myeloproliferative_neoplasm | 54 | 2 | 16828 | 46 |
SH2B3,CSF3R |
9.557e-03 | -4.65 | myeloproliferative_neoplasm | COSMIC cancer mutations | myeloproliferative_neoplasm | 54 | 2 | 16828 | 46 |
SH2B3,CSF3R |
9.571e-03 | -4.65 | LYN (LYN proto-oncogene, Src family tyrosine kinase) | protein interactions | 4067 | 713 | 6 | 19454 | 50 |
CSF3R,ABCC5,SH3KBP1,HCK,FCHO2,BLNK |
9.659e-03 | -4.64 | positive regulation of ossification | biological process | GO:0045778 | 54 | 2 | 18204 | 50 |
MEF2C,RXRA |
9.659e-03 | -4.64 | regulation of cholesterol efflux | biological process | GO:0010874 | 54 | 2 | 18204 | 50 |
RXRA,ABCA1 |
9.659e-03 | -4.64 | regulation of alcohol biosynthetic process | biological process | GO:1902930 | 54 | 2 | 18204 | 50 |
DAB2,PLEK |
9.659e-03 | -4.64 | positive regulation of dephosphorylation | biological process | GO:0035306 | 54 | 2 | 18204 | 50 |
PLEK,MEF2C |
9.695e-03 | -4.64 | regulation of intracellular signal transduction | biological process | GO:1902531 | 1832 | 11 | 18204 | 50 |
ABCA1,ARHGAP45,FNIP1,SH2B3,ADGRG3,SGMS1,ARAP1,DAB2,ARHGEF1,MEF2C,PLEK |
9.709e-03 | -4.63 | HNRNPL (heterogeneous nuclear ribonucleoprotein L) | protein interactions | 3191 | 1958 | 11 | 19454 | 50 |
SGMS1,RBM47,MICAL2,GLDC,RXRA,DAB2,DOCK4,FNIP1,ARAP1,BLNK,CERT1 |
9.713e-03 | -4.63 | - | gene3d domains | 6.10.140.110 | 3 | 1 | 14470 | 47 |
SH2B3 |
9.713e-03 | -4.63 | - | gene3d domains | 1.20.58.630 | 3 | 1 | 14470 | 47 |
DIAPH2 |
9.713e-03 | -4.63 | - | gene3d domains | 6.10.30.30 | 3 | 1 | 14470 | 47 |
DIAPH2 |
9.713e-03 | -4.63 | Formin, diaphanous GTPase-binding domain | gene3d domains | 1.10.20.40 | 3 | 1 | 14470 | 47 |
DIAPH2 |
9.713e-03 | -4.63 | CO dehydrogenase flavoprotein, C-terminal domain | gene3d domains | 3.30.390.50 | 3 | 1 | 14470 | 47 |
AOX1 |
9.763e-03 | -4.63 | FLI1 (Fli-1 proto-oncogene, ETS transcription factor) | protein interactions | 2313 | 58 | 2 | 19454 | 50 |
ETV6,FMNL1 |
9.763e-03 | -4.63 | CTXN3 (cortexin 3) | protein interactions | 613212 | 58 | 2 | 19454 | 50 |
ADGRG3,CD53 |
9.763e-03 | -4.63 | RRAGA (Ras related GTP binding A) | protein interactions | 10670 | 58 | 2 | 19454 | 50 |
TFEB,FNIP1 |
9.827e-03 | -4.62 | regulation of small GTPase mediated signal transduction | biological process | GO:0051056 | 306 | 4 | 18204 | 50 |
ABCA1,ARAP1,ARHGAP45,ARHGEF1 |
9.923e-03 | -4.61 | Mercaptopurine Action Pathway | SMPDB pathways | SMP0000428 | 45 | 2 | 1369 | 5 |
ABCC5,AOX1 |
9.923e-03 | -4.61 | Thioguanine Action Pathway | SMPDB pathways | SMP0000430 | 45 | 2 | 1369 | 5 |
ABCC5,AOX1 |
9.923e-03 | -4.61 | Azathioprine Action Pathway | SMPDB pathways | SMP0000427 | 45 | 2 | 1369 | 5 |
ABCC5,AOX1 |
9.956e-03 | -4.61 | glycine cleavage | BIOCYC pathways | HUMAN_GLYCLEAV-PWY | 3 | 1 | 902 | 3 |
GLDC |
9.956e-03 | -4.61 | glycine cleavage | BIOCYC pathways | META_GLYCLEAV-PWY | 3 | 1 | 902 | 3 |
GLDC |
9.956e-03 | -4.61 | nicotine degradation V | BIOCYC pathways | META_PWY66-221 | 3 | 1 | 902 | 3 |
AOX1 |
9.956e-03 | -4.61 | glycine biosynthesis II | BIOCYC pathways | META_GLYCINE-SYN2-PWY | 3 | 1 | 902 | 3 |
GLDC |
1.001e-02 | -4.60 | lipid translocation | biological process | GO:0034204 | 55 | 2 | 18204 | 50 |
ABCA1,ATP8A1 |
1.001e-02 | -4.60 | intermembrane lipid transfer | biological process | GO:0120009 | 55 | 2 | 18204 | 50 |
ABCA1,CERT1 |
1.004e-02 | -4.60 | NCOR1 (nuclear receptor corepressor 1) | protein interactions | 9611 | 329 | 4 | 19454 | 50 |
ETV6,CEBPB,RXRA,ETS1 |
1.005e-02 | -4.60 | DNA-binding transcription activator activity | molecular function | GO:0001216 | 478 | 5 | 18094 | 50 |
CEBPB,ETV6,ELF4,MEF2C,ETS1 |
1.009e-02 | -4.60 | TNKS2 (tankyrase 2) | protein interactions | 80351 | 59 | 2 | 19454 | 50 |
ARAP3,DISC1 |
1.009e-02 | -4.60 | organelle | cellular component | GO:0043226 | 14500 | 45 | 19108 | 50 |
CD53,SH3KBP1,FERMT3,CEBPB,CTSV,ETV6,MFSD1,ATP8A1,SRGN,AOX1,MAN1A1,FCHO2,ELF4,ARHGAP45,FLRT2,MARK4,RXRA,CD68,TFEB,MEF2C,ADGRG3,FMNL1,ARAP3,HCK,ARAP1,SGMS1,ABCA1,DIAPH2,BAZ2B,RHBDF1,MLKL,ABCC5,CERT1,ETS1,MICAL2,CSF3R,MYO1F,DAB2,DISC1,BLNK,GLDC,FNIP1,STAB1,DOCK4,RBM47 |
1.010e-02 | -4.60 | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma-medullomyoblastoma | COSMIC cancer mutations | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma-medullomyoblastoma | 485 | 5 | 16828 | 46 |
MICAL2,BAZ2B,DAB2,CSF3R,ATP8A1 |
1.010e-02 | -4.60 | medullomyoblastoma | COSMIC cancer mutations | medullomyoblastoma | 485 | 5 | 16828 | 46 |
DAB2,BAZ2B,MICAL2,ATP8A1,CSF3R |
1.015e-02 | -4.59 | receptor-mediated endocytosis | biological process | GO:0006898 | 163 | 3 | 18204 | 50 |
FCHO2,STAB1,DAB2 |
1.024e-02 | -4.58 | Actn4 (actinin alpha 4) | protein interactions | 60595 | 4 | 1 | 19454 | 50 |
SH3KBP1 |
1.024e-02 | -4.58 | Ap2a2 (adaptor-related protein complex 2, alpha 2 subunit) | protein interactions | 11772 | 4 | 1 | 19454 | 50 |
SH3KBP1 |
1.024e-02 | -4.58 | CREG2 (cellular repressor of E1A stimulated genes 2) | protein interactions | 200407 | 4 | 1 | 19454 | 50 |
GLDC |
1.024e-02 | -4.58 | Slc25a12 (solute carrier family 25 (mitochondrial carrier, Aralar), member 12) | protein interactions | 78830 | 4 | 1 | 19454 | 50 |
SH3KBP1 |
1.024e-02 | -4.58 | Ppp1ca (protein phosphatase 1 catalytic subunit alpha) | protein interactions | 19045 | 4 | 1 | 19454 | 50 |
SH3KBP1 |
1.024e-02 | -4.58 | Khdrbs1 (KH domain containing, RNA binding, signal transduction associated 1) | protein interactions | 20218 | 4 | 1 | 19454 | 50 |
SH3KBP1 |
1.024e-02 | -4.58 | MGAT3 (beta-1,4-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase) | protein interactions | 4248 | 4 | 1 | 19454 | 50 |
DISC1 |
1.024e-02 | -4.58 | Cblb (Casitas B-lineage lymphoma b) | protein interactions | 208650 | 4 | 1 | 19454 | 50 |
SH3KBP1 |
1.024e-02 | -4.58 | FBXO41 (F-box protein 41) | protein interactions | 150726 | 4 | 1 | 19454 | 50 |
DISC1 |
1.024e-02 | -4.58 | Ap2m1 (adaptor-related protein complex 2, mu 1 subunit) | protein interactions | 11773 | 4 | 1 | 19454 | 50 |
SH3KBP1 |
1.024e-02 | -4.58 | UNC5D (unc-5 netrin receptor D) | protein interactions | 137970 | 4 | 1 | 19454 | 50 |
FLRT2 |
1.024e-02 | -4.58 | Net1 (neuroepithelial cell transforming gene 1) | protein interactions | 56349 | 4 | 1 | 19454 | 50 |
SH3KBP1 |
1.024e-02 | -4.58 | Far1 (fatty acyl CoA reductase 1) | protein interactions | 67420 | 4 | 1 | 19454 | 50 |
SH3KBP1 |
1.024e-02 | -4.58 | VGLL2 (vestigial like family member 2) | protein interactions | 245806 | 4 | 1 | 19454 | 50 |
MEF2C |
1.036e-02 | -4.57 | immune response | biological process | GO:0006955 | 1349 | 9 | 18204 | 50 |
CEBPB,HCK,TFEB,BLNK,ETS1,MEF2C,CERT1,CTSV,CD68 |
1.042e-02 | -4.56 | PSG11 (pregnancy specific beta-1-glycoprotein 11) | protein interactions | 5680 | 60 | 2 | 19454 | 50 |
ARAP3,ARHGEF1 |
1.043e-02 | -4.56 | central region of growth cone | cellular component | GO:0090724 | 4 | 1 | 19108 | 50 |
DISC1 |
1.044e-02 | -4.56 | azurophil granule membrane | cellular component | GO:0035577 | 59 | 2 | 19108 | 50 |
CD68,ATP8A1 |
1.048e-02 | -4.56 | lipid transfer activity | molecular function | GO:0120013 | 56 | 2 | 18094 | 50 |
ABCA1,CERT1 |
1.061e-02 | -4.55 | PPARA activates gene expression | REACTOME pathways | R-HSA-1989781 | 124 | 3 | 10285 | 38 |
ABCA1,RXRA,RGL1 |
1.070e-02 | -4.54 | regulation of signaling | biological process | GO:0023051 | 3534 | 17 | 18204 | 50 |
DISC1,ADGRG3,SGMS1,ARAP1,DAB2,RHBDF1,PLEK,MEF2C,ARHGEF1,CTSV,ABCA1,ARHGAP45,RXRA,SH2B3,FNIP1,RBM47,MARK4 |
1.076e-02 | -4.53 | FAS1_domain | interpro domains | IPR000782 | 4 | 1 | 18521 | 50 |
STAB1 |
1.076e-02 | -4.53 | IgC2-like_lig-bd | interpro domains | IPR010457 | 4 | 1 | 18521 | 50 |
CSF3R |
1.076e-02 | -4.53 | MADS_MEF2-like | interpro domains | IPR033896 | 4 | 1 | 18521 | 50 |
MEF2C |
1.076e-02 | -4.53 | Retinoid-X_rcpt/HNF4 | interpro domains | IPR000003 | 4 | 1 | 18521 | 50 |
RXRA |
1.076e-02 | -4.53 | HJURP_C | interpro domains | IPR022102 | 4 | 1 | 18521 | 50 |
MEF2C |
1.076e-02 | -4.53 | C/EBP_chordates | interpro domains | IPR016468 | 4 | 1 | 18521 | 50 |
CEBPB |
1.076e-02 | -4.53 | MARK1-4_cat | interpro domains | IPR049508 | 4 | 1 | 18521 | 50 |
MARK4 |
1.076e-02 | -4.53 | MiT/TFE_C | interpro domains | IPR021802 | 4 | 1 | 18521 | 50 |
TFEB |
1.076e-02 | -4.53 | FAS1_dom_sf | interpro domains | IPR036378 | 4 | 1 | 18521 | 50 |
STAB1 |
1.076e-02 | -4.53 | Adaptor_Cbl_N_dom_sf | interpro domains | IPR036537 | 4 | 1 | 18521 | 50 |
MLKL |
1.077e-02 | -4.53 | CCL3 (C-C motif chemokine ligand 3) | protein interactions | 6348 | 178 | 3 | 19454 | 50 |
CTSV,SRGN,CEBPB |
1.082e-02 | -4.53 | regulation of cell motility | biological process | GO:2000145 | 1122 | 8 | 18204 | 50 |
ETS1,MEF2C,ATP8A1,ADGRG3,FLRT2,FERMT3,DOCK4,DAB2 |
1.084e-02 | -4.52 | lipid transporter activity | molecular function | GO:0005319 | 166 | 3 | 18094 | 50 |
CERT1,ABCA1,ATP8A1 |
1.089e-02 | -4.52 | kidney-other-mesoblastic_nephroma | COSMIC cancer mutations | kidney-other-mesoblastic_nephroma | 4 | 1 | 16828 | 46 |
ETV6 |
1.089e-02 | -4.52 | mesoblastic_nephroma | COSMIC cancer mutations | mesoblastic_nephroma | 4 | 1 | 16828 | 46 |
ETV6 |
1.089e-02 | -4.52 | central_nervous_system-medulla-other-ganglioglioma | COSMIC cancer mutations | central_nervous_system-medulla-other-ganglioglioma | 4 | 1 | 16828 | 46 |
ETV6 |
1.089e-02 | -4.52 | central_nervous_system-middle_cerebellar_peduncle-other-ganglioglioma | COSMIC cancer mutations | central_nervous_system-middle_cerebellar_peduncle-other-ganglioglioma | 4 | 1 | 16828 | 46 |
ETV6 |
1.089e-02 | -4.52 | haematopoietic_and_lymphoid_tissue-other-idiopathic_erythrocytosis | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-other-idiopathic_erythrocytosis | 4 | 1 | 16828 | 46 |
SH2B3 |
1.089e-02 | -4.52 | central_nervous_system-midbrain-other-ganglioglioma | COSMIC cancer mutations | central_nervous_system-midbrain-other-ganglioglioma | 4 | 1 | 16828 | 46 |
ETV6 |
1.089e-02 | -4.52 | central_nervous_system-spinal_cord-other-ganglioglioma | COSMIC cancer mutations | central_nervous_system-spinal_cord-other-ganglioglioma | 4 | 1 | 16828 | 46 |
ETV6 |
1.089e-02 | -4.52 | middle_cerebellar_peduncle | COSMIC cancer mutations | middle_cerebellar_peduncle | 4 | 1 | 16828 | 46 |
ETV6 |
1.089e-02 | -4.52 | idiopathic_erythrocytosis | COSMIC cancer mutations | idiopathic_erythrocytosis | 4 | 1 | 16828 | 46 |
SH2B3 |
1.092e-02 | -4.52 | regulation of cell communication | biological process | GO:0010646 | 3541 | 17 | 18204 | 50 |
DISC1,ADGRG3,SGMS1,ARAP1,DAB2,RHBDF1,PLEK,CTSV,MEF2C,ARHGEF1,ABCA1,ARHGAP45,RXRA,FNIP1,SH2B3,RBM47,MARK4 |
1.094e-02 | -4.52 | HIVEP1 (HIVEP zinc finger 1) | protein interactions | 3096 | 179 | 3 | 19454 | 50 |
SH3KBP1,RBM47,ETS1 |
1.094e-02 | -4.52 | negative regulation of lysosome organization | biological process | GO:1905672 | 4 | 1 | 18204 | 50 |
FNIP1 |
1.094e-02 | -4.52 | respiratory burst after phagocytosis | biological process | GO:0045728 | 4 | 1 | 18204 | 50 |
HCK |
1.094e-02 | -4.52 | regulation of high-density lipoprotein particle assembly | biological process | GO:0090107 | 4 | 1 | 18204 | 50 |
ABCA1 |
1.094e-02 | -4.52 | epithelial cell proliferation involved in renal tubule morphogenesis | biological process | GO:2001013 | 4 | 1 | 18204 | 50 |
MEF2C |
1.094e-02 | -4.52 | negative regulation of CREB transcription factor activity | biological process | GO:0032792 | 4 | 1 | 18204 | 50 |
ADGRG3 |
1.094e-02 | -4.52 | positive regulation of steroid hormone biosynthetic process | biological process | GO:0090031 | 4 | 1 | 18204 | 50 |
DAB2 |
1.094e-02 | -4.52 | negative regulation of dendritic cell antigen processing and presentation | biological process | GO:0002605 | 4 | 1 | 18204 | 50 |
CD68 |
1.094e-02 | -4.52 | vitellogenesis | biological process | GO:0007296 | 4 | 1 | 18204 | 50 |
ETV6 |
1.094e-02 | -4.52 | protein localization to secretory granule | biological process | GO:0033366 | 4 | 1 | 18204 | 50 |
SRGN |
1.097e-02 | -4.51 | DUF3371 | pfam domains | PF11851 | 4 | 1 | 17795 | 49 |
TFEB |
1.097e-02 | -4.51 | Fasciclin | pfam domains | PF02469 | 4 | 1 | 17795 | 49 |
STAB1 |
1.097e-02 | -4.51 | Lep_receptor_Ig | pfam domains | PF06328 | 4 | 1 | 17795 | 49 |
CSF3R |
1.097e-02 | -4.51 | DDT | pfam domains | PF02791 | 4 | 1 | 17795 | 49 |
BAZ2B |
1.097e-02 | -4.51 | HJURP_C | pfam domains | PF12347 | 4 | 1 | 17795 | 49 |
MEF2C |
1.097e-02 | -4.51 | Fer2 | pfam domains | PF00111 | 4 | 1 | 17795 | 49 |
AOX1 |
1.101e-02 | -4.51 | stem cell factor receptor binding | molecular function | GO:0005173 | 4 | 1 | 18094 | 50 |
SH2B3 |
1.101e-02 | -4.51 | sphingolipid floppase activity | molecular function | GO:0046623 | 4 | 1 | 18094 | 50 |
ABCA1 |
1.101e-02 | -4.51 | oxidoreductase activity, acting on the aldehyde or oxo group of donors, oxygen as acceptor | molecular function | GO:0016623 | 4 | 1 | 18094 | 50 |
AOX1 |
1.101e-02 | -4.51 | phospholipid binding | molecular function | GO:0005543 | 489 | 5 | 18094 | 50 |
CERT1,FCHO2,ARAP1,ARAP3,ABCA1 |
1.104e-02 | -4.51 | LAMP_2 | prosite domains | PS00311 | 3 | 1 | 12186 | 45 |
CD68 |
1.104e-02 | -4.51 | MOLYBDOPTERIN_EUK | prosite domains | PS00559 | 3 | 1 | 12186 | 45 |
AOX1 |
1.104e-02 | -4.51 | 2FE2S_FER_1 | prosite domains | PS00197 | 3 | 1 | 12186 | 45 |
AOX1 |
1.104e-02 | -4.51 | Progressive trimming of alpha-1,2-linked mannose residues from Man9/8/7GlcNAc2 to produce Man5GlcNAc2 | REACTOME pathways | R-HSA-964827 | 3 | 1 | 10285 | 38 |
MAN1A1 |
1.104e-02 | -4.51 | Vitamins B6 activation to pyridoxal phosphate | REACTOME pathways | R-HSA-964975 | 3 | 1 | 10285 | 38 |
AOX1 |
1.107e-02 | -4.50 | GTPase binding | molecular function | GO:0051020 | 315 | 4 | 18094 | 50 |
DIAPH2,ABCA1,DOCK4,FMNL1 |
1.108e-02 | -4.50 | regulation of phosphatase activity | biological process | GO:0010921 | 58 | 2 | 18204 | 50 |
MEF2C,PLEK |
1.132e-02 | -4.48 | Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) | REACTOME pathways | R-HSA-400206 | 127 | 3 | 10285 | 38 |
ABCA1,RXRA,RGL1 |
1.133e-02 | -4.48 | actin cytoskeleton | cellular component | GO:0015629 | 520 | 5 | 19108 | 50 |
MICAL2,DIAPH2,MYO1F,HCK,FERMT3 |
1.140e-02 | -4.47 | Sphingolipid de novo biosynthesis | REACTOME pathways | R-HSA-1660661 | 44 | 2 | 10285 | 38 |
SGMS1,CERT1 |
1.143e-02 | -4.47 | ABC_TRANSPORTER_1 | prosite domains | PS00211 | 44 | 2 | 12186 | 45 |
ABCC5,ABCA1 |
1.145e-02 | -4.47 | regulation of dendritic spine development | biological process | GO:0060998 | 59 | 2 | 18204 | 50 |
MEF2C,DISC1 |
1.161e-02 | -4.46 | HCK (HCK proto-oncogene, Src family tyrosine kinase) | protein interactions | 3055 | 183 | 3 | 19454 | 50 |
CSF3R,SH3KBP1,HCK |
1.162e-02 | -4.46 | Diurnally Regulated Genes with Circadian Orthologs | WikiPathways | WP410 | 49 | 2 | 5310 | 18 |
ETV6,CEBPB |
1.175e-02 | -4.44 | regulation of cell-cell adhesion | biological process | GO:0022407 | 500 | 5 | 18204 | 50 |
CD276,FERMT3,SH2B3,ETS1,CEBPB |
1.177e-02 | -4.44 | molecular function activator activity | molecular function | GO:0140677 | 1132 | 8 | 18094 | 50 |
FNIP1,ARAP3,ARHGEF1,FLRT2,ARAP1,CTSV,ARHGAP45,DOCK4 |
1.182e-02 | -4.44 | export across plasma membrane | biological process | GO:0140115 | 60 | 2 | 18204 | 50 |
ABCA1,ABCC5 |
1.191e-02 | -4.43 | Transcriptional activation of mitochondrial biogenesis | REACTOME pathways | R-HSA-2151201 | 45 | 2 | 10285 | 38 |
RXRA,MEF2C |
1.213e-02 | -4.41 | molecular adaptor activity | molecular function | GO:0060090 | 1138 | 8 | 18094 | 50 |
SH2B3,MARK4,DAB2,BLNK,RBM47,FLRT2,DISC1,ETS1 |
1.220e-02 | -4.41 | negative regulation of G protein-coupled receptor signaling pathway | biological process | GO:0045744 | 61 | 2 | 18204 | 50 |
SH2B3,PLEK |
1.235e-02 | -4.39 | protein kinase binding | molecular function | GO:0019901 | 701 | 6 | 18094 | 50 |
MICAL2,SH2B3,PLEK,DOCK4,BLNK,MLKL |
1.236e-02 | -4.39 | ruffle | cellular component | GO:0001726 | 184 | 3 | 19108 | 50 |
ARHGAP45,ARAP3,PLEK |
1.256e-02 | -4.38 | Platelet degranulation | REACTOME pathways | R-HSA-114608 | 132 | 3 | 10285 | 38 |
SRGN,FERMT3,PLEK |
1.259e-02 | -4.38 | regulation of membrane lipid distribution | biological process | GO:0097035 | 62 | 2 | 18204 | 50 |
ATP8A1,ABCA1 |
1.279e-02 | -4.36 | DENND2A (DENN domain containing 2A) | protein interactions | 27147 | 5 | 1 | 19454 | 50 |
SH3KBP1 |
1.279e-02 | -4.36 | Hip1r (huntingtin interacting protein 1 related) | protein interactions | 29816 | 5 | 1 | 19454 | 50 |
SH3KBP1 |
1.279e-02 | -4.36 | NPHS2 (NPHS2 stomatin family member, podocin) | protein interactions | 7827 | 5 | 1 | 19454 | 50 |
SH3KBP1 |
1.279e-02 | -4.36 | ATP8B3 (ATPase phospholipid transporting 8B3) | protein interactions | 148229 | 5 | 1 | 19454 | 50 |
ATP8A1 |
1.286e-02 | -4.35 | SP1 (Sp1 transcription factor) | protein interactions | 6667 | 354 | 4 | 19454 | 50 |
RXRA,ETS1,CEBPB,MEF2C |
1.287e-02 | -4.35 | NR1H2 (nuclear receptor subfamily 1 group H member 2) | protein interactions | 7376 | 67 | 2 | 19454 | 50 |
RXRA,ABCA1 |
1.291e-02 | -4.35 | upper_aerodigestive_tract-mouth-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-mouth-carcinoma-squamous_cell_carcinoma | 6953 | 27 | 16828 | 46 |
FLRT2,HCK,ABCA1,MEF2C,GLDC,FNIP1,DISC1,FCHO2,RHBDF1,ARAP3,RBM47,RXRA,ARHGEF1,MYO1F,STAB1,ARAP1,ATP8A1,FERMT3,ETV6,FMNL1,DOCK4,CSF3R,ETS1,AOX1,SRGN,DIAPH2,MICAL2 |
1.293e-02 | -4.35 | Adaptor protein Cbl, N-terminal domain | gene3d domains | 1.20.930.20 | 4 | 1 | 14470 | 47 |
MLKL |
1.293e-02 | -4.35 | FAS1 domain | gene3d domains | 2.30.180.10 | 4 | 1 | 14470 | 47 |
STAB1 |
1.298e-02 | -4.34 | TLE3 (TLE family member 3, transcriptional corepressor) | protein interactions | 7090 | 355 | 4 | 19454 | 50 |
ETS1,CEBPB,BAZ2B,ETV6 |
1.299e-02 | -4.34 | membrane-bounded organelle | cellular component | GO:0043227 | 13662 | 43 | 19108 | 50 |
ADGRG3,STAB1,DOCK4,MEF2C,FNIP1,RBM47,FMNL1,DAB2,TFEB,GLDC,BLNK,DISC1,CD68,RXRA,ETS1,MARK4,CSF3R,MICAL2,FLRT2,ARHGAP45,MAN1A1,ABCC5,ELF4,FCHO2,CERT1,RHBDF1,AOX1,SRGN,MLKL,FERMT3,ABCA1,HCK,CD53,ARAP1,SH3KBP1,SGMS1,ETV6,MFSD1,ATP8A1,CEBPB,DIAPH2,CTSV,BAZ2B |
1.302e-02 | -4.34 | apolipoprotein B mRNA editing enzyme complex | cellular component | GO:0030895 | 5 | 1 | 19108 | 50 |
RBM47 |
1.315e-02 | -4.33 | GPR56ORPHANR | prints domains | PR01422 | 3 | 1 | 5227 | 23 |
ADGRG3 |
1.328e-02 | -4.32 | phosphatidylinositol phosphate binding | molecular function | GO:1901981 | 179 | 3 | 18094 | 50 |
FCHO2,ARAP1,ARAP3 |
1.331e-02 | -4.32 | regulation of locomotion | biological process | GO:0040012 | 1164 | 8 | 18204 | 50 |
DAB2,DOCK4,FERMT3,ADGRG3,FLRT2,ATP8A1,MEF2C,ETS1 |
1.331e-02 | -4.32 | platelet alpha granule lumen | cellular component | GO:0031093 | 67 | 2 | 19108 | 50 |
FERMT3,SRGN |
1.335e-02 | -4.32 | KHDRBS1 (KH RNA binding domain containing, signal transduction associated 1) | protein interactions | 10657 | 358 | 4 | 19454 | 50 |
GLDC,DISC1,HCK,SH3KBP1 |
1.337e-02 | -4.31 | actin polymerization or depolymerization | biological process | GO:0008154 | 64 | 2 | 18204 | 50 |
DIAPH2,MICAL2 |
1.343e-02 | -4.31 | HnRNP_R/Q_splicing_fac | interpro domains | IPR006535 | 5 | 1 | 18521 | 50 |
RBM47 |
1.343e-02 | -4.31 | C/EBP | interpro domains | IPR031106 | 5 | 1 | 18521 | 50 |
CEBPB |
1.343e-02 | -4.31 | WHIM2_dom | interpro domains | IPR028941 | 5 | 1 | 18521 | 50 |
BAZ2B |
1.343e-02 | -4.31 | KA1_dom | interpro domains | IPR001772 | 5 | 1 | 18521 | 50 |
MARK4 |
1.343e-02 | -4.31 | TF_MADSbox_sf | interpro domains | IPR036879 | 5 | 1 | 18521 | 50 |
MEF2C |
1.343e-02 | -4.31 | Lamp2-like_luminal | interpro domains | IPR048528 | 5 | 1 | 18521 | 50 |
CD68 |
1.343e-02 | -4.31 | FAD-bd_PCMH_sub1 | interpro domains | IPR016167 | 5 | 1 | 18521 | 50 |
AOX1 |
1.343e-02 | -4.31 | FAD-bd | interpro domains | IPR002938 | 5 | 1 | 18521 | 50 |
MICAL2 |
1.343e-02 | -4.31 | DOCK_N | interpro domains | IPR032376 | 5 | 1 | 18521 | 50 |
DOCK4 |
1.343e-02 | -4.31 | DOCK_N_sub1 | interpro domains | IPR042455 | 5 | 1 | 18521 | 50 |
DOCK4 |
1.343e-02 | -4.31 | TF_MADSbox | interpro domains | IPR002100 | 5 | 1 | 18521 | 50 |
MEF2C |
1.343e-02 | -4.31 | DDT_dom | interpro domains | IPR018501 | 5 | 1 | 18521 | 50 |
BAZ2B |
1.343e-02 | -4.31 | Lysosome-assoc_membr_glycop | interpro domains | IPR002000 | 5 | 1 | 18521 | 50 |
CD68 |
1.343e-02 | -4.31 | autonomic_ganglia-neuroblastoma | COSMIC cancer mutations | autonomic_ganglia-neuroblastoma | 3970 | 18 | 16828 | 46 |
MYO1F,DAB2,DIAPH2,BLNK,RBM47,ELF4,AOX1,DOCK4,RHBDF1,FNIP1,MEF2C,GLDC,ATP8A1,MARK4,STAB1,ARAP1,PLEK,ABCA1 |
1.347e-02 | -4.31 | neuroblastoma | COSMIC cancer mutations | neuroblastoma | 3971 | 18 | 16828 | 46 |
ABCA1,PLEK,STAB1,ARAP1,MARK4,ATP8A1,GLDC,MEF2C,FNIP1,RHBDF1,DOCK4,AOX1,ELF4,RBM47,BLNK,MYO1F,DIAPH2,DAB2 |
1.350e-02 | -4.30 | ABC_TRANSPORTER_2 | prosite domains | PS50893 | 48 | 2 | 12186 | 45 |
ABCC5,ABCA1 |
1.359e-02 | -4.30 | lipoblastoma | COSMIC cancer mutations | lipoblastoma | 5 | 1 | 16828 | 46 |
ETV6 |
1.359e-02 | -4.30 | central_nervous_system-brainstem-other-ganglioglioma | COSMIC cancer mutations | central_nervous_system-brainstem-other-ganglioglioma | 5 | 1 | 16828 | 46 |
ETV6 |
1.359e-02 | -4.30 | minor | COSMIC cancer mutations | minor | 5 | 1 | 16828 | 46 |
ETV6 |
1.359e-02 | -4.30 | soft_tissue-fat-lipoblastoma | COSMIC cancer mutations | soft_tissue-fat-lipoblastoma | 5 | 1 | 16828 | 46 |
ETV6 |
1.361e-02 | -4.30 | KANSL2 (KAT8 regulatory NSL complex subunit 2) | protein interactions | 54934 | 69 | 2 | 19454 | 50 |
FERMT3,ELF4 |
1.366e-02 | -4.29 | regulation of sodium-dependent phosphate transport | biological process | GO:2000118 | 5 | 1 | 18204 | 50 |
CEBPB |
1.366e-02 | -4.29 | positive regulation of phospholipid translocation | biological process | GO:0061092 | 5 | 1 | 18204 | 50 |
ATP8A1 |
1.366e-02 | -4.29 | thrombopoietin-mediated signaling pathway | biological process | GO:0038163 | 5 | 1 | 18204 | 50 |
SH2B3 |
1.366e-02 | -4.29 | natural killer cell proliferation | biological process | GO:0001787 | 5 | 1 | 18204 | 50 |
ELF4 |
1.366e-02 | -4.29 | sphingolipid translocation | biological process | GO:0099039 | 5 | 1 | 18204 | 50 |
ABCA1 |
1.366e-02 | -4.29 | folate transmembrane transport | biological process | GO:0098838 | 5 | 1 | 18204 | 50 |
ABCC5 |
1.369e-02 | -4.29 | PRICHEXTENSN | prints domains | PR01217 | 41 | 2 | 5227 | 23 |
FMNL1,CEBPB |
1.369e-02 | -4.29 | SRF-TF | pfam domains | PF00319 | 5 | 1 | 17795 | 49 |
MEF2C |
1.369e-02 | -4.29 | WSD | pfam domains | PF15613 | 5 | 1 | 17795 | 49 |
BAZ2B |
1.369e-02 | -4.29 | DOCK_N | pfam domains | PF16172 | 5 | 1 | 17795 | 49 |
DOCK4 |
1.369e-02 | -4.29 | FAD_binding_3 | pfam domains | PF01494 | 5 | 1 | 17795 | 49 |
MICAL2 |
1.369e-02 | -4.29 | KA1 | pfam domains | PF02149 | 5 | 1 | 17795 | 49 |
MARK4 |
1.369e-02 | -4.29 | Lamp | pfam domains | PF01299 | 5 | 1 | 17795 | 49 |
CD68 |
1.374e-02 | -4.29 | apolipoprotein A-I binding | molecular function | GO:0034186 | 5 | 1 | 18094 | 50 |
ABCA1 |
1.374e-02 | -4.29 | phosphatidylserine flippase activity | molecular function | GO:0140346 | 5 | 1 | 18094 | 50 |
ATP8A1 |
1.374e-02 | -4.29 | glutathione transmembrane transporter activity | molecular function | GO:0034634 | 5 | 1 | 18094 | 50 |
ABCC5 |
1.374e-02 | -4.29 | ATPase inhibitor activity | molecular function | GO:0042030 | 5 | 1 | 18094 | 50 |
FNIP1 |
1.376e-02 | -4.29 | Myh9 (myosin, heavy polypeptide 9, non-muscle) | protein interactions | 17886 | 195 | 3 | 19454 | 50 |
SH3KBP1,FCHO2,DAB2 |
1.376e-02 | -4.29 | lung-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | lung-carcinoma-squamous_cell_carcinoma | 14664 | 45 | 16828 | 46 |
RHBDF1,MEF2C,GLDC,FNIP1,DISC1,FCHO2,BAZ2B,FLRT2,PLEK,HCK,ABCA1,MYO1F,BLNK,CD53,ARHGEF1,RBM47,RXRA,ELF4,MLKL,ARAP3,FERMT3,ETV6,MFSD1,CD276,ATP8A1,STAB1,ARAP1,MARK4,MAN1A1,SGMS1,RGL1,DIAPH2,DAB2,ABCC5,MICAL2,SH3KBP1,TFEB,CD68,AOX1,SRGN,FMNL1,DOCK4,CEBPB,CSF3R,ETS1 |
1.377e-02 | -4.29 | heart looping | biological process | GO:0001947 | 65 | 2 | 18204 | 50 |
MICAL2,MEF2C |
1.388e-02 | -4.28 | Response to elevated platelet cytosolic Ca2+ | REACTOME pathways | R-HSA-76005 | 137 | 3 | 10285 | 38 |
SRGN,FERMT3,PLEK |
1.388e-02 | -4.28 | Clathrin-mediated endocytosis | REACTOME pathways | R-HSA-8856828 | 137 | 3 | 10285 | 38 |
DAB2,FCHO2,SH3KBP1 |
1.399e-02 | -4.27 | ITGB3 (integrin subunit beta 3) | protein interactions | 3690 | 70 | 2 | 19454 | 50 |
FERMT3,DAB2 |
1.399e-02 | -4.27 | ACTR5 (actin related protein 5) | protein interactions | 79913 | 70 | 2 | 19454 | 50 |
ELF4,FMNL1 |
1.400e-02 | -4.27 | mixed_intestinal_and_diffuse_adenocarcinoma-unclassifiable | COSMIC cancer mutations | mixed_intestinal_and_diffuse_adenocarcinoma-unclassifiable | 951 | 7 | 16828 | 46 |
STAB1,SH2B3,FMNL1,HCK,FLRT2,FCHO2,MFSD1 |
1.400e-02 | -4.27 | stomach-carcinoma-mixed_intestinal_and_diffuse_adenocarcinoma-unclassifiable | COSMIC cancer mutations | stomach-carcinoma-mixed_intestinal_and_diffuse_adenocarcinoma-unclassifiable | 951 | 7 | 16828 | 46 |
MFSD1,FCHO2,HCK,FLRT2,FMNL1,SH2B3,STAB1 |
1.408e-02 | -4.26 | regulation of hydrolase activity | biological process | GO:0051336 | 726 | 6 | 18204 | 50 |
ARAP1,ARHGAP45,PLEK,MEF2C,CTSV,FNIP1 |
1.418e-02 | -4.26 | homotypic cell-cell adhesion | biological process | GO:0034109 | 66 | 2 | 18204 | 50 |
FERMT3,PLEK |
1.418e-02 | -4.26 | secretory granule organization | biological process | GO:0033363 | 66 | 2 | 18204 | 50 |
SRGN,ABCA1 |
1.421e-02 | -4.25 | testis | COSMIC cancer mutations | testis | 733 | 6 | 16828 | 46 |
STAB1,MARK4,MLKL,FLRT2,HCK,FNIP1 |
1.437e-02 | -4.24 | ITGB3BP (integrin subunit beta 3 binding protein) | protein interactions | 23421 | 71 | 2 | 19454 | 50 |
CERT1,RXRA |
1.437e-02 | -4.24 | SRA1 (steroid receptor RNA activator 1) | protein interactions | 10011 | 71 | 2 | 19454 | 50 |
ETS1,MLKL |
1.439e-02 | -4.24 | ABC transporters | KEGG pathways | hsa02010 | 44 | 2 | 7161 | 30 |
ABCC5,ABCA1 |
1.439e-02 | -4.24 | ABC transporters | KEGG pathways | ko02010 | 44 | 2 | 7161 | 30 |
ABCA1,ABCC5 |
1.448e-02 | -4.23 | cell differentiation | biological process | GO:0030154 | 3645 | 17 | 18204 | 50 |
CEBPB,HCK,ETV6,RBM47,ETS1,RXRA,BLNK,FNIP1,SH2B3,DAB2,DISC1,ADGRG3,FLRT2,PLEK,MEF2C,ELF4,DIAPH2 |
1.448e-02 | -4.23 | primitive_neuroectodermal_tumour-medulloblastoma | COSMIC cancer mutations | primitive_neuroectodermal_tumour-medulloblastoma | 15350 | 46 | 16828 | 46 |
AOX1,DOCK4,ETS1,ABCC5,MICAL2,DIAPH2,DAB2,SGMS1,STAB1,MAN1A1,MARK4,ETV6,ATP8A1,CD276,RXRA,ELF4,RBM47,ARAP3,CD53,BAZ2B,ABCA1,FLRT2,PLEK,HCK,GLDC,MEF2C,CD68,SRGN,TFEB,FMNL1,CEBPB,CSF3R,RGL1,SH3KBP1,ARAP1,FERMT3,MFSD1,SH2B3,MLKL,MYO1F,ARHGEF1,BLNK,RHBDF1,DISC1,FCHO2,FNIP1 |
1.460e-02 | -4.23 | cellular developmental process | biological process | GO:0048869 | 3648 | 17 | 18204 | 50 |
PLEK,MEF2C,ELF4,DIAPH2,DAB2,DISC1,ADGRG3,FLRT2,RBM47,ETS1,RXRA,BLNK,FNIP1,SH2B3,ETV6,HCK,CEBPB |
1.469e-02 | -4.22 | FAS1 | prosite domains | PS50213 | 4 | 1 | 12186 | 45 |
STAB1 |
1.469e-02 | -4.22 | LAMP_3 | prosite domains | PS51407 | 4 | 1 | 12186 | 45 |
CD68 |
1.470e-02 | -4.22 | autonomic_ganglia | COSMIC cancer mutations | autonomic_ganglia | 4005 | 18 | 16828 | 46 |
ELF4,AOX1,RBM47,DOCK4,DIAPH2,DAB2,MYO1F,BLNK,MARK4,ARAP1,STAB1,ABCA1,PLEK,RHBDF1,ATP8A1,FNIP1,MEF2C,GLDC |
1.470e-02 | -4.22 | Glycine degradation | REACTOME pathways | R-HSA-6783984 | 4 | 1 | 10285 | 38 |
GLDC |
1.470e-02 | -4.22 | Scavenging by Class H Receptors | REACTOME pathways | R-HSA-3000497 | 4 | 1 | 10285 | 38 |
STAB1 |
1.491e-02 | -4.21 | DBN1 (drebrin 1) | protein interactions | 1627 | 370 | 4 | 19454 | 50 |
DISC1,FCHO2,DAB2,GLDC |
1.515e-02 | -4.19 | FCHO1 (FCH and mu domain containing endocytic adaptor 1) | protein interactions | 23149 | 73 | 2 | 19454 | 50 |
FCHO2,DAB2 |
1.526e-02 | -4.18 | cellular response to lipid | biological process | GO:0071396 | 534 | 5 | 18204 | 50 |
HCK,MEF2C,CD68,ABCA1,RXRA |
1.532e-02 | -4.18 | RBP5 (retinol binding protein 5) | protein interactions | 83758 | 6 | 1 | 19454 | 50 |
ABCC5 |
1.532e-02 | -4.18 | ATP8A2 (ATPase phospholipid transporting 8A2) | protein interactions | 51761 | 6 | 1 | 19454 | 50 |
ATP8A1 |
1.532e-02 | -4.18 | Ncoa2 (nuclear receptor coactivator 2) | protein interactions | 17978 | 6 | 1 | 19454 | 50 |
RXRA |
1.554e-02 | -4.16 | GIMAP5 (GTPase, IMAP family member 5) | protein interactions | 55340 | 74 | 2 | 19454 | 50 |
ADGRG3,CD53 |
1.555e-02 | -4.16 | FAS1 | smart domains | SM00554 | 4 | 1 | 9717 | 38 |
STAB1 |
1.560e-02 | -4.16 | mRNA editing complex | cellular component | GO:0045293 | 6 | 1 | 19108 | 50 |
RBM47 |
1.561e-02 | -4.16 | CDC42 (cell division cycle 42) | protein interactions | 998 | 1280 | 8 | 19454 | 50 |
FCHO2,FMNL1,ABCC5,ARAP1,DIAPH2,ABCA1,MARK4,FLRT2 |
1.585e-02 | -4.14 | determination of heart left/right asymmetry | biological process | GO:0061371 | 70 | 2 | 18204 | 50 |
MEF2C,MICAL2 |
1.594e-02 | -4.14 | cell development | biological process | GO:0048468 | 2236 | 12 | 18204 | 50 |
FLRT2,ADGRG3,DISC1,DIAPH2,MEF2C,PLEK,CEBPB,ETV6,FNIP1,SH2B3,BLNK,RBM47 |
1.594e-02 | -4.14 | Cd2ap (CD2-associated protein) | protein interactions | 12488 | 75 | 2 | 19454 | 50 |
SH3KBP1,ARAP1 |
1.609e-02 | -4.13 | 2Fe-2S_ferredoxin-like_sf | interpro domains | IPR036010 | 6 | 1 | 18521 | 50 |
AOX1 |
1.609e-02 | -4.13 | FAD-bd_PCMH_sub2 | interpro domains | IPR016169 | 6 | 1 | 18521 | 50 |
AOX1 |
1.609e-02 | -4.13 | FAD-bd_PCMH-like_sf | interpro domains | IPR036318 | 6 | 1 | 18521 | 50 |
AOX1 |
1.609e-02 | -4.13 | FAD-bd_PCMH | interpro domains | IPR016166 | 6 | 1 | 18521 | 50 |
AOX1 |
1.609e-02 | -4.13 | 2Fe-2S_ferredoxin-type | interpro domains | IPR001041 | 6 | 1 | 18521 | 50 |
AOX1 |
1.613e-02 | -4.13 | GTSE1 (G2 and S-phase expressed 1) | protein interactions | 51512 | 207 | 3 | 19454 | 50 |
SH3KBP1,DAB2,FCHO2 |
1.614e-02 | -4.13 | Transcription factor, MADS-box | gene3d domains | 3.40.1810.10 | 5 | 1 | 14470 | 47 |
MEF2C |
1.614e-02 | -4.13 | Dedicator of cytokinesis N-terminal subdomain | gene3d domains | 1.20.1270.350 | 5 | 1 | 14470 | 47 |
DOCK4 |
1.614e-02 | -4.13 | Uridine Diphospho-n-acetylenolpyruvylglucosamine Reductase, domain 2 | gene3d domains | 3.30.43.10 | 5 | 1 | 14470 | 47 |
AOX1 |
1.614e-02 | -4.13 | Formin, FH3 diaphanous domain | gene3d domains | 1.10.238.150 | 5 | 1 | 14470 | 47 |
DIAPH2 |
1.615e-02 | -4.13 | organelle organization | biological process | GO:0006996 | 3091 | 15 | 18204 | 50 |
ABCA1,SH3KBP1,ARAP3,ETS1,CERT1,MARK4,FMNL1,SRGN,DISC1,ARAP1,TFEB,DIAPH2,MYO1F,MICAL2,PLEK |
1.624e-02 | -4.12 | EGF/EGFR Signaling Pathway | WikiPathways | WP437 | 162 | 3 | 5310 | 18 |
MEF2C,ARHGEF1,SH3KBP1 |
1.628e-02 | -4.12 | embryonic heart tube morphogenesis | biological process | GO:0003143 | 71 | 2 | 18204 | 50 |
MEF2C,MICAL2 |
1.629e-02 | -4.12 | soft_tissue-fibrous_tissue_and_uncertain_origin-nodular_fasciitis | COSMIC cancer mutations | soft_tissue-fibrous_tissue_and_uncertain_origin-nodular_fasciitis | 6 | 1 | 16828 | 46 |
ETV6 |
1.629e-02 | -4.12 | nodular_fasciitis | COSMIC cancer mutations | nodular_fasciitis | 6 | 1 | 16828 | 46 |
ETV6 |
1.633e-02 | -4.11 | bone | COSMIC cancer mutations | bone | 8157 | 30 | 16828 | 46 |
MICAL2,ABCC5,DIAPH2,DAB2,SH3KBP1,CD68,AOX1,CSF3R,FMNL1,DOCK4,ETV6,ATP8A1,MFSD1,MARK4,STAB1,ARAP1,MYO1F,ARHGEF1,BLNK,ELF4,RBM47,MLKL,RHBDF1,FNIP1,GLDC,MEF2C,BAZ2B,ABCA1,HCK,FLRT2 |
1.635e-02 | -4.11 | RUNX2 (RUNX family transcription factor 2) | protein interactions | 860 | 76 | 2 | 19454 | 50 |
CEBPB,ETS1 |
1.637e-02 | -4.11 | regulation of aldosterone secretion | biological process | GO:2000858 | 6 | 1 | 18204 | 50 |
DAB2 |
1.637e-02 | -4.11 | regulation of phospholipid translocation | biological process | GO:0061091 | 6 | 1 | 18204 | 50 |
ATP8A1 |
1.637e-02 | -4.11 | positive regulation of vitamin D receptor signaling pathway | biological process | GO:0070564 | 6 | 1 | 18204 | 50 |
RXRA |
1.637e-02 | -4.11 | apolipoprotein A-I-mediated signaling pathway | biological process | GO:0038027 | 6 | 1 | 18204 | 50 |
ABCA1 |
1.637e-02 | -4.11 | cell adhesion involved in heart morphogenesis | biological process | GO:0061343 | 6 | 1 | 18204 | 50 |
FLRT2 |
1.637e-02 | -4.11 | radial glia-guided pyramidal neuron migration | biological process | GO:0140650 | 6 | 1 | 18204 | 50 |
DISC1 |
1.637e-02 | -4.11 | regulation of mineralocorticoid secretion | biological process | GO:2000855 | 6 | 1 | 18204 | 50 |
DAB2 |
1.645e-02 | -4.11 | papillary_renal_cell_carcinoma | COSMIC cancer mutations | papillary_renal_cell_carcinoma | 6364 | 25 | 16828 | 46 |
SH2B3,RBM47,MLKL,ARAP3,MYO1F,CD53,BAZ2B,FLRT2,HCK,ABCA1,GLDC,FNIP1,FCHO2,AOX1,DOCK4,ETS1,RGL1,DAB2,ABCC5,SH3KBP1,ARAP1,STAB1,MARK4,FERMT3,MFSD1 |
1.645e-02 | -4.11 | kidney-carcinoma-papillary_renal_cell_carcinoma | COSMIC cancer mutations | kidney-carcinoma-papillary_renal_cell_carcinoma | 6364 | 25 | 16828 | 46 |
MYO1F,CD53,RBM47,SH2B3,MLKL,ARAP3,FNIP1,GLDC,FCHO2,BAZ2B,HCK,FLRT2,ABCA1,DAB2,RGL1,ABCC5,SH3KBP1,AOX1,ETS1,DOCK4,FERMT3,MFSD1,MARK4,STAB1,ARAP1 |
1.647e-02 | -4.11 | type 1 angiotensin receptor binding | molecular function | GO:0031702 | 6 | 1 | 18094 | 50 |
ARAP1 |
1.647e-02 | -4.11 | molybdopterin cofactor binding | molecular function | GO:0043546 | 6 | 1 | 18094 | 50 |
AOX1 |
1.647e-02 | -4.11 | retinoic acid-responsive element binding | molecular function | GO:0044323 | 6 | 1 | 18094 | 50 |
RXRA |
1.654e-02 | -4.10 | skin-leg-malignant_melanoma | COSMIC cancer mutations | skin-leg-malignant_melanoma | 549 | 5 | 16828 | 46 |
MLKL,HCK,SGMS1,STAB1,DIAPH2 |
1.656e-02 | -4.10 | nicotine degradation IV | BIOCYC pathways | META_PWY66-201 | 5 | 1 | 902 | 3 |
AOX1 |
1.672e-02 | -4.09 | negative regulation of protein binding | biological process | GO:0032091 | 72 | 2 | 18204 | 50 |
DISC1,DAB2 |
1.686e-02 | -4.08 | Mitochondrial biogenesis | REACTOME pathways | R-HSA-1592230 | 54 | 2 | 10285 | 38 |
RXRA,MEF2C |
1.709e-02 | -4.07 | human chr12q24.12 | chromosome location | human chr12q24.12 | 9 | 1 | 26134 | 50 |
SH2B3 |
1.715e-02 | -4.07 | TRIM24 (tripartite motif containing 24) | protein interactions | 8805 | 386 | 4 | 19454 | 50 |
ETS1,RXRA,MLKL,ELF4 |
1.718e-02 | -4.06 | SEC23B (SEC23 homolog B, COPII coat complex component) | protein interactions | 10483 | 212 | 3 | 19454 | 50 |
DAB2,MAN1A1,GLDC |
1.733e-02 | -4.06 | clathrin-coated pit | cellular component | GO:0005905 | 77 | 2 | 19108 | 50 |
DAB2,FCHO2 |
1.737e-02 | -4.05 | regulation of cellular process | biological process | GO:0050794 | 11468 | 39 | 18204 | 50 |
DAB2,SGMS1,FLRT2,DISC1,CTSV,BAZ2B,PLEK,MICAL2,ELF4,ETV6,CEBPB,ARHGAP45,ETS1,MLKL,CD53,RXRA,DOCK4,TFEB,ARAP1,RGL1,ADGRG3,FERMT3,SRGN,CD276,MEF2C,ARHGEF1,ATP8A1,RHBDF1,HCK,ARAP3,CSF3R,ABCA1,SH3KBP1,CERT1,MARK4,RBM47,FNIP1,SH2B3,BLNK |
1.748e-02 | -4.05 | positive regulation of immune system process | biological process | GO:0002684 | 986 | 7 | 18204 | 50 |
RBM47,MARK4,MEF2C,BLNK,HCK,CD276,SH3KBP1 |
1.749e-02 | -4.05 | RETINOIDXR | prints domains | PR00545 | 4 | 1 | 5227 | 23 |
RXRA |
1.749e-02 | -4.05 | LYSASSOCTDMP | prints domains | PR00336 | 4 | 1 | 5227 | 23 |
CD68 |
1.760e-02 | -4.04 | upper_aerodigestive_tract-pharynx-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-pharynx-carcinoma-squamous_cell_carcinoma | 1485 | 9 | 16828 | 46 |
ARHGEF1,MEF2C,MICAL2,ABCC5,DIAPH2,DAB2,ETS1,DOCK4,SGMS1 |
1.762e-02 | -4.04 | TRAF2 (TNF receptor associated factor 2) | protein interactions | 7186 | 592 | 5 | 19454 | 50 |
MLKL,SH3KBP1,ETV6,BAZ2B,RXRA |
1.772e-02 | -4.03 | skin-head_neck-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | skin-head_neck-carcinoma-squamous_cell_carcinoma | 14191 | 44 | 16828 | 46 |
MYO1F,ARHGEF1,BLNK,SH2B3,MLKL,RHBDF1,DISC1,FCHO2,FNIP1,RGL1,SH3KBP1,CD68,SRGN,TFEB,FMNL1,CSF3R,FERMT3,MFSD1,ARAP1,CD53,RXRA,ELF4,RBM47,ARAP3,GLDC,MEF2C,BAZ2B,ABCA1,FLRT2,PLEK,HCK,ABCC5,MICAL2,DIAPH2,DAB2,AOX1,DOCK4,ETS1,ETV6,ATP8A1,SGMS1,STAB1,MARK4,MAN1A1 |
1.786e-02 | -4.03 | SOX18 (SRY-box transcription factor 18) | protein interactions | 54345 | 7 | 1 | 19454 | 50 |
MEF2C |
1.786e-02 | -4.03 | DDN (dendrin) | protein interactions | 23109 | 7 | 1 | 19454 | 50 |
SH3KBP1 |
1.786e-02 | -4.03 | IL4 (interleukin 4) | protein interactions | 3565 | 7 | 1 | 19454 | 50 |
CD53 |
1.786e-02 | -4.03 | ALG1L1P (ALG1 like 1, pseudogene) | protein interactions | 200810 | 7 | 1 | 19454 | 50 |
ARAP3 |
1.786e-02 | -4.03 | Sptan1 (spectrin alpha, non-erythrocytic 1) | protein interactions | 20740 | 7 | 1 | 19454 | 50 |
SH3KBP1 |
1.786e-02 | -4.03 | Otud5 (OTU domain containing 5) | protein interactions | 54644 | 7 | 1 | 19454 | 50 |
FMNL1 |
1.786e-02 | -4.03 | MYT1L (myelin transcription factor 1 like) | protein interactions | 23040 | 7 | 1 | 19454 | 50 |
DISC1 |
1.786e-02 | -4.03 | Gadd45b (growth arrest and DNA-damage-inducible 45 beta) | protein interactions | 17873 | 7 | 1 | 19454 | 50 |
RXRA |
1.786e-02 | -4.03 | ZCCHC24 (zinc finger CCHC-type containing 24) | protein interactions | 219654 | 7 | 1 | 19454 | 50 |
RBM47 |
1.793e-02 | -4.02 | AH/BAR_dom_sf | interpro domains | IPR027267 | 76 | 2 | 18521 | 50 |
ARHGAP45,FCHO2 |
1.797e-02 | -4.02 | HNRNPC (heterogeneous nuclear ribonucleoprotein C) | protein interactions | 3183 | 595 | 5 | 19454 | 50 |
GLDC,RBM47,DISC1,HCK,SH3KBP1 |
1.801e-02 | -4.02 | STX2 (syntaxin 2) | protein interactions | 2054 | 80 | 2 | 19454 | 50 |
CD53,CERT1 |
1.815e-02 | -4.01 | Vitamin B6 Metabolism | SMPDB pathways | SMP0000017 | 5 | 1 | 1369 | 5 |
AOX1 |
1.815e-02 | -4.01 | Hypophosphatasia | SMPDB pathways | SMP0000503 | 5 | 1 | 1369 | 5 |
AOX1 |
1.823e-02 | -4.00 | immune response-regulating signaling pathway | biological process | GO:0002764 | 368 | 4 | 18204 | 50 |
CD276,BLNK,HCK,MEF2C |
1.823e-02 | -4.00 | activation of immune response | biological process | GO:0002253 | 368 | 4 | 18204 | 50 |
BLNK,CD276,MEF2C,HCK |
1.824e-02 | -4.00 | inflammatory response | biological process | GO:0006954 | 559 | 5 | 18204 | 50 |
BLNK,STAB1,CD68,CEBPB,HCK |
1.828e-02 | -4.00 | regulation of molecular function | biological process | GO:0065009 | 2005 | 11 | 18204 | 50 |
ADGRG3,DISC1,HCK,ARAP1,DAB2,ARHGAP45,FNIP1,RXRA,CTSV,MEF2C,PLEK |
1.828e-02 | -4.00 | protein-macromolecule adaptor activity | molecular function | GO:0030674 | 989 | 7 | 18094 | 50 |
RBM47,MARK4,DAB2,SH2B3,ETS1,BLNK,FLRT2 |
1.829e-02 | -4.00 | ovary-other-neoplasm | COSMIC cancer mutations | ovary-other-neoplasm | 12717 | 41 | 16828 | 46 |
SH3KBP1,RGL1,DAB2,DIAPH2,ABCC5,MICAL2,FMNL1,DOCK4,ETS1,CSF3R,CEBPB,TFEB,AOX1,SRGN,ATP8A1,FERMT3,ETV6,STAB1,ARAP1,MAN1A1,SGMS1,BLNK,CD53,ARHGEF1,MYO1F,MLKL,ARAP3,RBM47,SH2B3,RXRA,ELF4,GLDC,MEF2C,FNIP1,FCHO2,RHBDF1,FLRT2,PLEK,HCK,ABCA1,BAZ2B |
1.833e-02 | -4.00 | pleura-mesothelioma-biphasic | COSMIC cancer mutations | pleura-mesothelioma-biphasic | 76 | 2 | 16828 | 46 |
SH2B3,FNIP1 |
1.833e-02 | -4.00 | MADS_BOX_1 | prosite domains | PS00350 | 5 | 1 | 12186 | 45 |
MEF2C |
1.833e-02 | -4.00 | KA1 | prosite domains | PS50032 | 5 | 1 | 12186 | 45 |
MARK4 |
1.833e-02 | -4.00 | MADS_BOX_2 | prosite domains | PS50066 | 5 | 1 | 12186 | 45 |
MEF2C |
1.833e-02 | -4.00 | DDT | prosite domains | PS50827 | 5 | 1 | 12186 | 45 |
BAZ2B |
1.834e-02 | -4.00 | Hyaluronan biosynthesis and export | REACTOME pathways | R-HSA-2142850 | 5 | 1 | 10285 | 38 |
ABCC5 |
1.834e-02 | -4.00 | Reelin signalling pathway | REACTOME pathways | R-HSA-8866376 | 5 | 1 | 10285 | 38 |
SH3KBP1 |
1.834e-02 | -4.00 | N-glycan trimming and elongation in the cis-Golgi | REACTOME pathways | R-HSA-964739 | 5 | 1 | 10285 | 38 |
MAN1A1 |
1.843e-02 | -3.99 | DNMT3L (DNA methyltransferase 3 like) | protein interactions | 29947 | 81 | 2 | 19454 | 50 |
RXRA,ETS1 |
1.847e-02 | -3.99 | regulation of multicellular organismal development | biological process | GO:2000026 | 1484 | 9 | 18204 | 50 |
STAB1,CSF3R,CEBPB,DISC1,SRGN,FLRT2,ETS1,MEF2C,RXRA |
1.866e-02 | -3.98 | cell projection | cellular component | GO:0042995 | 2398 | 12 | 19108 | 50 |
FERMT3,HCK,SH3KBP1,MYO1F,ARAP3,PLEK,MARK4,ARHGAP45,FLRT2,DOCK4,FMNL1,DISC1 |
1.871e-02 | -3.98 | MGA (MAX dimerization protein MGA) | protein interactions | 23269 | 219 | 3 | 19454 | 50 |
ELF4,ARHGEF1,ETS1 |
1.874e-02 | -3.98 | upper_aerodigestive_tract-mouth-carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-mouth-carcinoma | 6426 | 25 | 16828 | 46 |
RHBDF1,GLDC,FCHO2,BAZ2B,HCK,PLEK,FLRT2,ABCA1,MYO1F,ARHGEF1,RBM47,ARAP3,FERMT3,ATP8A1,MAN1A1,MARK4,ARAP1,STAB1,SGMS1,DIAPH2,MICAL2,ABCC5,AOX1,FMNL1,DOCK4 |
1.875e-02 | -3.98 | MYSc_Myo1 | interpro domains | IPR036072 | 7 | 1 | 18521 | 50 |
MYO1F |
1.875e-02 | -3.98 | PH_16 | interpro domains | IPR041020 | 7 | 1 | 18521 | 50 |
ARHGEF1 |
1.875e-02 | -3.98 | KA1/Ssp2_C | interpro domains | IPR028375 | 7 | 1 | 18521 | 50 |
MARK4 |
1.875e-02 | -3.98 | Glyco_hydro_47 | interpro domains | IPR001382 | 7 | 1 | 18521 | 50 |
MAN1A1 |
1.875e-02 | -3.98 | Seven-hairpin_glycosidases | interpro domains | IPR036026 | 7 | 1 | 18521 | 50 |
MAN1A1 |
1.875e-02 | -3.98 | Prot_inhib_I29 | interpro domains | IPR013201 | 7 | 1 | 18521 | 50 |
CTSV |
1.875e-02 | -3.98 | Hematopoietin_rcpt_Gp130_CS | interpro domains | IPR003529 | 7 | 1 | 18521 | 50 |
CSF3R |
1.886e-02 | -3.97 | STAT6 (signal transducer and activator of transcription 6) | protein interactions | 6778 | 82 | 2 | 19454 | 50 |
CEBPB,ETS1 |
1.886e-02 | -3.97 | GINM1 (glycosylated integral membrane protein 1) | protein interactions | 116254 | 82 | 2 | 19454 | 50 |
CTSV,MAN1A1 |
1.886e-02 | -3.97 | PALS1 (protein associated with LIN7 1, MAGUK p55 family member) | protein interactions | 64398 | 82 | 2 | 19454 | 50 |
GLDC,SH3KBP1 |
1.886e-02 | -3.97 | MEF2D (myocyte enhancer factor 2D) | protein interactions | 4209 | 82 | 2 | 19454 | 50 |
MEF2C,RXRA |
1.888e-02 | -3.97 | positive regulation of response to external stimulus | biological process | GO:0032103 | 564 | 5 | 18204 | 50 |
MARK4,HCK,ETS1,CEBPB,RBM47 |
1.898e-02 | -3.96 | regulation of synaptic transmission, glutamatergic | biological process | GO:0051966 | 77 | 2 | 18204 | 50 |
DISC1,MEF2C |
1.898e-02 | -3.96 | regulation of cholesterol transport | biological process | GO:0032374 | 77 | 2 | 18204 | 50 |
RXRA,ABCA1 |
1.898e-02 | -3.96 | regulation of sterol transport | biological process | GO:0032371 | 77 | 2 | 18204 | 50 |
ABCA1,RXRA |
1.907e-02 | -3.96 | mannose trimming involved in glycoprotein ERAD pathway | biological process | GO:1904382 | 7 | 1 | 18204 | 50 |
MAN1A1 |
1.907e-02 | -3.96 | positive regulation of behavioral fear response | biological process | GO:2000987 | 7 | 1 | 18204 | 50 |
MEF2C |
1.907e-02 | -3.96 | protein alpha-1,2-demannosylation | biological process | GO:0036508 | 7 | 1 | 18204 | 50 |
MAN1A1 |
1.907e-02 | -3.96 | positive regulation of skeletal muscle cell differentiation | biological process | GO:2001016 | 7 | 1 | 18204 | 50 |
MEF2C |
1.907e-02 | -3.96 | PML body organization | biological process | GO:0030578 | 7 | 1 | 18204 | 50 |
ETS1 |
1.907e-02 | -3.96 | protein demannosylation | biological process | GO:0036507 | 7 | 1 | 18204 | 50 |
MAN1A1 |
1.907e-02 | -3.96 | hyaluronan biosynthetic process | biological process | GO:0030213 | 7 | 1 | 18204 | 50 |
ABCC5 |
1.907e-02 | -3.96 | aminophospholipid translocation | biological process | GO:0140331 | 7 | 1 | 18204 | 50 |
ATP8A1 |
1.907e-02 | -3.96 | regulation of phosphate transport | biological process | GO:0010966 | 7 | 1 | 18204 | 50 |
CEBPB |
1.907e-02 | -3.96 | hepatocyte proliferation | biological process | GO:0072574 | 7 | 1 | 18204 | 50 |
CEBPB |
1.907e-02 | -3.96 | regulation of thyroid hormone mediated signaling pathway | biological process | GO:0002155 | 7 | 1 | 18204 | 50 |
RXRA |
1.907e-02 | -3.96 | ubiquitin-dependent glycoprotein ERAD pathway | biological process | GO:0097466 | 7 | 1 | 18204 | 50 |
MAN1A1 |
1.907e-02 | -3.96 | cellular response to interleukin-3 | biological process | GO:0036016 | 7 | 1 | 18204 | 50 |
SH2B3 |
1.907e-02 | -3.96 | glutathione transmembrane transport | biological process | GO:0034775 | 7 | 1 | 18204 | 50 |
ABCC5 |
1.907e-02 | -3.96 | ceramide 1-phosphate transport | biological process | GO:1902389 | 7 | 1 | 18204 | 50 |
CERT1 |
1.907e-02 | -3.96 | platelet degranulation | biological process | GO:0002576 | 7 | 1 | 18204 | 50 |
PLEK |
1.907e-02 | -3.96 | epithelial cell proliferation involved in liver morphogenesis | biological process | GO:0072575 | 7 | 1 | 18204 | 50 |
CEBPB |
1.907e-02 | -3.96 | positive regulation of corticosteroid hormone secretion | biological process | GO:2000848 | 7 | 1 | 18204 | 50 |
DAB2 |
1.907e-02 | -3.96 | protein deglycosylation involved in glycoprotein catabolic process | biological process | GO:0035977 | 7 | 1 | 18204 | 50 |
MAN1A1 |
1.907e-02 | -3.96 | positive regulation of protein localization to centrosome | biological process | GO:1904781 | 7 | 1 | 18204 | 50 |
MARK4 |
1.907e-02 | -3.96 | response to interleukin-3 | biological process | GO:0036015 | 7 | 1 | 18204 | 50 |
SH2B3 |
1.912e-02 | -3.96 | Glyco_hydro_47 | pfam domains | PF01532 | 7 | 1 | 17795 | 49 |
MAN1A1 |
1.912e-02 | -3.96 | PH_16 | pfam domains | PF17838 | 7 | 1 | 17795 | 49 |
ARHGEF1 |
1.912e-02 | -3.96 | Inhibitor_I29 | pfam domains | PF08246 | 7 | 1 | 17795 | 49 |
CTSV |
1.915e-02 | -3.96 | GSK3B (glycogen synthase kinase 3 beta) | protein interactions | 2932 | 831 | 6 | 19454 | 50 |
DISC1,CEBPB,FNIP1,DAB2,CSF3R,RXRA |
1.919e-02 | -3.95 | mannosyl-oligosaccharide 1,2-alpha-mannosidase activity | molecular function | GO:0004571 | 7 | 1 | 18094 | 50 |
MAN1A1 |
1.919e-02 | -3.95 | aminophospholipid flippase activity | molecular function | GO:0015247 | 7 | 1 | 18094 | 50 |
ATP8A1 |
1.919e-02 | -3.95 | LBD domain binding | molecular function | GO:0050693 | 7 | 1 | 18094 | 50 |
RXRA |
1.919e-02 | -3.95 | ceramide 1-phosphate transfer activity | molecular function | GO:1902388 | 7 | 1 | 18094 | 50 |
CERT1 |
1.919e-02 | -3.95 | tripeptide transmembrane transporter activity | molecular function | GO:0042937 | 7 | 1 | 18094 | 50 |
ABCC5 |
1.919e-02 | -3.95 | ceramide 1-phosphate binding | molecular function | GO:1902387 | 7 | 1 | 18094 | 50 |
CERT1 |
1.930e-02 | -3.95 | TMEM30B (transmembrane protein 30B) | protein interactions | 161291 | 83 | 2 | 19454 | 50 |
MAN1A1,CD276 |
1.930e-02 | -3.95 | N4BP2 (NEDD4 binding protein 2) | protein interactions | 55728 | 83 | 2 | 19454 | 50 |
RBM47,DISC1 |
1.930e-02 | -3.95 | GGA2 (golgi associated, gamma adaptin ear containing, ARF binding protein 2) | protein interactions | 23062 | 83 | 2 | 19454 | 50 |
ETS1,STAB1 |
1.930e-02 | -3.95 | CYBC1 (cytochrome b-245 chaperone 1) | protein interactions | 79415 | 83 | 2 | 19454 | 50 |
ETS1,CD53 |
1.930e-02 | -3.95 | R3HDM1 (R3H domain containing 1) | protein interactions | 23518 | 83 | 2 | 19454 | 50 |
RBM47,GLDC |
1.933e-02 | -3.95 | - | gene3d domains | 3.30.465.10 | 6 | 1 | 14470 | 47 |
AOX1 |
1.933e-02 | -3.95 | - | gene3d domains | 2.40.160.110 | 6 | 1 | 14470 | 47 |
CD68 |
1.940e-02 | -3.94 | DDT | smart domains | SM00571 | 5 | 1 | 9717 | 38 |
BAZ2B |
1.940e-02 | -3.94 | MADS | smart domains | SM00432 | 5 | 1 | 9717 | 38 |
MEF2C |
1.944e-02 | -3.94 | positive regulation of osteoblast differentiation | biological process | GO:0045669 | 78 | 2 | 18204 | 50 |
MEF2C,CEBPB |
1.974e-02 | -3.93 | SRF (serum response factor) | protein interactions | 6722 | 84 | 2 | 19454 | 50 |
RXRA,CEBPB |
1.974e-02 | -3.93 | NFKBIB (NFKB inhibitor beta) | protein interactions | 4793 | 84 | 2 | 19454 | 50 |
RXRA,ARAP3 |
1.974e-02 | -3.93 | Chmp4b (charged multivesicular body protein 4B) | protein interactions | 75608 | 84 | 2 | 19454 | 50 |
BAZ2B,FNIP1 |
1.974e-02 | -3.93 | PTAR1 (protein prenyltransferase alpha subunit repeat containing 1) | protein interactions | 375743 | 84 | 2 | 19454 | 50 |
SGMS1,CERT1 |
1.983e-02 | -3.92 | large_intestine-colon-carcinoma | COSMIC cancer mutations | large_intestine-colon-carcinoma | 2612 | 13 | 16828 | 46 |
DAB2,MYO1F,RGL1,MICAL2,ARHGEF1,AOX1,MLKL,ETV6,FNIP1,ATP8A1,BAZ2B,ARAP1,ABCA1 |
1.990e-02 | -3.92 | Endochondral Ossification | WikiPathways | WP474 | 65 | 2 | 5310 | 18 |
CTSV,MEF2C |
1.991e-02 | -3.92 | myeloid cell development | biological process | GO:0061515 | 79 | 2 | 18204 | 50 |
CEBPB,SH2B3 |
1.991e-02 | -3.92 | CLTC (clathrin heavy chain) | protein interactions | 1213 | 611 | 5 | 19454 | 50 |
FCHO2,DAB2,SH3KBP1,GLDC,ARHGEF1 |
2.018e-02 | -3.90 | Nicotine Metabolism | WikiPathways | WP1600 | 6 | 1 | 5310 | 18 |
AOX1 |
2.032e-02 | -3.90 | TGM2 (transglutaminase 2) | protein interactions | 7052 | 226 | 3 | 19454 | 50 |
ABCA1,CERT1,DISC1 |
2.038e-02 | -3.89 | CNIH2 (cornichon family AMPA receptor auxiliary protein 2) | protein interactions | 254263 | 8 | 1 | 19454 | 50 |
CD53 |
2.038e-02 | -3.89 | CD37 (CD37 molecule) | protein interactions | 951 | 8 | 1 | 19454 | 50 |
CD53 |
2.038e-02 | -3.89 | Ap2b1 (adaptor-related protein complex 2, beta 1 subunit) | protein interactions | 71770 | 8 | 1 | 19454 | 50 |
SH3KBP1 |
2.038e-02 | -3.89 | Fem1b (fem 1 homolog b) | protein interactions | 14155 | 8 | 1 | 19454 | 50 |
FNIP1 |
2.038e-02 | -3.89 | MINAR1 (membrane integral NOTCH2 associated receptor 1) | protein interactions | 23251 | 8 | 1 | 19454 | 50 |
CERT1 |
2.038e-02 | -3.89 | KMO (kynurenine 3-monooxygenase) | protein interactions | 8564 | 8 | 1 | 19454 | 50 |
DISC1 |
2.040e-02 | -3.89 | HSPH1 (heat shock protein family H (Hsp110) member 1) | protein interactions | 10808 | 407 | 4 | 19454 | 50 |
SH3KBP1,DAB2,BLNK,GLDC |
2.042e-02 | -3.89 | RAC3 (Rac family small GTPase 3) | protein interactions | 5881 | 615 | 5 | 19454 | 50 |
FCHO2,ARAP3,DIAPH2,ABCC5,FLRT2 |
2.042e-02 | -3.89 | UBE2I (ubiquitin conjugating enzyme E2 I) | protein interactions | 7329 | 615 | 5 | 19454 | 50 |
RXRA,ETS1,SH3KBP1,ETV6,MEF2C |
2.042e-02 | -3.89 | positive regulation of cell activation | biological process | GO:0050867 | 381 | 4 | 18204 | 50 |
CD276,SH3KBP1,MEF2C,PLEK |
2.063e-02 | -3.88 | RBFOX1 (RNA binding fox-1 homolog 1) | protein interactions | 54715 | 86 | 2 | 19454 | 50 |
RBM47,CTSV |
2.063e-02 | -3.88 | SYNJ1 (synaptojanin 1) | protein interactions | 8867 | 86 | 2 | 19454 | 50 |
SH3KBP1,RBM47 |
2.064e-02 | -3.88 | negative regulation of cell population proliferation | biological process | GO:0008285 | 791 | 6 | 18204 | 50 |
FNIP1,SH2B3,MEF2C,ETS1,CEBPB,DAB2 |
2.075e-02 | -3.88 | presynaptic endocytic zone membrane | cellular component | GO:0098835 | 8 | 1 | 19108 | 50 |
FCHO2 |
2.092e-02 | -3.87 | positive regulation of macromolecule metabolic process | biological process | GO:0010604 | 3485 | 16 | 18204 | 50 |
BLNK,RXRA,FNIP1,RBM47,ETS1,CEBPB,ETV6,ELF4,MICAL2,MEF2C,CTSV,CD276,DISC1,ARAP1,DAB2,TFEB |
2.100e-02 | -3.86 | rhabdomyosarcoma | COSMIC cancer mutations | rhabdomyosarcoma | 4150 | 18 | 16828 | 46 |
RHBDF1,ETV6,CD276,FNIP1,ABCA1,ABCC5,RGL1,DAB2,DIAPH2,SH3KBP1,AOX1,SH2B3,FMNL1,DOCK4,ARAP3,ETS1,CEBPB,MLKL |
2.105e-02 | -3.86 | diffuse_large_B_cell_lymphoma | COSMIC cancer mutations | diffuse_large_B_cell_lymphoma | 4151 | 18 | 16828 | 46 |
BAZ2B,MAN1A1,FLRT2,HCK,ETV6,ATP8A1,MEF2C,FNIP1,SRGN,ARAP3,ETS1,MLKL,MICAL2,DIAPH2,ARHGEF1,SH3KBP1,BLNK,CD53 |
2.108e-02 | -3.86 | TAF1B (TATA-box binding protein associated factor, RNA polymerase I subunit B) | protein interactions | 9014 | 87 | 2 | 19454 | 50 |
FERMT3,RXRA |
2.108e-02 | -3.86 | GK (glycerol kinase) | protein interactions | 2710 | 87 | 2 | 19454 | 50 |
RXRA,AOX1 |
2.108e-02 | -3.86 | PLCG2 (phospholipase C gamma 2) | protein interactions | 5336 | 87 | 2 | 19454 | 50 |
HCK,BLNK |
2.127e-02 | -3.85 | CD44 (CD44 molecule (IN blood group)) | protein interactions | 960 | 230 | 3 | 19454 | 50 |
FMNL1,ARHGEF1,SRGN |
2.127e-02 | -3.85 | developmental process | biological process | GO:0032502 | 5716 | 23 | 18204 | 50 |
MEF2C,TFEB,SRGN,ADGRG3,RBM47,MARK4,CERT1,BLNK,SH2B3,FNIP1,CSF3R,HCK,MICAL2,PLEK,ELF4,DIAPH2,DAB2,DISC1,FLRT2,ETS1,RXRA,CEBPB,ETV6 |
2.127e-02 | -3.85 | positive regulation of metabolic process | biological process | GO:0009893 | 3796 | 17 | 18204 | 50 |
CTSV,MEF2C,PLEK,MICAL2,ELF4,DAB2,TFEB,ARAP1,CD276,DISC1,ETS1,RBM47,FNIP1,RXRA,BLNK,ETV6,CEBPB |
2.138e-02 | -3.85 | mesothelioma | COSMIC cancer mutations | mesothelioma | 4477 | 19 | 16828 | 46 |
MAN1A1,MARK4,SGMS1,HCK,ETV6,MEF2C,FNIP1,TFEB,SH2B3,ELF4,MLKL,ARAP3,CEBPB,ETS1,RGL1,DAB2,DIAPH2,ARHGEF1,SH3KBP1 |
2.140e-02 | -3.84 | bMERB_dom | interpro domains | IPR022735 | 8 | 1 | 18521 | 50 |
MICAL2 |
2.140e-02 | -3.84 | Peptidase_C1A_papain-like | interpro domains | IPR039417 | 8 | 1 | 18521 | 50 |
CTSV |
2.140e-02 | -3.84 | Myosin_TH1 | interpro domains | IPR010926 | 8 | 1 | 18521 | 50 |
MYO1F |
2.175e-02 | -3.83 | Nicotine Metabolism Pathway | SMPDB pathways | SMP0000628 | 6 | 1 | 1369 | 5 |
AOX1 |
2.177e-02 | -3.83 | regulation of Cdc42 protein signal transduction | biological process | GO:0032489 | 8 | 1 | 18204 | 50 |
ABCA1 |
2.177e-02 | -3.83 | cardiac ventricle formation | biological process | GO:0003211 | 8 | 1 | 18204 | 50 |
MEF2C |
2.177e-02 | -3.83 | regulation of aldosterone biosynthetic process | biological process | GO:0032347 | 8 | 1 | 18204 | 50 |
DAB2 |
2.177e-02 | -3.83 | regulation of aldosterone metabolic process | biological process | GO:0032344 | 8 | 1 | 18204 | 50 |
DAB2 |
2.177e-02 | -3.83 | positive regulation of fear response | biological process | GO:1903367 | 8 | 1 | 18204 | 50 |
MEF2C |
2.177e-02 | -3.83 | regulation of germinal center formation | biological process | GO:0002634 | 8 | 1 | 18204 | 50 |
MEF2C |
2.177e-02 | -3.83 | regulation of pro-B cell differentiation | biological process | GO:2000973 | 8 | 1 | 18204 | 50 |
FNIP1 |
2.177e-02 | -3.83 | granzyme-mediated programmed cell death signaling pathway | biological process | GO:0140507 | 8 | 1 | 18204 | 50 |
SRGN |
2.177e-02 | -3.83 | necroptotic signaling pathway | biological process | GO:0097527 | 8 | 1 | 18204 | 50 |
MLKL |
2.182e-02 | -3.83 | RNGMNOXGNASE | prints domains | PR00420 | 5 | 1 | 5227 | 23 |
MICAL2 |
2.182e-02 | -3.83 | MADSDOMAIN | prints domains | PR00404 | 5 | 1 | 5227 | 23 |
MEF2C |
2.182e-02 | -3.82 | Myosin_TH1 | pfam domains | PF06017 | 8 | 1 | 17795 | 49 |
MYO1F |
2.182e-02 | -3.82 | bMERB_dom | pfam domains | PF12130 | 8 | 1 | 17795 | 49 |
MICAL2 |
2.184e-02 | -3.82 | positive regulation of B cell activation | biological process | GO:0050871 | 83 | 2 | 18204 | 50 |
SH3KBP1,MEF2C |
2.190e-02 | -3.82 | phosphatidylcholine floppase activity | molecular function | GO:0090554 | 8 | 1 | 18094 | 50 |
ABCA1 |
2.190e-02 | -3.82 | ceramide transfer activity | molecular function | GO:0120017 | 8 | 1 | 18094 | 50 |
CERT1 |
2.196e-02 | -3.82 | FAD_PCMH | prosite domains | PS51387 | 6 | 1 | 12186 | 45 |
AOX1 |
2.196e-02 | -3.82 | 2FE2S_FER_2 | prosite domains | PS51085 | 6 | 1 | 12186 | 45 |
AOX1 |
2.199e-02 | -3.82 | SLC25A41 (solute carrier family 25 member 41) | protein interactions | 284427 | 89 | 2 | 19454 | 50 |
DAB2,FCHO2 |
2.212e-02 | -3.81 | RHOJ (ras homolog family member J) | protein interactions | 57381 | 628 | 5 | 19454 | 50 |
DIAPH2,FCHO2,FMNL1,FLRT2,ABCC5 |
2.214e-02 | -3.81 | Endocytosis | KEGG pathways | ko04144 | 260 | 4 | 7161 | 30 |
ARAP3,ARAP1,SH3KBP1,DAB2 |
2.214e-02 | -3.81 | Endocytosis | KEGG pathways | hsa04144 | 260 | 4 | 7161 | 30 |
DAB2,SH3KBP1,ARAP1,ARAP3 |
2.219e-02 | -3.81 | Signaling mediated by p38-alpha and p38-beta | Pathway Interaction DB | p38alphabetadownstreampathway | 35 | 2 | 2226 | 15 |
CEBPB,MEF2C |
2.224e-02 | -3.81 | SEC24B (SEC24 homolog B, COPII coat complex component) | protein interactions | 10427 | 234 | 3 | 19454 | 50 |
DAB2,MAN1A1,GLDC |
2.241e-02 | -3.80 | large_intestine-colon | COSMIC cancer mutations | large_intestine-colon | 1291 | 8 | 16828 | 46 |
MAN1A1,STAB1,ABCA1,FLRT2,ETV6,MICAL2,ABCC5,MEF2C |
2.262e-02 | -3.79 | soft_tissue | COSMIC cancer mutations | soft_tissue | 5828 | 23 | 16828 | 46 |
ABCC5,RGL1,DIAPH2,DAB2,SH3KBP1,BLNK,AOX1,SH2B3,ARAP3,DOCK4,FMNL1,ETS1,CEBPB,MLKL,RHBDF1,ETV6,ATP8A1,GLDC,FNIP1,CD276,BAZ2B,ABCA1,PLEK |
2.272e-02 | -3.78 | human chr3q25.32 | chromosome location | human chr3q25.32 | 12 | 1 | 26134 | 50 |
MFSD1 |
2.273e-02 | -3.78 | embryonal | COSMIC cancer mutations | embryonal | 2659 | 13 | 16828 | 46 |
FNIP1,RHBDF1,ETV6,ABCA1,SH3KBP1,ABCC5,DIAPH2,DAB2,FMNL1,DOCK4,ETS1,CEBPB,SH2B3 |
2.273e-02 | -3.78 | soft_tissue-striated_muscle-rhabdomyosarcoma-embryonal | COSMIC cancer mutations | soft_tissue-striated_muscle-rhabdomyosarcoma-embryonal | 2659 | 13 | 16828 | 46 |
RHBDF1,ETV6,FNIP1,ABCA1,DAB2,DIAPH2,ABCC5,SH3KBP1,SH2B3,FMNL1,DOCK4,CEBPB,ETS1 |
2.274e-02 | -3.78 | positive regulation of cell migration | biological process | GO:0030335 | 592 | 5 | 18204 | 50 |
ETS1,DAB2,DOCK4,ATP8A1,FERMT3 |
2.283e-02 | -3.78 | embryonic heart tube development | biological process | GO:0035050 | 85 | 2 | 18204 | 50 |
MICAL2,MEF2C |
2.289e-02 | -3.78 | supramolecular fiber organization | biological process | GO:0097435 | 593 | 5 | 18204 | 50 |
DIAPH2,SH3KBP1,MYO1F,MICAL2,ARAP1 |
2.290e-02 | -3.78 | PCNX4 (pecanex 4) | protein interactions | 64430 | 9 | 1 | 19454 | 50 |
DISC1 |
2.290e-02 | -3.78 | RTKN2 (rhotekin 2) | protein interactions | 219790 | 9 | 1 | 19454 | 50 |
SH3KBP1 |
2.290e-02 | -3.78 | PPFIA4 (PTPRF interacting protein alpha 4) | protein interactions | 8497 | 9 | 1 | 19454 | 50 |
DISC1 |
2.290e-02 | -3.78 | SEMA3A (semaphorin 3A) | protein interactions | 10371 | 9 | 1 | 19454 | 50 |
DISC1 |
2.290e-02 | -3.78 | CHI3L2 (chitinase 3 like 2) | protein interactions | 1117 | 9 | 1 | 19454 | 50 |
ETS1 |
2.290e-02 | -3.78 | ALG14 (ALG14 UDP-N-acetylglucosaminyltransferase subunit) | protein interactions | 199857 | 9 | 1 | 19454 | 50 |
CD53 |
2.290e-02 | -3.78 | RBM46 (RNA binding motif protein 46) | protein interactions | 166863 | 9 | 1 | 19454 | 50 |
RBM47 |
2.292e-02 | -3.78 | SOS1 (SOS Ras/Rac guanine nucleotide exchange factor 1) | protein interactions | 6654 | 91 | 2 | 19454 | 50 |
HCK,SH3KBP1 |
2.292e-02 | -3.78 | TRIO (trio Rho guanine nucleotide exchange factor) | protein interactions | 7204 | 91 | 2 | 19454 | 50 |
DAB2,DISC1 |
2.299e-02 | -3.77 | CAMK2A (calcium/calmodulin dependent protein kinase II alpha) | protein interactions | 815 | 237 | 3 | 19454 | 50 |
CEBPB,RBM47,ETS1 |
2.313e-02 | -3.77 | nicotine degradation III | BIOCYC pathways | HUMAN_PWY66-221 | 7 | 1 | 902 | 3 |
AOX1 |
2.313e-02 | -3.77 | sphingomyelin metabolism/ceramide salvage | BIOCYC pathways | HUMAN_PWY3DJ-11281 | 7 | 1 | 902 | 3 |
SGMS1 |
2.324e-02 | -3.76 | TAF6 (TATA-box binding protein associated factor 6) | protein interactions | 6878 | 238 | 3 | 19454 | 50 |
ELF4,SH3KBP1,ETS1 |
2.324e-02 | -3.76 | CDC16 (cell division cycle 16) | protein interactions | 8881 | 238 | 3 | 19454 | 50 |
SH3KBP1,DISC1,DAB2 |
2.331e-02 | -3.76 | chromaffin granule membrane | cellular component | GO:0042584 | 9 | 1 | 19108 | 50 |
ATP8A1 |
2.331e-02 | -3.76 | bleb | cellular component | GO:0032059 | 9 | 1 | 19108 | 50 |
FMNL1 |
2.331e-02 | -3.76 | presynaptic endocytic zone | cellular component | GO:0098833 | 9 | 1 | 19108 | 50 |
FCHO2 |
2.331e-02 | -3.76 | unconventional myosin complex | cellular component | GO:0016461 | 9 | 1 | 19108 | 50 |
MYO1F |
2.334e-02 | -3.76 | vascular transport | biological process | GO:0010232 | 86 | 2 | 18204 | 50 |
ATP8A1,ABCC5 |
2.334e-02 | -3.76 | transport across blood-brain barrier | biological process | GO:0150104 | 86 | 2 | 18204 | 50 |
ATP8A1,ABCC5 |
2.350e-02 | -3.75 | Effects of Nitric Oxide | WikiPathways | WP1995 | 7 | 1 | 5310 | 18 |
AOX1 |
2.370e-02 | -3.74 | platelet alpha granule | cellular component | GO:0031091 | 91 | 2 | 19108 | 50 |
SRGN,FERMT3 |
2.378e-02 | -3.74 | negative regulation of intracellular signal transduction | biological process | GO:1902532 | 599 | 5 | 18204 | 50 |
ADGRG3,FNIP1,SH2B3,PLEK,DAB2 |
2.384e-02 | -3.74 | embryonic placenta development | biological process | GO:0001892 | 87 | 2 | 18204 | 50 |
TFEB,CEBPB |
2.387e-02 | -3.74 | ARHGAP17 (Rho GTPase activating protein 17) | protein interactions | 55114 | 93 | 2 | 19454 | 50 |
SH3KBP1,FMNL1 |
2.387e-02 | -3.74 | MPDZ (multiple PDZ domain crumbs cell polarity complex component) | protein interactions | 8777 | 93 | 2 | 19454 | 50 |
ABCA1,GLDC |
2.387e-02 | -3.74 | ATF4 (activating transcription factor 4) | protein interactions | 468 | 93 | 2 | 19454 | 50 |
DISC1,CEBPB |
2.404e-02 | -3.73 | Peptidase_S54_rhomboid_dom | interpro domains | IPR022764 | 9 | 1 | 18521 | 50 |
RHBDF1 |
2.411e-02 | -3.73 | localization | biological process | GO:0051179 | 4474 | 19 | 18204 | 50 |
CD68,PLEK,ATP8A1,MYO1F,RHBDF1,MAN1A1,DAB2,TFEB,FCHO2,ABCC5,DISC1,MFSD1,SRGN,CERT1,STAB1,ARAP3,HCK,SH3KBP1,ABCA1 |
2.434e-02 | -3.72 | storiform_pleomorphic | COSMIC cancer mutations | storiform_pleomorphic | 9 | 1 | 16828 | 46 |
ETV6 |
2.434e-02 | -3.72 | soft_tissue-fibrous_tissue_and_uncertain_origin-malignant_fibrous_histiocytoma-pleomorphic_sarcoma-storiform_pleomorphic | COSMIC cancer mutations | soft_tissue-fibrous_tissue_and_uncertain_origin-malignant_fibrous_histiocytoma-pleomorphic_sarcoma-storiform_pleomorphic | 9 | 1 | 16828 | 46 |
ETV6 |
2.435e-02 | -3.72 | KANSL1 (KAT8 regulatory NSL complex subunit 1) | protein interactions | 284058 | 94 | 2 | 19454 | 50 |
DISC1,ELF4 |
2.439e-02 | -3.71 | regulation of proteolysis | biological process | GO:0030162 | 603 | 5 | 18204 | 50 |
FNIP1,DISC1,RHBDF1,CTSV,DAB2 |
2.441e-02 | -3.71 | response to endoplasmic reticulum stress | biological process | GO:0034976 | 227 | 3 | 18204 | 50 |
CERT1,CEBPB,MAN1A1 |
2.446e-02 | -3.71 | positive regulation of Wnt signaling pathway, planar cell polarity pathway | biological process | GO:2000096 | 9 | 1 | 18204 | 50 |
DAB2 |
2.446e-02 | -3.71 | positive regulation of hormone biosynthetic process | biological process | GO:0046886 | 9 | 1 | 18204 | 50 |
DAB2 |
2.446e-02 | -3.71 | negative regulation of antigen processing and presentation | biological process | GO:0002578 | 9 | 1 | 18204 | 50 |
CD68 |
2.446e-02 | -3.71 | negative regulation of chemokine-mediated signaling pathway | biological process | GO:0070100 | 9 | 1 | 18204 | 50 |
SH2B3 |
2.446e-02 | -3.71 | tripeptide transmembrane transport | biological process | GO:0035443 | 9 | 1 | 18204 | 50 |
ABCC5 |
2.446e-02 | -3.71 | positive regulation of early endosome to late endosome transport | biological process | GO:2000643 | 9 | 1 | 18204 | 50 |
DAB2 |
2.446e-02 | -3.71 | glomerulus morphogenesis | biological process | GO:0072102 | 9 | 1 | 18204 | 50 |
MEF2C |
2.446e-02 | -3.71 | positive regulation of myeloid cell apoptotic process | biological process | GO:0033034 | 9 | 1 | 18204 | 50 |
MEF2C |
2.446e-02 | -3.71 | glutathione transport | biological process | GO:0034635 | 9 | 1 | 18204 | 50 |
ABCC5 |
2.446e-02 | -3.71 | respiratory burst involved in defense response | biological process | GO:0002679 | 9 | 1 | 18204 | 50 |
HCK |
2.446e-02 | -3.71 | liver morphogenesis | biological process | GO:0072576 | 9 | 1 | 18204 | 50 |
CEBPB |
2.446e-02 | -3.71 | heme transport | biological process | GO:0015886 | 9 | 1 | 18204 | 50 |
ABCC5 |
2.446e-02 | -3.71 | aminophospholipid transport | biological process | GO:0015917 | 9 | 1 | 18204 | 50 |
ATP8A1 |
2.446e-02 | -3.71 | antibacterial innate immune response | biological process | GO:0140367 | 9 | 1 | 18204 | 50 |
TFEB |
2.446e-02 | -3.71 | peroxisome proliferator activated receptor signaling pathway | biological process | GO:0035357 | 9 | 1 | 18204 | 50 |
RXRA |
2.446e-02 | -3.71 | regulation of vascular associated smooth muscle contraction | biological process | GO:0003056 | 9 | 1 | 18204 | 50 |
DOCK4 |
2.452e-02 | -3.71 | Rhomboid | pfam domains | PF01694 | 9 | 1 | 17795 | 49 |
RHBDF1 |
2.452e-02 | -3.71 | MBD | pfam domains | PF01429 | 9 | 1 | 17795 | 49 |
BAZ2B |
2.459e-02 | -3.71 | human chr4p13 | chromosome location | human chr4p13 | 13 | 1 | 26134 | 50 |
ATP8A1 |
2.459e-02 | -3.71 | human chr11p15.3 | chromosome location | human chr11p15.3 | 13 | 1 | 26134 | 50 |
MICAL2 |
2.460e-02 | -3.70 | sphingolipid transfer activity | molecular function | GO:0120016 | 9 | 1 | 18094 | 50 |
CERT1 |
2.460e-02 | -3.70 | heme transmembrane transporter activity | molecular function | GO:0015232 | 9 | 1 | 18094 | 50 |
ABCC5 |
2.460e-02 | -3.70 | NAD(P)H oxidase H2O2-forming activity | molecular function | GO:0016174 | 9 | 1 | 18094 | 50 |
MICAL2 |
2.460e-02 | -3.70 | mannosyl-oligosaccharide mannosidase activity | molecular function | GO:0015924 | 9 | 1 | 18094 | 50 |
MAN1A1 |
2.460e-02 | -3.70 | angiotensin receptor binding | molecular function | GO:0031701 | 9 | 1 | 18094 | 50 |
ARAP1 |
2.463e-02 | -3.70 | flavin adenine dinucleotide binding | molecular function | GO:0050660 | 88 | 2 | 18094 | 50 |
MICAL2,AOX1 |
2.471e-02 | -3.70 | macromolecule localization | biological process | GO:0033036 | 2376 | 12 | 18204 | 50 |
ABCA1,CERT1,DAB2,FCHO2,SRGN,MFSD1,DISC1,CD68,ATP8A1,PLEK,RHBDF1,MAN1A1 |
2.487e-02 | -3.69 | regulation of leukocyte apoptotic process | biological process | GO:2000106 | 89 | 2 | 18204 | 50 |
MEF2C,FNIP1 |
2.488e-02 | -3.69 | N-glycan precursor trimming | KEGG pathways | hsa_M00073 | 6 | 1 | 7161 | 30 |
MAN1A1 |
2.488e-02 | -3.69 | Vitamin B6 metabolism | KEGG pathways | hsa00750 | 6 | 1 | 7161 | 30 |
AOX1 |
2.488e-02 | -3.69 | Vitamin B6 metabolism | KEGG pathways | ko00750 | 6 | 1 | 7161 | 30 |
AOX1 |
2.488e-02 | -3.69 | N-glycan precursor trimming | KEGG pathways | M00073 | 6 | 1 | 7161 | 30 |
MAN1A1 |
2.496e-02 | -3.69 | regulation of proteolysis involved in protein catabolic process | biological process | GO:1903050 | 229 | 3 | 18204 | 50 |
DISC1,RHBDF1,DAB2 |
2.507e-02 | -3.69 | guanyl-nucleotide exchange factor activity | molecular function | GO:0005085 | 228 | 3 | 18094 | 50 |
RGL1,DOCK4,ARHGEF1 |
2.519e-02 | -3.68 | striated_muscle | COSMIC cancer mutations | striated_muscle | 4228 | 18 | 16828 | 46 |
MLKL,ETS1,CEBPB,ARAP3,FMNL1,DOCK4,SH2B3,AOX1,SH3KBP1,DIAPH2,DAB2,RGL1,ABCC5,ABCA1,CD276,FNIP1,ETV6,RHBDF1 |
2.525e-02 | -3.68 | focal adhesion | cellular component | GO:0005925 | 427 | 4 | 19108 | 50 |
SH3KBP1,HCK,DAB2,FLRT2 |
2.527e-02 | -3.68 | Arfaptin homology (AH) domain/BAR domain | gene3d domains | 1.20.1270.60 | 76 | 2 | 14470 | 47 |
FCHO2,ARHGAP45 |
2.532e-02 | -3.68 | TRIM35 (tripartite motif containing 35) | protein interactions | 23087 | 96 | 2 | 19454 | 50 |
ARAP3,MYO1F |
2.532e-02 | -3.68 | SMARCD3 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily d, member 3) | protein interactions | 6604 | 96 | 2 | 19454 | 50 |
ETS1,RXRA |
2.532e-02 | -3.68 | RPRM (reprimo, TP53 dependent G2 arrest mediator homolog) | protein interactions | 56475 | 96 | 2 | 19454 | 50 |
CD53,ADGRG3 |
2.534e-02 | -3.68 | Citalopram Metabolism Pathway | SMPDB pathways | SMP0000627 | 7 | 1 | 1369 | 5 |
AOX1 |
2.541e-02 | -3.67 | PLA2G1B (phospholipase A2 group IB) | protein interactions | 5319 | 10 | 1 | 19454 | 50 |
CSF3R |
2.541e-02 | -3.67 | MACC1 (MET transcriptional regulator MACC1) | protein interactions | 346389 | 10 | 1 | 19454 | 50 |
FCHO2 |
2.541e-02 | -3.67 | Cltc (clathrin heavy chain) | protein interactions | 67300 | 10 | 1 | 19454 | 50 |
SH3KBP1 |
2.541e-02 | -3.67 | PRTG (protogenin) | protein interactions | 283659 | 10 | 1 | 19454 | 50 |
DISC1 |
2.541e-02 | -3.67 | ARHGAP27 (Rho GTPase activating protein 27) | protein interactions | 201176 | 10 | 1 | 19454 | 50 |
SH3KBP1 |
2.541e-02 | -3.67 | CYGB (cytoglobin) | protein interactions | 114757 | 10 | 1 | 19454 | 50 |
SH3KBP1 |
2.541e-02 | -3.67 | AOX1 (aldehyde oxidase 1) | protein interactions | 316 | 10 | 1 | 19454 | 50 |
ABCA1 |
2.541e-02 | -3.67 | METTL26 (methyltransferase like 26) | protein interactions | 84326 | 10 | 1 | 19454 | 50 |
DISC1 |
2.541e-02 | -3.67 | LSMEM1 (leucine rich single-pass membrane protein 1) | protein interactions | 286006 | 10 | 1 | 19454 | 50 |
CD53 |
2.541e-02 | -3.67 | RASGEF1B (RasGEF domain family member 1B) | protein interactions | 153020 | 10 | 1 | 19454 | 50 |
BAZ2B |
2.553e-02 | -3.67 | cellular response to nutrient levels | biological process | GO:0031669 | 231 | 3 | 18204 | 50 |
TFEB,CD68,FNIP1 |
2.557e-02 | -3.67 | HEMATOPO_REC_L_F2 | prosite domains | PS01353 | 7 | 1 | 12186 | 45 |
CSF3R |
2.558e-02 | -3.67 | PICALM (phosphatidylinositol binding clathrin assembly protein) | protein interactions | 8301 | 247 | 3 | 19454 | 50 |
FCHO2,DAB2,RBM47 |
2.561e-02 | -3.66 | enzyme regulator activity | molecular function | GO:0030234 | 1305 | 8 | 18094 | 50 |
FNIP1,ARAP3,CTSV,ARAP1,ARHGEF1,DOCK4,ARHGAP45,RGL1 |
2.570e-02 | -3.66 | Kinase associated domain 1, KA1 | gene3d domains | 3.30.310.80 | 8 | 1 | 14470 | 47 |
MARK4 |
2.581e-02 | -3.66 | CBLB (Cbl proto-oncogene B) | protein interactions | 868 | 97 | 2 | 19454 | 50 |
SH3KBP1,BLNK |
2.581e-02 | -3.66 | SOCS3 (suppressor of cytokine signaling 3) | protein interactions | 9021 | 97 | 2 | 19454 | 50 |
ETV6,CSF3R |
2.585e-02 | -3.66 | KAT2B (lysine acetyltransferase 2B) | protein interactions | 8850 | 248 | 3 | 19454 | 50 |
ELF4,ETS1,CEBPB |
2.585e-02 | -3.66 | MET (MET proto-oncogene, receptor tyrosine kinase) | protein interactions | 4233 | 248 | 3 | 19454 | 50 |
HCK,SH3KBP1,SH2B3 |
2.587e-02 | -3.65 | Golgi trans cisterna | cellular component | GO:0000138 | 10 | 1 | 19108 | 50 |
SGMS1 |
2.592e-02 | -3.65 | regulation of smooth muscle cell migration | biological process | GO:0014910 | 91 | 2 | 18204 | 50 |
DOCK4,MEF2C |
2.595e-02 | -3.65 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-myelofibrosis | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-myelofibrosis | 413 | 4 | 16828 | 46 |
DIAPH2,SH2B3,CSF3R,ETS1 |
2.595e-02 | -3.65 | myelofibrosis | COSMIC cancer mutations | myelofibrosis | 413 | 4 | 16828 | 46 |
ETS1,CSF3R,SH2B3,DIAPH2 |
2.631e-02 | -3.64 | WDCP (WD repeat and coiled coil containing) | protein interactions | 80304 | 98 | 2 | 19454 | 50 |
ETV6,HCK |
2.644e-02 | -3.63 | RHOQ (ras homolog family member Q) | protein interactions | 23433 | 441 | 4 | 19454 | 50 |
FCHO2,DIAPH2,ABCC5,FLRT2 |
2.646e-02 | -3.63 | human chr14q31.3 | chromosome location | human chr14q31.3 | 14 | 1 | 26134 | 50 |
FLRT2 |
2.648e-02 | -3.63 | cell junction | cellular component | GO:0030054 | 2224 | 11 | 19108 | 50 |
ATP8A1,FCHO2,FERMT3,SH3KBP1,HCK,CD53,MEF2C,FLRT2,MLKL,DISC1,DAB2 |
2.649e-02 | -3.63 | chromatin | cellular component | GO:0000785 | 1387 | 8 | 19108 | 50 |
ETS1,TFEB,MEF2C,RXRA,CEBPB,BAZ2B,ELF4,ETV6 |
2.666e-02 | -3.62 | TGFBR1 (transforming growth factor beta receptor 1) | protein interactions | 7046 | 251 | 3 | 19454 | 50 |
DAB2,SH3KBP1,PLEK |
2.668e-02 | -3.62 | Pept_asp_AS | interpro domains | IPR025661 | 10 | 1 | 18521 | 50 |
CTSV |
2.680e-02 | -3.62 | Flnb (filamin, beta) | protein interactions | 286940 | 99 | 2 | 19454 | 50 |
DAB2,FCHO2 |
2.682e-02 | -3.62 | Folate-Alcohol and Cancer Pathway | WikiPathways | WP1589 | 8 | 1 | 5310 | 18 |
CEBPB |
2.693e-02 | -3.61 | positive regulation of cell motility | biological process | GO:2000147 | 619 | 5 | 18204 | 50 |
DAB2,DOCK4,ATP8A1,ETS1,FERMT3 |
2.693e-02 | -3.61 | NCK2 (NCK adaptor protein 2) | protein interactions | 8440 | 252 | 3 | 19454 | 50 |
DISC1,ARAP1,BLNK |
2.701e-02 | -3.61 | NK_cell_leukaemia | COSMIC cancer mutations | NK_cell_leukaemia | 10 | 1 | 16828 | 46 |
CSF3R |
2.701e-02 | -3.61 | lung-carcinoma-blastoma | COSMIC cancer mutations | lung-carcinoma-blastoma | 10 | 1 | 16828 | 46 |
ETV6 |
2.701e-02 | -3.61 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-NK_cell_leukaemia | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-NK_cell_leukaemia | 10 | 1 | 16828 | 46 |
CSF3R |
2.706e-02 | -3.61 | Inhibitor_I29 | smart domains | SM00848 | 7 | 1 | 9717 | 38 |
CTSV |
2.714e-02 | -3.61 | cellular response to parathyroid hormone stimulus | biological process | GO:0071374 | 10 | 1 | 18204 | 50 |
MEF2C |
2.714e-02 | -3.61 | thrombin-activated receptor signaling pathway | biological process | GO:0070493 | 10 | 1 | 18204 | 50 |
PLEK |
2.714e-02 | -3.61 | regulation of behavioral fear response | biological process | GO:2000822 | 10 | 1 | 18204 | 50 |
MEF2C |
2.714e-02 | -3.61 | folic acid transport | biological process | GO:0015884 | 10 | 1 | 18204 | 50 |
ABCC5 |
2.714e-02 | -3.61 | germinal center formation | biological process | GO:0002467 | 10 | 1 | 18204 | 50 |
MEF2C |
2.714e-02 | -3.61 | regulation of odontoblast differentiation | biological process | GO:1901329 | 10 | 1 | 18204 | 50 |
CEBPB |
2.714e-02 | -3.61 | high-density lipoprotein particle assembly | biological process | GO:0034380 | 10 | 1 | 18204 | 50 |
ABCA1 |
2.714e-02 | -3.61 | regulation of vitamin D receptor signaling pathway | biological process | GO:0070562 | 10 | 1 | 18204 | 50 |
RXRA |
2.714e-02 | -3.61 | integrin activation | biological process | GO:0033622 | 10 | 1 | 18204 | 50 |
FERMT3 |
2.715e-02 | -3.61 | haematopoietic_and_lymphoid_tissue | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue | 14368 | 44 | 16828 | 46 |
MAN1A1,MARK4,ARAP1,STAB1,SGMS1,FERMT3,ETV6,CD276,MFSD1,ATP8A1,TFEB,SRGN,AOX1,CD68,CSF3R,ETS1,FMNL1,DOCK4,DIAPH2,DAB2,RGL1,MICAL2,ABCC5,SH3KBP1,BAZ2B,HCK,PLEK,FLRT2,ABCA1,RHBDF1,FNIP1,GLDC,MEF2C,FCHO2,RBM47,SH2B3,ELF4,RXRA,MLKL,ARAP3,MYO1F,CD53,BLNK,ARHGEF1 |
2.717e-02 | -3.61 | MYH9 (myosin heavy chain 9) | protein interactions | 4627 | 663 | 5 | 19454 | 50 |
FCHO2,DAB2,MARK4,GLDC,RXRA |
2.721e-02 | -3.60 | MED23 (mediator complex subunit 23) | protein interactions | 9439 | 253 | 3 | 19454 | 50 |
RXRA,ETS1,CEBPB |
2.727e-02 | -3.60 | regulation of lymphocyte proliferation | biological process | GO:0050670 | 237 | 3 | 18204 | 50 |
MEF2C,CEBPB,CD276 |
2.729e-02 | -3.60 | protein dimerization activity | molecular function | GO:0046983 | 1074 | 7 | 18094 | 50 |
MEF2C,TFEB,PLEK,CEBPB,MFSD1,AOX1,GLDC |
2.730e-02 | -3.60 | ATPase-coupled inorganic anion transmembrane transporter activity | molecular function | GO:0043225 | 10 | 1 | 18094 | 50 |
ABCC5 |
2.730e-02 | -3.60 | minor groove of adenine-thymine-rich DNA binding | molecular function | GO:0003680 | 10 | 1 | 18094 | 50 |
MEF2C |
2.731e-02 | -3.60 | AP2S1 (adaptor related protein complex 2 subunit sigma 1) | protein interactions | 1175 | 100 | 2 | 19454 | 50 |
FCHO2,ARHGEF1 |
2.731e-02 | -3.60 | REPS1 (RALBP1 associated Eps domain containing 1) | protein interactions | 85021 | 100 | 2 | 19454 | 50 |
DAB2,RXRA |
2.738e-02 | -3.60 | cellular response to chemical stimulus | biological process | GO:0070887 | 2411 | 12 | 18204 | 50 |
DOCK4,ABCC5,CD68,MEF2C,GLDC,CSF3R,AOX1,CEBPB,HCK,ABCA1,RXRA,SH2B3 |
2.781e-02 | -3.58 | PRKCG (protein kinase C gamma) | protein interactions | 5582 | 101 | 2 | 19454 | 50 |
MARK4,DAB2 |
2.792e-02 | -3.58 | Fcho2 (FCH domain only 2) | protein interactions | 218503 | 11 | 1 | 19454 | 50 |
DAB2 |
2.792e-02 | -3.58 | BIVM (basic, immunoglobulin-like variable motif containing) | protein interactions | 54841 | 11 | 1 | 19454 | 50 |
BAZ2B |
2.792e-02 | -3.58 | RUBCNL (rubicon like autophagy enhancer) | protein interactions | 80183 | 11 | 1 | 19454 | 50 |
CERT1 |
2.792e-02 | -3.58 | CD302 (CD302 molecule) | protein interactions | 9936 | 11 | 1 | 19454 | 50 |
CD53 |
2.792e-02 | -3.58 | MEF2B (myocyte enhancer factor 2B) | protein interactions | 100271849 | 11 | 1 | 19454 | 50 |
MEF2C |
2.792e-02 | -3.58 | CCDC141 (coiled-coil domain containing 141) | protein interactions | 285025 | 11 | 1 | 19454 | 50 |
DISC1 |
2.809e-02 | -3.57 | enzyme-linked receptor protein signaling pathway | biological process | GO:0007167 | 626 | 5 | 18204 | 50 |
FLRT2,SH2B3,BLNK,HCK,DAB2 |
2.815e-02 | -3.57 | Circadian Clock | REACTOME pathways | R-HSA-400253 | 71 | 2 | 10285 | 38 |
MEF2C,RXRA |
2.832e-02 | -3.56 | FASLG (Fas ligand) | protein interactions | 356 | 102 | 2 | 19454 | 50 |
HCK,DOCK4 |
2.832e-02 | -3.56 | PATJ (PATJ crumbs cell polarity complex component) | protein interactions | 10207 | 102 | 2 | 19454 | 50 |
GLDC,SH3KBP1 |
2.832e-02 | -3.56 | TMPRSS13 (transmembrane serine protease 13) | protein interactions | 84000 | 102 | 2 | 19454 | 50 |
CTSV,MAN1A1 |
2.853e-02 | -3.56 | bone-femur-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | COSMIC cancer mutations | bone-femur-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | 633 | 5 | 16828 | 46 |
ELF4,STAB1,BAZ2B,ABCA1,GLDC |
2.860e-02 | -3.55 | UBAP2L (ubiquitin associated protein 2 like) | protein interactions | 9898 | 258 | 3 | 19454 | 50 |
GLDC,RBM47,DISC1 |
2.875e-02 | -3.55 | ruffle membrane | cellular component | GO:0032587 | 101 | 2 | 19108 | 50 |
ARHGAP45,PLEK |
2.876e-02 | -3.55 | regulation of mononuclear cell proliferation | biological process | GO:0032944 | 242 | 3 | 18204 | 50 |
MEF2C,CEBPB,CD276 |
2.879e-02 | -3.55 | FLOT1 (flotillin 1) | protein interactions | 10211 | 453 | 4 | 19454 | 50 |
ETV6,ELF4,ABCA1,DISC1 |
2.886e-02 | -3.55 | prostate | COSMIC cancer mutations | prostate | 13883 | 43 | 16828 | 46 |
DAB2,DIAPH2,MICAL2,ABCC5,ETS1,DOCK4,AOX1,CD276,ATP8A1,ETV6,MAN1A1,MARK4,STAB1,SGMS1,CD53,ARAP3,RBM47,ELF4,RXRA,MEF2C,GLDC,HCK,PLEK,FLRT2,ABCA1,BAZ2B,SH3KBP1,RGL1,CSF3R,FMNL1,TFEB,SRGN,FERMT3,ARAP1,BLNK,ARHGEF1,MYO1F,MLKL,SH2B3,FNIP1,FCHO2,DISC1,RHBDF1 |
2.889e-02 | -3.54 | MARK2 (microtubule affinity regulating kinase 2) | protein interactions | 2011 | 259 | 3 | 19454 | 50 |
CERT1,GLDC,MARK4 |
2.902e-02 | -3.54 | regulation of hemopoiesis | biological process | GO:1903706 | 425 | 4 | 18204 | 50 |
CSF3R,CEBPB,ETS1,MEF2C |
2.906e-02 | -3.54 | HNRNPK (heterogeneous nuclear ribonucleoprotein K) | protein interactions | 3190 | 675 | 5 | 19454 | 50 |
MARK4,GLDC,CEBPB,HCK,SH3KBP1 |
2.906e-02 | -3.54 | anatomical structure development | biological process | GO:0048856 | 5207 | 21 | 18204 | 50 |
SRGN,FLRT2,ADGRG3,DISC1,TFEB,DAB2,DIAPH2,MEF2C,MICAL2,PLEK,CEBPB,ETV6,HCK,CSF3R,FNIP1,SH2B3,BLNK,RXRA,CERT1,MARK4,RBM47 |
2.917e-02 | -3.53 | ceramide metabolic process | biological process | GO:0006672 | 97 | 2 | 18204 | 50 |
SGMS1,CERT1 |
2.917e-02 | -3.53 | leukocyte homeostasis | biological process | GO:0001776 | 97 | 2 | 18204 | 50 |
MEF2C,SH2B3 |
2.917e-02 | -3.53 | TH1 | prosite domains | PS51757 | 8 | 1 | 12186 | 45 |
MYO1F |
2.917e-02 | -3.53 | BMERB | prosite domains | PS51848 | 8 | 1 | 12186 | 45 |
MICAL2 |
2.919e-02 | -3.53 | Axonal growth inhibition (RHOA activation) | REACTOME pathways | R-HSA-193634 | 8 | 1 | 10285 | 38 |
ARHGEF1 |
2.919e-02 | -3.53 | Nef and signal transduction | REACTOME pathways | R-HSA-164944 | 8 | 1 | 10285 | 38 |
HCK |
2.920e-02 | -3.53 | LCK (LCK proto-oncogene, Src family tyrosine kinase) | protein interactions | 3932 | 455 | 4 | 19454 | 50 |
CSF3R,SH2B3,HCK,SH3KBP1 |
2.928e-02 | -3.53 | positive regulation of locomotion | biological process | GO:0040017 | 633 | 5 | 18204 | 50 |
ETS1,DAB2,DOCK4,ATP8A1,FERMT3 |
2.931e-02 | -3.53 | DOCKER_Lobe_B | interpro domains | IPR046770 | 11 | 1 | 18521 | 50 |
DOCK4 |
2.931e-02 | -3.53 | Methyl_CpG_DNA-bd | interpro domains | IPR001739 | 11 | 1 | 18521 | 50 |
BAZ2B |
2.931e-02 | -3.53 | DOCK | interpro domains | IPR026791 | 11 | 1 | 18521 | 50 |
DOCK4 |
2.931e-02 | -3.53 | Pept_his_AS | interpro domains | IPR025660 | 11 | 1 | 18521 | 50 |
CTSV |
2.931e-02 | -3.53 | DOCKER_Lobe_C | interpro domains | IPR046773 | 11 | 1 | 18521 | 50 |
DOCK4 |
2.931e-02 | -3.53 | DOCKER_Lobe_A | interpro domains | IPR046769 | 11 | 1 | 18521 | 50 |
DOCK4 |
2.931e-02 | -3.53 | DNA-bd_dom_sf | interpro domains | IPR016177 | 11 | 1 | 18521 | 50 |
BAZ2B |
2.931e-02 | -3.53 | C2_DOCK-type_domain | interpro domains | IPR027007 | 11 | 1 | 18521 | 50 |
DOCK4 |
2.931e-02 | -3.53 | DOCK_C_lobe_C | interpro domains | IPR043162 | 11 | 1 | 18521 | 50 |
DOCK4 |
2.931e-02 | -3.53 | DOCK_C_lobe_A | interpro domains | IPR043161 | 11 | 1 | 18521 | 50 |
DOCK4 |
2.931e-02 | -3.53 | DOCKER_dom | interpro domains | IPR027357 | 11 | 1 | 18521 | 50 |
DOCK4 |
2.952e-02 | -3.52 | anchoring junction | cellular component | GO:0070161 | 902 | 6 | 19108 | 50 |
DAB2,HCK,CD53,SH3KBP1,FERMT3,FLRT2 |
2.968e-02 | -3.52 | regulation of inflammatory response | biological process | GO:0050727 | 428 | 4 | 18204 | 50 |
HCK,CEBPB,ETS1,ELF4 |
2.968e-02 | -3.52 | cell surface receptor protein tyrosine kinase signaling pathway | biological process | GO:0007169 | 428 | 4 | 18204 | 50 |
FLRT2,SH2B3,BLNK,HCK |
2.981e-02 | -3.51 | cardiac chamber formation | biological process | GO:0003207 | 11 | 1 | 18204 | 50 |
MEF2C |
2.981e-02 | -3.51 | regulation of dendritic cell antigen processing and presentation | biological process | GO:0002604 | 11 | 1 | 18204 | 50 |
CD68 |
2.981e-02 | -3.51 | positive regulation of cardiac muscle cell differentiation | biological process | GO:2000727 | 11 | 1 | 18204 | 50 |
MEF2C |
2.981e-02 | -3.51 | response to glycoprotein | biological process | GO:1904587 | 11 | 1 | 18204 | 50 |
MAN1A1 |
2.981e-02 | -3.51 | secondary heart field specification | biological process | GO:0003139 | 11 | 1 | 18204 | 50 |
MEF2C |
2.981e-02 | -3.51 | regulation of macrophage apoptotic process | biological process | GO:2000109 | 11 | 1 | 18204 | 50 |
MEF2C |
2.981e-02 | -3.51 | positive regulation of steroid hormone secretion | biological process | GO:2000833 | 11 | 1 | 18204 | 50 |
DAB2 |
2.981e-02 | -3.51 | cyclic nucleotide transport | biological process | GO:0070729 | 11 | 1 | 18204 | 50 |
ABCC5 |
2.981e-02 | -3.51 | negative regulation of platelet aggregation | biological process | GO:0090331 | 11 | 1 | 18204 | 50 |
SH2B3 |
2.981e-02 | -3.51 | positive regulation of integrin activation | biological process | GO:0033625 | 11 | 1 | 18204 | 50 |
PLEK |
2.981e-02 | -3.51 | negative regulation of cholesterol storage | biological process | GO:0010887 | 11 | 1 | 18204 | 50 |
ABCA1 |
2.981e-02 | -3.51 | tripeptide transport | biological process | GO:0042939 | 11 | 1 | 18204 | 50 |
ABCC5 |
2.981e-02 | -3.51 | pyramidal neuron development | biological process | GO:0021860 | 11 | 1 | 18204 | 50 |
DISC1 |
2.981e-02 | -3.51 | regulation of fear response | biological process | GO:1903365 | 11 | 1 | 18204 | 50 |
MEF2C |
2.981e-02 | -3.51 | regulation of cell-cell adhesion mediated by integrin | biological process | GO:0033632 | 11 | 1 | 18204 | 50 |
FERMT3 |
2.981e-02 | -3.51 | guanine nucleotide transport | biological process | GO:0001408 | 11 | 1 | 18204 | 50 |
ABCC5 |
2.981e-02 | -3.51 | sphingomyelin biosynthetic process | biological process | GO:0006686 | 11 | 1 | 18204 | 50 |
SGMS1 |
2.987e-02 | -3.51 | Class I PI3K signaling events | Pathway Interaction DB | pi3kcipathway | 41 | 2 | 2226 | 15 |
HCK,ARAP3 |
2.988e-02 | -3.51 | bZIP_2 | pfam domains | PF07716 | 11 | 1 | 17795 | 49 |
CEBPB |
2.988e-02 | -3.51 | DHR-2_Lobe_A | pfam domains | PF06920 | 11 | 1 | 17795 | 49 |
DOCK4 |
2.988e-02 | -3.51 | DOCK-C2 | pfam domains | PF14429 | 11 | 1 | 17795 | 49 |
DOCK4 |
2.988e-02 | -3.51 | DHR-2_Lobe_C | pfam domains | PF20421 | 11 | 1 | 17795 | 49 |
DOCK4 |
2.988e-02 | -3.51 | LRRCT | pfam domains | PF01463 | 11 | 1 | 17795 | 49 |
FLRT2 |
2.988e-02 | -3.51 | DHR-2_Lobe_B | pfam domains | PF20422 | 11 | 1 | 17795 | 49 |
DOCK4 |
2.990e-02 | -3.51 | response to xenobiotic stimulus | biological process | GO:0009410 | 429 | 4 | 18204 | 50 |
ABCA1,ABCC5,AOX1,MEF2C |
2.990e-02 | -3.51 | superficial_spreading | COSMIC cancer mutations | superficial_spreading | 1110 | 7 | 16828 | 46 |
ATP8A1,DIAPH2,FLRT2,ABCA1,STAB1,ARAP1,AOX1 |
2.999e-02 | -3.51 | glycine binding | molecular function | GO:0016594 | 11 | 1 | 18094 | 50 |
GLDC |
2.999e-02 | -3.51 | GTPase activating protein binding | molecular function | GO:0032794 | 11 | 1 | 18094 | 50 |
FMNL1 |
2.999e-02 | -3.51 | oligopeptide transmembrane transporter activity | molecular function | GO:0035673 | 11 | 1 | 18094 | 50 |
ABCC5 |
2.999e-02 | -3.51 | regulation of synapse organization | biological process | GO:0050807 | 246 | 3 | 18204 | 50 |
MEF2C,FLRT2,DISC1 |
3.018e-02 | -3.50 | human chrXp22.12 | chromosome location | human chrXp22.12 | 16 | 1 | 26134 | 50 |
SH3KBP1 |
3.030e-02 | -3.50 | humoral immune response | biological process | GO:0006959 | 247 | 3 | 18204 | 50 |
BLNK,MEF2C,TFEB |
3.039e-02 | -3.49 | Lipoprotein metabolism | REACTOME pathways | R-HSA-174824 | 74 | 2 | 10285 | 38 |
ABCA1,SH3KBP1 |
3.042e-02 | -3.49 | GLYHDRLASE47 | prints domains | PR00747 | 7 | 1 | 5227 | 23 |
MAN1A1 |
3.042e-02 | -3.49 | NUDT4 (nudix hydrolase 4) | protein interactions | 11163 | 12 | 1 | 19454 | 50 |
DISC1 |
3.042e-02 | -3.49 | TM7SF2 (transmembrane 7 superfamily member 2) | protein interactions | 7108 | 12 | 1 | 19454 | 50 |
DISC1 |
3.042e-02 | -3.49 | C8orf76 (chromosome 8 open reading frame 76) | protein interactions | 84933 | 12 | 1 | 19454 | 50 |
DISC1 |
3.042e-02 | -3.49 | ROBO4 (roundabout guidance receptor 4) | protein interactions | 54538 | 12 | 1 | 19454 | 50 |
RXRA |
3.042e-02 | -3.49 | TLDC2 (TBC/LysM-associated domain containing 2) | protein interactions | 140711 | 12 | 1 | 19454 | 50 |
GLDC |
3.042e-02 | -3.49 | PNMT (phenylethanolamine N-methyltransferase) | protein interactions | 5409 | 12 | 1 | 19454 | 50 |
HCK |
3.042e-02 | -3.49 | SOWAHB (sosondowah ankyrin repeat domain family member B) | protein interactions | 345079 | 12 | 1 | 19454 | 50 |
DIAPH2 |
3.087e-02 | -3.48 | DUF3585 | smart domains | SM01203 | 8 | 1 | 9717 | 38 |
MICAL2 |
3.100e-02 | -3.47 | RHOA (ras homolog family member A) | protein interactions | 387 | 1186 | 7 | 19454 | 50 |
DIAPH2,DAB2,FMNL1,FLRT2,ARHGEF1,ABCC5,SGMS1 |
3.104e-02 | -3.47 | regulation of cellular component organization | biological process | GO:0051128 | 2455 | 12 | 18204 | 50 |
PLEK,ATP8A1,MEF2C,MARK4,FNIP1,CD53,ARAP1,DAB2,HCK,DISC1,ABCA1,FLRT2 |
3.113e-02 | -3.47 | response to other organism | biological process | GO:0051707 | 1363 | 8 | 18204 | 50 |
MLKL,MEF2C,CD68,ABCA1,HCK,CEBPB,STAB1,TFEB |
3.114e-02 | -3.47 | testis-germ_cell_tumour-seminoma | COSMIC cancer mutations | testis-germ_cell_tumour-seminoma | 648 | 5 | 16828 | 46 |
STAB1,MARK4,FLRT2,MLKL,HCK |
3.121e-02 | -3.47 | RANGAP1 (Ran GTPase activating protein 1) | protein interactions | 5905 | 267 | 3 | 19454 | 50 |
DISC1,CERT1,GLDC |
3.121e-02 | -3.47 | DNM2 (dynamin 2) | protein interactions | 1785 | 267 | 3 | 19454 | 50 |
HCK,SH3KBP1,ARHGEF1 |
3.142e-02 | -3.46 | platelet activation | biological process | GO:0030168 | 101 | 2 | 18204 | 50 |
PLEK,FERMT3 |
3.147e-02 | -3.46 | TRADD (TNFRSF1A associated via death domain) | protein interactions | 8717 | 108 | 2 | 19454 | 50 |
RXRA,SH3KBP1 |
3.147e-02 | -3.46 | PHF12 (PHD finger protein 12) | protein interactions | 57649 | 108 | 2 | 19454 | 50 |
ETS1,ELF4 |
3.149e-02 | -3.46 | response to external biotic stimulus | biological process | GO:0043207 | 1366 | 8 | 18204 | 50 |
HCK,CEBPB,TFEB,STAB1,ABCA1,MEF2C,CD68,MLKL |
3.150e-02 | -3.46 | stomach-carcinoma | COSMIC cancer mutations | stomach-carcinoma | 439 | 4 | 16828 | 46 |
CSF3R,MLKL,HCK,MARK4 |
3.160e-02 | -3.45 | clear_cell_renal_cell_carcinoma | COSMIC cancer mutations | clear_cell_renal_cell_carcinoma | 13924 | 43 | 16828 | 46 |
MLKL,MYO1F,BLNK,ARHGEF1,RHBDF1,FNIP1,DISC1,FCHO2,TFEB,SRGN,FMNL1,CEBPB,CSF3R,RGL1,SH3KBP1,ARAP1,FERMT3,MFSD1,RBM47,RXRA,ELF4,ARAP3,CD53,BAZ2B,PLEK,FLRT2,HCK,ABCA1,MEF2C,GLDC,AOX1,DOCK4,ETS1,DIAPH2,DAB2,ABCC5,MICAL2,STAB1,MARK4,MAN1A1,SGMS1,ETV6,ATP8A1 |
3.160e-02 | -3.45 | kidney-carcinoma-clear_cell_renal_cell_carcinoma | COSMIC cancer mutations | kidney-carcinoma-clear_cell_renal_cell_carcinoma | 13924 | 43 | 16828 | 46 |
TFEB,SRGN,CSF3R,CEBPB,FMNL1,RGL1,SH3KBP1,ARAP1,FERMT3,MFSD1,MLKL,MYO1F,BLNK,ARHGEF1,RHBDF1,FNIP1,FCHO2,DISC1,AOX1,ETS1,DOCK4,DIAPH2,DAB2,MICAL2,ABCC5,MARK4,MAN1A1,STAB1,SGMS1,ETV6,ATP8A1,RBM47,ELF4,RXRA,ARAP3,CD53,BAZ2B,HCK,FLRT2,PLEK,ABCA1,GLDC,MEF2C |
3.161e-02 | -3.45 | actin binding | molecular function | GO:0003779 | 434 | 4 | 18094 | 50 |
MYO1F,MICAL2,DIAPH2,FMNL1 |
3.181e-02 | -3.45 | regulation of response to external stimulus | biological process | GO:0032101 | 1116 | 7 | 18204 | 50 |
SH2B3,ELF4,MARK4,HCK,CEBPB,ETS1,RBM47 |
3.189e-02 | -3.45 | regulation of synapse structure or activity | biological process | GO:0050803 | 252 | 3 | 18204 | 50 |
FLRT2,DISC1,MEF2C |
3.193e-02 | -3.44 | ABCA | interpro domains | IPR026082 | 12 | 1 | 18521 | 50 |
ABCA1 |
3.200e-02 | -3.44 | SIPA1L3 (signal induced proliferation associated 1 like 3) | protein interactions | 23094 | 109 | 2 | 19454 | 50 |
GLDC,FMNL1 |
3.202e-02 | -3.44 | Rhomboid-like | gene3d domains | 1.20.1540.10 | 10 | 1 | 14470 | 47 |
RHBDF1 |
3.225e-02 | -3.43 | Neutrophil degranulation | REACTOME pathways | R-HSA-6798695 | 487 | 5 | 10285 | 38 |
ATP8A1,CD53,ARHGAP45,ADGRG3,CD68 |
3.232e-02 | -3.43 | bone-sacrum-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | COSMIC cancer mutations | bone-sacrum-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | 12 | 1 | 16828 | 46 |
STAB1 |
3.232e-02 | -3.43 | blastoma | COSMIC cancer mutations | blastoma | 12 | 1 | 16828 | 46 |
ETV6 |
3.232e-02 | -3.43 | central_nervous_system-cerebellum-other-ganglioglioma | COSMIC cancer mutations | central_nervous_system-cerebellum-other-ganglioglioma | 12 | 1 | 16828 | 46 |
ETV6 |
3.232e-02 | -3.43 | desmoid_tumour-fibromatosis | COSMIC cancer mutations | desmoid_tumour-fibromatosis | 12 | 1 | 16828 | 46 |
ETV6 |
3.232e-02 | -3.43 | soft_tissue-fibrous_tissue_and_uncertain_origin-desmoid_tumour-fibromatosis | COSMIC cancer mutations | soft_tissue-fibrous_tissue_and_uncertain_origin-desmoid_tumour-fibromatosis | 12 | 1 | 16828 | 46 |
ETV6 |
3.248e-02 | -3.43 | iron coordination entity transport | biological process | GO:1901678 | 12 | 1 | 18204 | 50 |
ABCC5 |
3.248e-02 | -3.43 | B cell apoptotic process | biological process | GO:0001783 | 12 | 1 | 18204 | 50 |
FNIP1 |
3.248e-02 | -3.43 | mesenchymal cell apoptotic process | biological process | GO:0097152 | 12 | 1 | 18204 | 50 |
ETV6 |
3.248e-02 | -3.43 | negative regulation of vasoconstriction | biological process | GO:0045906 | 12 | 1 | 18204 | 50 |
DOCK4 |
3.248e-02 | -3.43 | heart field specification | biological process | GO:0003128 | 12 | 1 | 18204 | 50 |
MEF2C |
3.248e-02 | -3.43 | regulation of protein localization to centrosome | biological process | GO:1904779 | 12 | 1 | 18204 | 50 |
MARK4 |
3.248e-02 | -3.43 | oligopeptide transmembrane transport | biological process | GO:0035672 | 12 | 1 | 18204 | 50 |
ABCC5 |
3.248e-02 | -3.43 | actin filament depolymerization | biological process | GO:0030042 | 12 | 1 | 18204 | 50 |
MICAL2 |
3.248e-02 | -3.43 | regulation of lysosome organization | biological process | GO:1905671 | 12 | 1 | 18204 | 50 |
FNIP1 |
3.248e-02 | -3.43 | immature B cell differentiation | biological process | GO:0002327 | 12 | 1 | 18204 | 50 |
FNIP1 |
3.248e-02 | -3.43 | cytidine to uridine editing | biological process | GO:0016554 | 12 | 1 | 18204 | 50 |
RBM47 |
3.248e-02 | -3.43 | regulation of lymphoid progenitor cell differentiation | biological process | GO:1905456 | 12 | 1 | 18204 | 50 |
FNIP1 |
3.248e-02 | -3.43 | serine family amino acid catabolic process | biological process | GO:0009071 | 12 | 1 | 18204 | 50 |
GLDC |
3.248e-02 | -3.43 | regulation of chemokine-mediated signaling pathway | biological process | GO:0070099 | 12 | 1 | 18204 | 50 |
SH2B3 |
3.248e-02 | -3.43 | cellular response to antibiotic | biological process | GO:0071236 | 12 | 1 | 18204 | 50 |
MEF2C |
3.248e-02 | -3.43 | negative regulation of smooth muscle contraction | biological process | GO:0045986 | 12 | 1 | 18204 | 50 |
DOCK4 |
3.256e-02 | -3.42 | ABC2_membrane_3 | pfam domains | PF12698 | 12 | 1 | 17795 | 49 |
ABCA1 |
3.264e-02 | -3.42 | IL6-mediated signaling events | Pathway Interaction DB | il6_7pathway | 43 | 2 | 2226 | 15 |
CEBPB,HCK |
3.278e-02 | -3.42 | PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 | REACTOME pathways | R-HSA-8849469 | 9 | 1 | 10285 | 38 |
ARAP1 |
3.278e-02 | -3.42 | Formation of annular gap junctions | REACTOME pathways | R-HSA-196025 | 9 | 1 | 10285 | 38 |
DAB2 |
3.278e-02 | -3.42 | p75NTR regulates axonogenesis | REACTOME pathways | R-HSA-193697 | 9 | 1 | 10285 | 38 |
ARHGEF1 |
3.291e-02 | -3.41 | Kif20b (kinesin family member 20B) | protein interactions | 240641 | 13 | 1 | 19454 | 50 |
DIAPH2 |
3.291e-02 | -3.41 | IL2 (interleukin 2) | protein interactions | 3558 | 13 | 1 | 19454 | 50 |
CD53 |
3.291e-02 | -3.41 | Septin2 (septin 2) | protein interactions | 18000 | 13 | 1 | 19454 | 50 |
SH3KBP1 |
3.291e-02 | -3.41 | KCTD20 (potassium channel tetramerization domain containing 20) | protein interactions | 222658 | 13 | 1 | 19454 | 50 |
MARK4 |
3.291e-02 | -3.41 | MYBPC3 (myosin binding protein C3) | protein interactions | 4607 | 13 | 1 | 19454 | 50 |
BLNK |
3.291e-02 | -3.41 | CRYGC (crystallin gamma C) | protein interactions | 1420 | 13 | 1 | 19454 | 50 |
DISC1 |
3.291e-02 | -3.41 | C1orf74 (chromosome 1 open reading frame 74) | protein interactions | 148304 | 13 | 1 | 19454 | 50 |
HCK |
3.291e-02 | -3.41 | SERTM1 (serine rich and transmembrane domain containing 1) | protein interactions | 400120 | 13 | 1 | 19454 | 50 |
CD53 |
3.293e-02 | -3.41 | nicotine degradation IV | BIOCYC pathways | HUMAN_PWY66-201 | 10 | 1 | 902 | 3 |
AOX1 |
3.302e-02 | -3.41 | FLOT2 (flotillin 2) | protein interactions | 2319 | 273 | 3 | 19454 | 50 |
ELF4,ETV6,DISC1 |
3.315e-02 | -3.41 | positive regulation of ubiquitin-dependent protein catabolic process | biological process | GO:2000060 | 104 | 2 | 18204 | 50 |
DISC1,DAB2 |
3.315e-02 | -3.41 | lytic vacuole organization | biological process | GO:0080171 | 104 | 2 | 18204 | 50 |
TFEB,ABCA1 |
3.315e-02 | -3.41 | regulation of dephosphorylation | biological process | GO:0035303 | 104 | 2 | 18204 | 50 |
MEF2C,PLEK |
3.315e-02 | -3.41 | lysosome organization | biological process | GO:0007040 | 104 | 2 | 18204 | 50 |
ABCA1,TFEB |
3.322e-02 | -3.40 | protein domain specific binding | molecular function | GO:0019904 | 651 | 5 | 18094 | 50 |
ETV6,DOCK4,RXRA,BLNK,SH3KBP1 |
3.341e-02 | -3.40 | Liver X Receptor Pathway | WikiPathways | WP2874 | 10 | 1 | 5310 | 18 |
RXRA |
3.341e-02 | -3.40 | Vitamin D Metabolism | WikiPathways | WP1531 | 10 | 1 | 5310 | 18 |
RXRA |
3.353e-02 | -3.40 | Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | COSMIC cancer mutations | Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | 7434 | 27 | 16828 | 46 |
ARAP1,STAB1,MARK4,MFSD1,ETV6,DOCK4,FMNL1,CSF3R,CD68,AOX1,SH3KBP1,ABCC5,MICAL2,DAB2,ABCA1,FLRT2,HCK,BAZ2B,MEF2C,GLDC,FNIP1,RHBDF1,MLKL,ELF4,ARHGEF1,BLNK,MYO1F |
3.363e-02 | -3.39 | NFRKB (nuclear factor related to kappaB binding protein) | protein interactions | 4798 | 112 | 2 | 19454 | 50 |
ETS1,ELF4 |
3.363e-02 | -3.39 | MYO18A (myosin XVIIIA) | protein interactions | 399687 | 275 | 3 | 19454 | 50 |
DAB2,GLDC,MARK4 |
3.381e-02 | -3.39 | positive regulation of developmental process | biological process | GO:0051094 | 1385 | 8 | 18204 | 50 |
DAB2,CEBPB,DISC1,FLRT2,ETS1,MEF2C,RXRA,CD53 |
3.384e-02 | -3.39 | small GTPase-mediated signal transduction | biological process | GO:0007264 | 258 | 3 | 18204 | 50 |
DOCK4,ARHGEF1,RGL1 |
3.385e-02 | -3.39 | protein-DNA complex | cellular component | GO:0032993 | 1454 | 8 | 19108 | 50 |
MEF2C,ELF4,ETV6,CEBPB,RXRA,BAZ2B,ETS1,TFEB |
3.394e-02 | -3.38 | FLII (FLII actin remodeling protein) | protein interactions | 2314 | 276 | 3 | 19454 | 50 |
DISC1,FMNL1,GLDC |
3.418e-02 | -3.38 | RBM6 (RNA binding motif protein 6) | protein interactions | 10180 | 113 | 2 | 19454 | 50 |
DISC1,GLDC |
3.432e-02 | -3.37 | response to retinoic acid | biological process | GO:0032526 | 106 | 2 | 18204 | 50 |
RXRA,ABCA1 |
3.432e-02 | -3.37 | regulation of actin filament bundle assembly | biological process | GO:0032231 | 106 | 2 | 18204 | 50 |
ARAP1,PLEK |
3.447e-02 | -3.37 | SH3_1 | pfam domains | PF00018 | 106 | 2 | 17795 | 49 |
MYO1F,HCK |
3.454e-02 | -3.37 | Peptidase_C1A | interpro domains | IPR013128 | 13 | 1 | 18521 | 50 |
CTSV |
3.454e-02 | -3.37 | Peptidase_C1A_C | interpro domains | IPR000668 | 13 | 1 | 18521 | 50 |
CTSV |
3.457e-02 | -3.36 | TJP2 (tight junction protein 2) | protein interactions | 9414 | 278 | 3 | 19454 | 50 |
GLDC,DISC1,SH3KBP1 |
3.457e-02 | -3.36 | bone-humerus-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | COSMIC cancer mutations | bone-humerus-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | 107 | 2 | 16828 | 46 |
ABCA1,GLDC |
3.472e-02 | -3.36 | response to stress | biological process | GO:0006950 | 3388 | 15 | 18204 | 50 |
TFEB,FERMT3,CD68,PLEK,MEF2C,MAN1A1,STAB1,CSF3R,CEBPB,HCK,ABCA1,CERT1,BLNK,FNIP1,MLKL |
3.474e-02 | -3.36 | ACVR1 (activin A receptor type 1) | protein interactions | 90 | 114 | 2 | 19454 | 50 |
PLEK,RXRA |
3.514e-02 | -3.35 | response to parathyroid hormone | biological process | GO:0071107 | 13 | 1 | 18204 | 50 |
MEF2C |
3.514e-02 | -3.35 | type II interferon-mediated signaling pathway | biological process | GO:0060333 | 13 | 1 | 18204 | 50 |
HCK |
3.514e-02 | -3.35 | negative regulation of homotypic cell-cell adhesion | biological process | GO:0034111 | 13 | 1 | 18204 | 50 |
SH2B3 |
3.514e-02 | -3.35 | positive regulation of actin filament depolymerization | biological process | GO:0030836 | 13 | 1 | 18204 | 50 |
PLEK |
3.514e-02 | -3.35 | positive regulation of platelet activation | biological process | GO:0010572 | 13 | 1 | 18204 | 50 |
PLEK |
3.514e-02 | -3.35 | phospholipid efflux | biological process | GO:0033700 | 13 | 1 | 18204 | 50 |
ABCA1 |
3.517e-02 | -3.35 | - | gene3d domains | 1.25.40.410 | 11 | 1 | 14470 | 47 |
DOCK4 |
3.517e-02 | -3.35 | - | gene3d domains | 1.20.58.740 | 11 | 1 | 14470 | 47 |
DOCK4 |
3.520e-02 | -3.35 | TSG101 (tumor susceptibility 101) | protein interactions | 7251 | 280 | 3 | 19454 | 50 |
HCK,SH3KBP1,MLKL |
3.522e-02 | -3.35 | Peptidase_C1 | pfam domains | PF00112 | 13 | 1 | 17795 | 49 |
CTSV |
3.535e-02 | -3.34 | high-density lipoprotein particle binding | molecular function | GO:0008035 | 13 | 1 | 18094 | 50 |
ABCA1 |
3.535e-02 | -3.34 | glycerophospholipid flippase activity | molecular function | GO:0140333 | 13 | 1 | 18094 | 50 |
ATP8A1 |
3.540e-02 | -3.34 | PLA2G12A (phospholipase A2 group XIIA) | protein interactions | 81579 | 14 | 1 | 19454 | 50 |
MEF2C |
3.540e-02 | -3.34 | PALMD (palmdelphin) | protein interactions | 54873 | 14 | 1 | 19454 | 50 |
SH3KBP1 |
3.540e-02 | -3.34 | Asap1 (ArfGAP with SH3 domain, ankyrin repeat and PH domain1) | protein interactions | 13196 | 14 | 1 | 19454 | 50 |
SH3KBP1 |
3.540e-02 | -3.34 | CSF3 (colony stimulating factor 3) | protein interactions | 1440 | 14 | 1 | 19454 | 50 |
CSF3R |
3.540e-02 | -3.34 | LINC02872 (long intergenic non-protein coding RNA 2872) | protein interactions | 401535 | 14 | 1 | 19454 | 50 |
GLDC |
3.540e-02 | -3.34 | BORCS8-MEF2B (BORCS8-MEF2B readthrough) | protein interactions | 4207 | 14 | 1 | 19454 | 50 |
MEF2C |
3.540e-02 | -3.34 | Septin7 (septin 7) | protein interactions | 235072 | 14 | 1 | 19454 | 50 |
SH3KBP1 |
3.540e-02 | -3.34 | TFEC (transcription factor EC) | protein interactions | 22797 | 14 | 1 | 19454 | 50 |
TFEB |
3.546e-02 | -3.34 | stomach-carcinoma-diffuse_adenocarcinoma | COSMIC cancer mutations | stomach-carcinoma-diffuse_adenocarcinoma | 4383 | 18 | 16828 | 46 |
MICAL2,RGL1,MYO1F,DIAPH2,ARHGEF1,BLNK,RXRA,SH2B3,RBM47,FMNL1,DOCK4,FERMT3,ATP8A1,BAZ2B,STAB1,MAN1A1,ABCA1,FLRT2 |
3.546e-02 | -3.34 | diffuse_adenocarcinoma | COSMIC cancer mutations | diffuse_adenocarcinoma | 4383 | 18 | 16828 | 46 |
MICAL2,RGL1,DIAPH2,MYO1F,ARHGEF1,BLNK,RXRA,SH2B3,RBM47,DOCK4,FMNL1,FERMT3,ATP8A1,STAB1,BAZ2B,MAN1A1,ABCA1,FLRT2 |
3.551e-02 | -3.34 | Thromboxane A2 receptor signaling | Pathway Interaction DB | txa2pathway | 45 | 2 | 2226 | 15 |
HCK,ARHGEF1 |
3.551e-02 | -3.34 | SKP2 (S-phase kinase associated protein 2) | protein interactions | 6502 | 281 | 3 | 19454 | 50 |
DISC1,MEF2C,ELF4 |
3.574e-02 | -3.33 | human chrXq26.1 | chromosome location | human chrXq26.1 | 19 | 1 | 26134 | 50 |
ELF4 |
3.576e-02 | -3.33 | LAMTOR1 (late endosomal/lysosomal adaptor, MAPK and MTOR activator 1) | protein interactions | 55004 | 714 | 5 | 19454 | 50 |
ATP8A1,ABCC5,FCHO2,DAB2,DIAPH2 |
3.578e-02 | -3.33 | breast-carcinoma | COSMIC cancer mutations | breast-carcinoma | 15030 | 45 | 16828 | 46 |
CSF3R,FMNL1,SRGN,CD68,TFEB,SH3KBP1,RGL1,ARAP1,MFSD1,FERMT3,MLKL,SH2B3,ARHGEF1,BLNK,MYO1F,FCHO2,DISC1,FNIP1,RHBDF1,ETS1,DOCK4,AOX1,MICAL2,ABCC5,DAB2,DIAPH2,SGMS1,MAN1A1,MARK4,STAB1,ATP8A1,CD276,ETV6,ARAP3,ELF4,RXRA,RBM47,CD53,ABCA1,HCK,FLRT2,PLEK,BAZ2B,MEF2C,GLDC |
3.586e-02 | -3.33 | GGA1 (golgi associated, gamma adaptin ear containing, ARF binding protein 1) | protein interactions | 26088 | 116 | 2 | 19454 | 50 |
STAB1,ETS1 |
3.593e-02 | -3.33 | positive regulation of DNA-templated transcription | biological process | GO:0045893 | 1667 | 9 | 18204 | 50 |
TFEB,DAB2,ETV6,CEBPB,ELF4,RXRA,MICAL2,ETS1,MEF2C |
3.603e-02 | -3.32 | phospholipid-translocating ATPase complex | cellular component | GO:1990531 | 14 | 1 | 19108 | 50 |
ATP8A1 |
3.603e-02 | -3.32 | cytolytic granule | cellular component | GO:0044194 | 14 | 1 | 19108 | 50 |
SRGN |
3.603e-02 | -3.32 | chromaffin granule | cellular component | GO:0042583 | 14 | 1 | 19108 | 50 |
ATP8A1 |
3.629e-02 | -3.32 | positive regulation of RNA biosynthetic process | biological process | GO:1902680 | 1670 | 9 | 18204 | 50 |
TFEB,DAB2,CEBPB,ETV6,RXRA,ELF4,MICAL2,MEF2C,ETS1 |
3.633e-02 | -3.32 | THIOL_PROTEASE_ASN | prosite domains | PS00640 | 10 | 1 | 12186 | 45 |
CTSV |
3.635e-02 | -3.31 | Gap junction degradation | REACTOME pathways | R-HSA-190873 | 10 | 1 | 10285 | 38 |
DAB2 |
3.677e-02 | -3.30 | response to biotic stimulus | biological process | GO:0009607 | 1408 | 8 | 18204 | 50 |
STAB1,TFEB,HCK,CEBPB,ABCA1,CD68,MEF2C,MLKL |
3.680e-02 | -3.30 | ATXN2 (ataxin 2) | protein interactions | 6311 | 285 | 3 | 19454 | 50 |
GLDC,RBM47,SH3KBP1 |
3.699e-02 | -3.30 | BCL7A (BAF chromatin remodeling complex subunit BCL7A) | protein interactions | 605 | 118 | 2 | 19454 | 50 |
ETS1,ELF4 |
3.699e-02 | -3.30 | B4GALT2 (beta-1,4-galactosyltransferase 2) | protein interactions | 8704 | 118 | 2 | 19454 | 50 |
ETV6,ARAP3 |
3.704e-02 | -3.30 | Golgi cisterna | cellular component | GO:0031985 | 116 | 2 | 19108 | 50 |
ARAP1,SGMS1 |
3.715e-02 | -3.29 | Beta-grasp_dom_sf | interpro domains | IPR012675 | 14 | 1 | 18521 | 50 |
AOX1 |
3.715e-02 | -3.29 | MHD | interpro domains | IPR028565 | 14 | 1 | 18521 | 50 |
FCHO2 |
3.715e-02 | -3.29 | P-type_ATPase_N | interpro domains | IPR032631 | 14 | 1 | 18521 | 50 |
ATP8A1 |
3.715e-02 | -3.29 | P_typ_ATPase_c | interpro domains | IPR032630 | 14 | 1 | 18521 | 50 |
ATP8A1 |
3.715e-02 | -3.29 | Rhomboid-like_sf | interpro domains | IPR035952 | 14 | 1 | 18521 | 50 |
RHBDF1 |
3.715e-02 | -3.29 | P-type_ATPase_IV | interpro domains | IPR006539 | 14 | 1 | 18521 | 50 |
ATP8A1 |
3.715e-02 | -3.29 | Ras_G-nucl-exch_fac_CS | interpro domains | IPR019804 | 14 | 1 | 18521 | 50 |
RGL1 |
3.715e-02 | -3.29 | Link_dom | interpro domains | IPR000538 | 14 | 1 | 18521 | 50 |
STAB1 |
3.724e-02 | -3.29 | regulation of leukocyte proliferation | biological process | GO:0070663 | 268 | 3 | 18204 | 50 |
CD276,MEF2C,CEBPB |
3.733e-02 | -3.29 | negative regulation of binding | biological process | GO:0051100 | 111 | 2 | 18204 | 50 |
DAB2,DISC1 |
3.744e-02 | -3.29 | protein localization | biological process | GO:0008104 | 1954 | 10 | 18204 | 50 |
DAB2,FCHO2,DISC1,MFSD1,SRGN,ABCA1,CD68,PLEK,RHBDF1,MAN1A1 |
3.745e-02 | -3.28 | HSPA1B (heat shock protein family A (Hsp70) member 1B) | protein interactions | 3304 | 287 | 3 | 19454 | 50 |
FNIP1,DAB2,FMNL1 |
3.754e-02 | -3.28 | nasopharyngeal_carcinoma | COSMIC cancer mutations | nasopharyngeal_carcinoma | 1425 | 8 | 16828 | 46 |
RHBDF1,ABCC5,FNIP1,SH2B3,STAB1,MARK4,MLKL,FLRT2 |
3.754e-02 | -3.28 | upper_aerodigestive_tract-pharynx-carcinoma-nasopharyngeal_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-pharynx-carcinoma-nasopharyngeal_carcinoma | 1425 | 8 | 16828 | 46 |
ABCC5,RHBDF1,FNIP1,STAB1,SH2B3,MARK4,FLRT2,MLKL |
3.755e-02 | -3.28 | MAPK1 (mitogen-activated protein kinase 1) | protein interactions | 5594 | 493 | 4 | 19454 | 50 |
ARHGAP45,RXRA,ETS1,CEBPB |
3.759e-02 | -3.28 | regulation of actin filament organization | biological process | GO:0110053 | 269 | 3 | 18204 | 50 |
ARAP1,PLEK,HCK |
3.777e-02 | -3.28 | MAP4 (microtubule associated protein 4) | protein interactions | 4134 | 288 | 3 | 19454 | 50 |
MARK4,GLDC,SH3KBP1 |
3.779e-02 | -3.28 | positive regulation of phospholipid transport | biological process | GO:2001140 | 14 | 1 | 18204 | 50 |
ATP8A1 |
3.779e-02 | -3.28 | mammary gland epithelial cell proliferation | biological process | GO:0033598 | 14 | 1 | 18204 | 50 |
CEBPB |
3.779e-02 | -3.28 | negative regulation of macrophage derived foam cell differentiation | biological process | GO:0010745 | 14 | 1 | 18204 | 50 |
ABCA1 |
3.779e-02 | -3.28 | ventricular cardiac muscle cell differentiation | biological process | GO:0055012 | 14 | 1 | 18204 | 50 |
MEF2C |
3.779e-02 | -3.28 | oligopeptide transport | biological process | GO:0006857 | 14 | 1 | 18204 | 50 |
ABCC5 |
3.779e-02 | -3.28 | positive regulation of receptor recycling | biological process | GO:0001921 | 14 | 1 | 18204 | 50 |
ARAP1 |
3.779e-02 | -3.28 | alpha-beta T cell proliferation | biological process | GO:0046633 | 14 | 1 | 18204 | 50 |
ELF4 |
3.779e-02 | -3.28 | regulation of podosome assembly | biological process | GO:0071801 | 14 | 1 | 18204 | 50 |
HCK |
3.779e-02 | -3.28 | cellular response to oxidised low-density lipoprotein particle stimulus | biological process | GO:0140052 | 14 | 1 | 18204 | 50 |
CD68 |
3.788e-02 | -3.27 | GCK (glucokinase) | protein interactions | 2645 | 15 | 1 | 19454 | 50 |
CSF3R |
3.788e-02 | -3.27 | TIAM2 (TIAM Rac1 associated GEF 2) | protein interactions | 26230 | 15 | 1 | 19454 | 50 |
DISC1 |
3.788e-02 | -3.27 | ASCL4 (achaete-scute family bHLH transcription factor 4) | protein interactions | 121549 | 15 | 1 | 19454 | 50 |
ARAP3 |
3.788e-02 | -3.27 | UCP3 (uncoupling protein 3) | protein interactions | 7352 | 15 | 1 | 19454 | 50 |
RBM47 |
3.788e-02 | -3.27 | CASTOR1 (cytosolic arginine sensor for mTORC1 subunit 1) | protein interactions | 652968 | 15 | 1 | 19454 | 50 |
RXRA |
3.788e-02 | -3.27 | LRRC24 (leucine rich repeat containing 24) | protein interactions | 441381 | 15 | 1 | 19454 | 50 |
MAN1A1 |
3.788e-02 | -3.27 | Xlink | pfam domains | PF00193 | 14 | 1 | 17795 | 49 |
STAB1 |
3.788e-02 | -3.27 | PhoLip_ATPase_C | pfam domains | PF16212 | 14 | 1 | 17795 | 49 |
ATP8A1 |
3.788e-02 | -3.27 | PhoLip_ATPase_N | pfam domains | PF16209 | 14 | 1 | 17795 | 49 |
ATP8A1 |
3.801e-02 | -3.27 | ABC-type xenobiotic transporter activity | molecular function | GO:0008559 | 14 | 1 | 18094 | 50 |
ABCC5 |
3.801e-02 | -3.27 | alpha-mannosidase activity | molecular function | GO:0004559 | 14 | 1 | 18094 | 50 |
MAN1A1 |
3.814e-02 | -3.27 | FRS3 (fibroblast growth factor receptor substrate 3) | protein interactions | 10817 | 120 | 2 | 19454 | 50 |
HCK,SH3KBP1 |
3.814e-02 | -3.27 | SRCAP (Snf2 related CREBBP activator protein) | protein interactions | 10847 | 120 | 2 | 19454 | 50 |
ETS1,ELF4 |
3.814e-02 | -3.27 | LIMD1 (LIM domain containing 1) | protein interactions | 8994 | 120 | 2 | 19454 | 50 |
ETV6,DISC1 |
3.836e-02 | -3.26 | cellular macromolecule localization | biological process | GO:0070727 | 1962 | 10 | 18204 | 50 |
RHBDF1,MAN1A1,CD68,PLEK,DISC1,MFSD1,ABCA1,SRGN,DAB2,FCHO2 |
3.838e-02 | -3.26 | negative regulation of transcription by RNA polymerase II | biological process | GO:0000122 | 915 | 6 | 18204 | 50 |
RXRA,FNIP1,DAB2,ETV6,MEF2C,CEBPB |
3.856e-02 | -3.26 | positive regulation of plasma membrane bounded cell projection assembly | biological process | GO:0120034 | 113 | 2 | 18204 | 50 |
MARK4,ARAP1 |
3.863e-02 | -3.25 | skin-head_neck-malignant_melanoma-superficial_spreading | COSMIC cancer mutations | skin-head_neck-malignant_melanoma-superficial_spreading | 923 | 6 | 16828 | 46 |
ATP8A1,STAB1,ARAP1,AOX1,FLRT2,ABCA1 |
3.899e-02 | -3.24 | signaling adaptor activity | molecular function | GO:0035591 | 113 | 2 | 18094 | 50 |
SH2B3,BLNK |
3.900e-02 | -3.24 | vascular process in circulatory system | biological process | GO:0003018 | 273 | 3 | 18204 | 50 |
ATP8A1,DOCK4,ABCC5 |
3.910e-02 | -3.24 | NFKB1 (nuclear factor kappa B subunit 1) | protein interactions | 4790 | 292 | 3 | 19454 | 50 |
ETS1,RXRA,CEBPB |
3.922e-02 | -3.24 | prostate-carcinoma | COSMIC cancer mutations | prostate-carcinoma | 9000 | 31 | 16828 | 46 |
GLDC,MEF2C,FNIP1,RHBDF1,ABCA1,HCK,BAZ2B,ARHGEF1,BLNK,MYO1F,ARAP3,RXRA,ELF4,RBM47,ATP8A1,CD276,ETV6,FERMT3,SGMS1,STAB1,MAN1A1,SH3KBP1,ABCC5,MICAL2,RGL1,DAB2,DIAPH2,ETS1,CSF3R,AOX1,TFEB |
3.929e-02 | -3.24 | SH2DOMAIN | prints domains | PR00401 | 72 | 2 | 5227 | 23 |
SH2B3,HCK |
3.930e-02 | -3.24 | OGA (O-GlcNAcase) | protein interactions | 10724 | 122 | 2 | 19454 | 50 |
CEBPB,ARHGEF1 |
3.959e-02 | -3.23 | Ammonia Recycling | SMPDB pathways | SMP0000009 | 11 | 1 | 1369 | 5 |
GLDC |
3.961e-02 | -3.23 | transcription coregulator binding | molecular function | GO:0001221 | 114 | 2 | 18094 | 50 |
RXRA,ETS1 |
3.975e-02 | -3.23 | START_lipid-bd_dom | interpro domains | IPR002913 | 15 | 1 | 18521 | 50 |
CERT1 |
3.985e-02 | -3.22 | fibrous_tissue_and_uncertain_origin | COSMIC cancer mutations | fibrous_tissue_and_uncertain_origin | 277 | 3 | 16828 | 46 |
ABCC5,ETV6,BAZ2B |
3.988e-02 | -3.22 | GABPA (GA binding protein transcription factor subunit alpha) | protein interactions | 2551 | 123 | 2 | 19454 | 50 |
CTSV,ELF4 |
3.989e-02 | -3.22 | DOCKER | prosite domains | PS51651 | 11 | 1 | 12186 | 45 |
DOCK4 |
3.989e-02 | -3.22 | MBD | prosite domains | PS50982 | 11 | 1 | 12186 | 45 |
BAZ2B |
3.989e-02 | -3.22 | C2_DOCK | prosite domains | PS51650 | 11 | 1 | 12186 | 45 |
DOCK4 |
3.989e-02 | -3.22 | THIOL_PROTEASE_HIS | prosite domains | PS00639 | 11 | 1 | 12186 | 45 |
CTSV |
3.991e-02 | -3.22 | regulation of response to stress | biological process | GO:0080134 | 1431 | 8 | 18204 | 50 |
ELF4,SH2B3,RBM47,MARK4,MEF2C,ETS1,HCK,CEBPB |
3.991e-02 | -3.22 | defense response | biological process | GO:0006952 | 1431 | 8 | 18204 | 50 |
CD68,MLKL,BLNK,HCK,CEBPB,CSF3R,STAB1,TFEB |
3.992e-02 | -3.22 | Import of palmitoyl-CoA into the mitochondrial matrix | REACTOME pathways | R-HSA-200425 | 11 | 1 | 10285 | 38 |
RXRA |
3.994e-02 | -3.22 | chondrosarcoma | COSMIC cancer mutations | chondrosarcoma | 1181 | 7 | 16828 | 46 |
DAB2,RBM47,BLNK,CSF3R,ABCA1,ATP8A1,DOCK4 |
4.011e-02 | -3.22 | RUNX1 (RUNX family transcription factor 1) | protein interactions | 861 | 295 | 3 | 19454 | 50 |
CEBPB,FERMT3,ELF4 |
4.024e-02 | -3.21 | soft_tissue-fibrous_tissue_and_uncertain_origin-synovial_sarcoma-biphasic | COSMIC cancer mutations | soft_tissue-fibrous_tissue_and_uncertain_origin-synovial_sarcoma-biphasic | 15 | 1 | 16828 | 46 |
ETV6 |
4.024e-02 | -3.21 | monophasic | COSMIC cancer mutations | monophasic | 15 | 1 | 16828 | 46 |
ETV6 |
4.024e-02 | -3.21 | soft_tissue-nerve_sheath-neurofibroma | COSMIC cancer mutations | soft_tissue-nerve_sheath-neurofibroma | 15 | 1 | 16828 | 46 |
ETV6 |
4.024e-02 | -3.21 | soft_tissue-fibrous_tissue_and_uncertain_origin-synovial_sarcoma-monophasic | COSMIC cancer mutations | soft_tissue-fibrous_tissue_and_uncertain_origin-synovial_sarcoma-monophasic | 15 | 1 | 16828 | 46 |
ETV6 |
4.035e-02 | -3.21 | IL1RL2 (interleukin 1 receptor like 2) | protein interactions | 8808 | 16 | 1 | 19454 | 50 |
MYO1F |
4.035e-02 | -3.21 | DEFB106A (defensin beta 106A) | protein interactions | 245909 | 16 | 1 | 19454 | 50 |
CTSV |
4.035e-02 | -3.21 | AKAP6 (A-kinase anchoring protein 6) | protein interactions | 9472 | 16 | 1 | 19454 | 50 |
DISC1 |
4.035e-02 | -3.21 | EPO (erythropoietin) | protein interactions | 2056 | 16 | 1 | 19454 | 50 |
MAN1A1 |
4.035e-02 | -3.21 | NUDT6 (nudix hydrolase 6) | protein interactions | 11162 | 16 | 1 | 19454 | 50 |
GLDC |
4.035e-02 | -3.21 | GPNMB (glycoprotein nmb) | protein interactions | 10457 | 16 | 1 | 19454 | 50 |
TFEB |
4.035e-02 | -3.21 | CTSK (cathepsin K) | protein interactions | 1513 | 16 | 1 | 19454 | 50 |
CTSV |
4.035e-02 | -3.21 | Clspn (claspin) | protein interactions | 269582 | 16 | 1 | 19454 | 50 |
FNIP1 |
4.035e-02 | -3.21 | CASTOR2 (cytosolic arginine sensor for mTORC1 subunit 2) | protein interactions | 729438 | 16 | 1 | 19454 | 50 |
RXRA |
4.035e-02 | -3.21 | CAPN6 (calpain 6) | protein interactions | 827 | 16 | 1 | 19454 | 50 |
GLDC |
4.035e-02 | -3.21 | TWIST2 (twist family bHLH transcription factor 2) | protein interactions | 117581 | 16 | 1 | 19454 | 50 |
MEF2C |
4.035e-02 | -3.21 | ZSCAN4 (zinc finger and SCAN domain containing 4) | protein interactions | 201516 | 16 | 1 | 19454 | 50 |
HCK |
4.043e-02 | -3.21 | response to laminar fluid shear stress | biological process | GO:0034616 | 15 | 1 | 18204 | 50 |
ABCA1 |
4.043e-02 | -3.21 | positive regulation of hormone metabolic process | biological process | GO:0032352 | 15 | 1 | 18204 | 50 |
DAB2 |
4.043e-02 | -3.21 | regulation of phospholipid transport | biological process | GO:2001138 | 15 | 1 | 18204 | 50 |
ATP8A1 |
4.043e-02 | -3.21 | regulation of dendritic cell differentiation | biological process | GO:2001198 | 15 | 1 | 18204 | 50 |
CEBPB |
4.043e-02 | -3.21 | protein homotrimerization | biological process | GO:0070207 | 15 | 1 | 18204 | 50 |
MLKL |
4.043e-02 | -3.21 | regulation of inositol phosphate biosynthetic process | biological process | GO:0010919 | 15 | 1 | 18204 | 50 |
PLEK |
4.043e-02 | -3.21 | actin filament severing | biological process | GO:0051014 | 15 | 1 | 18204 | 50 |
FMNL1 |
4.043e-02 | -3.21 | positive regulation of non-canonical Wnt signaling pathway | biological process | GO:2000052 | 15 | 1 | 18204 | 50 |
DAB2 |
4.043e-02 | -3.21 | negative regulation of androgen receptor signaling pathway | biological process | GO:0060766 | 15 | 1 | 18204 | 50 |
DAB2 |
4.043e-02 | -3.21 | cytoplasm organization | biological process | GO:0007028 | 15 | 1 | 18204 | 50 |
ETV6 |
4.043e-02 | -3.21 | protein deglycosylation | biological process | GO:0006517 | 15 | 1 | 18204 | 50 |
MAN1A1 |
4.043e-02 | -3.21 | positive regulation of myoblast fusion | biological process | GO:1901741 | 15 | 1 | 18204 | 50 |
CD53 |
4.043e-02 | -3.21 | pyramidal neuron differentiation | biological process | GO:0021859 | 15 | 1 | 18204 | 50 |
DISC1 |
4.043e-02 | -3.21 | regulation of steroid hormone biosynthetic process | biological process | GO:0090030 | 15 | 1 | 18204 | 50 |
DAB2 |
4.047e-02 | -3.21 | DAB2 (DAB adaptor protein 2) | protein interactions | 1601 | 124 | 2 | 19454 | 50 |
SH3KBP1,FCHO2 |
4.053e-02 | -3.21 | START | pfam domains | PF01852 | 15 | 1 | 17795 | 49 |
CERT1 |
4.067e-02 | -3.20 | fat | COSMIC cancer mutations | fat | 117 | 2 | 16828 | 46 |
ETV6,ARAP3 |
4.067e-02 | -3.20 | low-density lipoprotein particle receptor activity | molecular function | GO:0005041 | 15 | 1 | 18094 | 50 |
STAB1 |
4.067e-02 | -3.20 | mannosidase activity | molecular function | GO:0015923 | 15 | 1 | 18094 | 50 |
MAN1A1 |
4.067e-02 | -3.20 | efflux transmembrane transporter activity | molecular function | GO:0015562 | 15 | 1 | 18094 | 50 |
ABCC5 |
4.067e-02 | -3.20 | nuclear vitamin D receptor binding | molecular function | GO:0042809 | 15 | 1 | 18094 | 50 |
RXRA |
4.068e-02 | -3.20 | phosphatidylinositol binding | molecular function | GO:0035091 | 276 | 3 | 18094 | 50 |
ARAP3,ARAP1,FCHO2 |
4.107e-02 | -3.19 | regulation of synapse assembly | biological process | GO:0051963 | 117 | 2 | 18204 | 50 |
FLRT2,MEF2C |
4.131e-02 | -3.19 | seminoma | COSMIC cancer mutations | seminoma | 700 | 5 | 16828 | 46 |
MLKL,FLRT2,HCK,STAB1,MARK4 |
4.144e-02 | -3.18 | RHOH (ras homolog family member H) | protein interactions | 399 | 509 | 4 | 19454 | 50 |
FLRT2,ABCC5,DAB2,FMNL1 |
4.156e-02 | -3.18 | SAM | smart domains | SM00454 | 83 | 2 | 9717 | 38 |
ARAP1,ARAP3 |
4.166e-02 | -3.18 | RNF115 (ring finger protein 115) | protein interactions | 27246 | 126 | 2 | 19454 | 50 |
DOCK4,CTSV |
4.170e-02 | -3.18 | Transcriptional regulation of white adipocyte differentiation | REACTOME pathways | R-HSA-381340 | 88 | 2 | 10285 | 38 |
RXRA,CEBPB |
4.195e-02 | -3.17 | positive regulation of cellular metabolic process | biological process | GO:0031325 | 3164 | 14 | 18204 | 50 |
CEBPB,ETV6,ETS1,RBM47,FNIP1,RXRA,BLNK,TFEB,DAB2,CD276,MEF2C,MICAL2,PLEK,ELF4 |
4.221e-02 | -3.17 | MBD | smart domains | SM00391 | 11 | 1 | 9717 | 38 |
BAZ2B |
4.233e-02 | -3.16 | RNA polymerase II cis-regulatory region sequence-specific DNA binding | molecular function | GO:0000978 | 1180 | 7 | 18094 | 50 |
MEF2C,ETS1,CEBPB,ETV6,ELF4,TFEB,RXRA |
4.248e-02 | -3.16 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma | 3511 | 15 | 16828 | 46 |
ARHGEF1,DIAPH2,DAB2,ARAP3,FMNL1,DOCK4,CSF3R,TFEB,RBM47,ELF4,MFSD1,ETV6,FLRT2,HCK,BAZ2B |
4.248e-02 | -3.16 | chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma | COSMIC cancer mutations | chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma | 3511 | 15 | 16828 | 46 |
FLRT2,HCK,BAZ2B,MFSD1,ETV6,ARAP3,FMNL1,DOCK4,CSF3R,ELF4,RBM47,TFEB,ARHGEF1,DAB2,DIAPH2 |
4.282e-02 | -3.15 | IL31 (interleukin 31) | protein interactions | 386653 | 17 | 1 | 19454 | 50 |
MAN1A1 |
4.282e-02 | -3.15 | SPATA13 (spermatogenesis associated 13) | protein interactions | 221178 | 17 | 1 | 19454 | 50 |
GLDC |
4.282e-02 | -3.15 | OLFM1 (olfactomedin 1) | protein interactions | 10439 | 17 | 1 | 19454 | 50 |
DISC1 |
4.282e-02 | -3.15 | Tsg101 (tumor susceptibility gene 101) | protein interactions | 22088 | 17 | 1 | 19454 | 50 |
SH3KBP1 |
4.282e-02 | -3.15 | AFD1 (acrofacial dysostosis 1, Nager type) | protein interactions | 171 | 17 | 1 | 19454 | 50 |
GLDC |
4.282e-02 | -3.15 | ALKBH2 (alkB homolog 2, alpha-ketoglutarate dependent dioxygenase) | protein interactions | 121642 | 17 | 1 | 19454 | 50 |
FERMT3 |
4.282e-02 | -3.15 | Abr (active BCR-related gene) | protein interactions | 109934 | 17 | 1 | 19454 | 50 |
DOCK4 |
4.282e-02 | -3.15 | ST6GAL2 (ST6 beta-galactoside alpha-2,6-sialyltransferase 2) | protein interactions | 84620 | 17 | 1 | 19454 | 50 |
CD53 |
4.286e-02 | -3.15 | BTK (Bruton tyrosine kinase) | protein interactions | 695 | 128 | 2 | 19454 | 50 |
HCK,BLNK |
4.286e-02 | -3.15 | ATF7IP (activating transcription factor 7 interacting protein) | protein interactions | 55729 | 128 | 2 | 19454 | 50 |
DISC1,ELF4 |
4.287e-02 | -3.15 | central_nervous_system-temporal_lobe-glioma-astrocytoma_Grade_II | COSMIC cancer mutations | central_nervous_system-temporal_lobe-glioma-astrocytoma_Grade_II | 16 | 1 | 16828 | 46 |
FLRT2 |
4.287e-02 | -3.15 | renal_pelvis | COSMIC cancer mutations | renal_pelvis | 16 | 1 | 16828 | 46 |
ETV6 |
4.307e-02 | -3.14 | regulation of corticosteroid hormone secretion | biological process | GO:2000846 | 16 | 1 | 18204 | 50 |
DAB2 |
4.307e-02 | -3.14 | positive regulation of lymphocyte apoptotic process | biological process | GO:0070230 | 16 | 1 | 18204 | 50 |
FNIP1 |
4.307e-02 | -3.14 | regulation of Wnt signaling pathway, planar cell polarity pathway | biological process | GO:2000095 | 16 | 1 | 18204 | 50 |
DAB2 |
4.307e-02 | -3.14 | xenobiotic transmembrane transport | biological process | GO:0006855 | 16 | 1 | 18204 | 50 |
ABCC5 |
4.307e-02 | -3.14 | neutrophil homeostasis | biological process | GO:0001780 | 16 | 1 | 18204 | 50 |
SH2B3 |
4.307e-02 | -3.14 | glycine metabolic process | biological process | GO:0006544 | 16 | 1 | 18204 | 50 |
GLDC |
4.323e-02 | -3.14 | SRF and miRs in Smooth Muscle Differentiation and Proliferation | WikiPathways | WP1991 | 13 | 1 | 5310 | 18 |
MEF2C |
4.325e-02 | -3.14 | cell adhesion | biological process | GO:0007155 | 942 | 6 | 18204 | 50 |
FLRT2,FERMT3,HCK,CSF3R,PLEK,STAB1 |
4.333e-02 | -3.14 | flippase activity | molecular function | GO:0140327 | 16 | 1 | 18094 | 50 |
ATP8A1 |
4.333e-02 | -3.14 | oxidoreductase activity, acting on NAD(P)H, oxygen as acceptor | molecular function | GO:0050664 | 16 | 1 | 18094 | 50 |
MICAL2 |
4.343e-02 | -3.14 | Sphingolipid metabolism | REACTOME pathways | R-HSA-428157 | 90 | 2 | 10285 | 38 |
CERT1,SGMS1 |
4.344e-02 | -3.14 | LINK_1 | prosite domains | PS01241 | 12 | 1 | 12186 | 45 |
STAB1 |
4.346e-02 | -3.14 | Lima1 (LIM domain and actin binding 1) | protein interactions | 65970 | 129 | 2 | 19454 | 50 |
FCHO2,DAB2 |
4.347e-02 | -3.14 | Endosomal/Vacuolar pathway | REACTOME pathways | R-HSA-1236977 | 12 | 1 | 10285 | 38 |
CTSV |
4.349e-02 | -3.14 | testis-germ_cell_tumour-non_seminoma | COSMIC cancer mutations | testis-germ_cell_tumour-non_seminoma | 487 | 4 | 16828 | 46 |
MLKL,FNIP1,HCK,MARK4 |
4.356e-02 | -3.13 | ATAD3A (ATPase family AAA domain containing 3A) | protein interactions | 55210 | 305 | 3 | 19454 | 50 |
GLDC,SH3KBP1,FMNL1 |
4.363e-02 | -3.13 | regulation of immune response | biological process | GO:0050776 | 944 | 6 | 18204 | 50 |
RBM47,HCK,MARK4,MEF2C,CD276,BLNK |
4.379e-02 | -3.13 | export from cell | biological process | GO:0140352 | 485 | 4 | 18204 | 50 |
ABCC5,HCK,PLEK,ABCA1 |
4.379e-02 | -3.13 | response to nutrient levels | biological process | GO:0031667 | 485 | 4 | 18204 | 50 |
ABCA1,FNIP1,TFEB,CD68 |
4.407e-02 | -3.12 | positive regulation of cell adhesion | biological process | GO:0045785 | 486 | 4 | 18204 | 50 |
CD276,DISC1,ETS1,DAB2 |
4.445e-02 | -3.11 | follicular_lymphoma | COSMIC cancer mutations | follicular_lymphoma | 1209 | 7 | 16828 | 46 |
BAZ2B,DIAPH2,RXRA,FLRT2,HCK,ATP8A1,ABCA1 |
4.453e-02 | -3.11 | positive regulation of innate immune response | biological process | GO:0045089 | 288 | 3 | 18204 | 50 |
RBM47,MARK4,HCK |
4.455e-02 | -3.11 | - | gene3d domains | 3.10.20.30 | 14 | 1 | 14470 | 47 |
AOX1 |
4.468e-02 | -3.11 | GATAD1 (GATA zinc finger domain containing 1) | protein interactions | 57798 | 131 | 2 | 19454 | 50 |
ELF4,ETS1 |
4.468e-02 | -3.11 | NCOA2 (nuclear receptor coactivator 2) | protein interactions | 10499 | 131 | 2 | 19454 | 50 |
MEF2C,RXRA |
4.475e-02 | -3.11 | positive regulation of macromolecule biosynthetic process | biological process | GO:0010557 | 2592 | 12 | 18204 | 50 |
DAB2,TFEB,ETV6,CEBPB,CD276,MICAL2,RBM47,MEF2C,ETS1,ELF4,BLNK,RXRA |
4.477e-02 | -3.11 | SH3 domain binding | molecular function | GO:0017124 | 122 | 2 | 18094 | 50 |
SH3KBP1,DOCK4 |
4.487e-02 | -3.10 | non_seminoma | COSMIC cancer mutations | non_seminoma | 492 | 4 | 16828 | 46 |
MARK4,FNIP1,HCK,MLKL |
4.493e-02 | -3.10 | ABC2_TM | interpro domains | IPR013525 | 17 | 1 | 18521 | 50 |
ABCA1 |
4.494e-02 | -3.10 | human chr11q24.3 | chromosome location | human chr11q24.3 | 24 | 1 | 26134 | 50 |
ETS1 |
4.529e-02 | -3.09 | KLF13 (KLF transcription factor 13) | protein interactions | 51621 | 18 | 1 | 19454 | 50 |
SH3KBP1 |
4.529e-02 | -3.09 | ADO (2-aminoethanethiol dioxygenase) | protein interactions | 84890 | 18 | 1 | 19454 | 50 |
DISC1 |
4.529e-02 | -3.09 | SRR (serine racemase) | protein interactions | 63826 | 18 | 1 | 19454 | 50 |
DISC1 |
4.529e-02 | -3.09 | SPARCL1 (SPARC like 1) | protein interactions | 8404 | 18 | 1 | 19454 | 50 |
DISC1 |
4.529e-02 | -3.09 | ACTL8 (actin like 8) | protein interactions | 81569 | 18 | 1 | 19454 | 50 |
CERT1 |
4.529e-02 | -3.09 | ZNF365 (zinc finger protein 365) | protein interactions | 22891 | 18 | 1 | 19454 | 50 |
DISC1 |
4.529e-02 | -3.09 | Tnks2 (tankyrase, TRF1-interacting ankyrin-related ADP-ribose polymerase 2) | protein interactions | 74493 | 18 | 1 | 19454 | 50 |
FMNL1 |
4.529e-02 | -3.09 | SLC13A2 (solute carrier family 13 member 2) | protein interactions | 9058 | 18 | 1 | 19454 | 50 |
CERT1 |
4.529e-02 | -3.09 | ANKRD29 (ankyrin repeat domain 29) | protein interactions | 147463 | 18 | 1 | 19454 | 50 |
FERMT3 |
4.529e-02 | -3.09 | MVB12B (multivesicular body subunit 12B) | protein interactions | 89853 | 18 | 1 | 19454 | 50 |
MLKL |
4.530e-02 | -3.09 | lymphocyte differentiation | biological process | GO:0030098 | 290 | 3 | 18204 | 50 |
BLNK,FNIP1,ADGRG3 |
4.549e-02 | -3.09 | neurofibroma | COSMIC cancer mutations | neurofibroma | 17 | 1 | 16828 | 46 |
ETV6 |
4.560e-02 | -3.09 | positive regulation of cell-substrate adhesion | biological process | GO:0010811 | 124 | 2 | 18204 | 50 |
DISC1,DAB2 |
4.570e-02 | -3.09 | reverse cholesterol transport | biological process | GO:0043691 | 17 | 1 | 18204 | 50 |
ABCA1 |
4.570e-02 | -3.09 | mammary gland epithelial cell differentiation | biological process | GO:0060644 | 17 | 1 | 18204 | 50 |
CEBPB |
4.570e-02 | -3.09 | iron ion transmembrane transport | biological process | GO:0034755 | 17 | 1 | 18204 | 50 |
ABCC5 |
4.570e-02 | -3.09 | muscle cell fate commitment | biological process | GO:0042693 | 17 | 1 | 18204 | 50 |
MEF2C |
4.570e-02 | -3.09 | nuclear body organization | biological process | GO:0030575 | 17 | 1 | 18204 | 50 |
ETS1 |
4.570e-02 | -3.09 | protein trimerization | biological process | GO:0070206 | 17 | 1 | 18204 | 50 |
MLKL |
4.570e-02 | -3.09 | regulation of integrin activation | biological process | GO:0033623 | 17 | 1 | 18204 | 50 |
PLEK |
4.570e-02 | -3.09 | protein kinase C signaling | biological process | GO:0070528 | 17 | 1 | 18204 | 50 |
PLEK |
4.570e-02 | -3.09 | specification of animal organ identity | biological process | GO:0010092 | 17 | 1 | 18204 | 50 |
MEF2C |
4.570e-02 | -3.09 | phospholipid homeostasis | biological process | GO:0055091 | 17 | 1 | 18204 | 50 |
ABCA1 |
4.591e-02 | -3.08 | PLAUR (plasminogen activator, urokinase receptor) | protein interactions | 5329 | 133 | 2 | 19454 | 50 |
HCK,MAN1A1 |
4.597e-02 | -3.08 | low-density lipoprotein particle binding | molecular function | GO:0030169 | 17 | 1 | 18094 | 50 |
STAB1 |
4.597e-02 | -3.08 | apolipoprotein binding | molecular function | GO:0034185 | 17 | 1 | 18094 | 50 |
ABCA1 |
4.615e-02 | -3.08 | skin-malignant_melanoma | COSMIC cancer mutations | skin-malignant_melanoma | 15741 | 46 | 16828 | 46 |
SH2B3,MLKL,MYO1F,ARHGEF1,BLNK,RHBDF1,DISC1,FCHO2,FNIP1,CD68,SRGN,TFEB,FMNL1,CSF3R,CEBPB,RGL1,SH3KBP1,ARAP1,FERMT3,MFSD1,RXRA,ELF4,RBM47,ARAP3,CD53,BAZ2B,ABCA1,FLRT2,PLEK,HCK,GLDC,MEF2C,AOX1,DOCK4,ETS1,ABCC5,MICAL2,DAB2,DIAPH2,SGMS1,STAB1,MARK4,MAN1A1,ETV6,ATP8A1,CD276 |
4.620e-02 | -3.07 | cis-regulatory region sequence-specific DNA binding | molecular function | GO:0000987 | 1203 | 7 | 18094 | 50 |
MEF2C,ETS1,ETV6,CEBPB,TFEB,ELF4,RXRA |
4.636e-02 | -3.07 | lung-carcinoma-adenocarcinoma | COSMIC cancer mutations | lung-carcinoma-adenocarcinoma | 15133 | 45 | 16828 | 46 |
RHBDF1,FNIP1,FCHO2,DISC1,MYO1F,BLNK,ARHGEF1,SH2B3,MLKL,FERMT3,MFSD1,ARAP1,RGL1,SH3KBP1,TFEB,SRGN,CSF3R,CEBPB,FMNL1,GLDC,MEF2C,BAZ2B,HCK,PLEK,FLRT2,ABCA1,CD53,RBM47,ELF4,RXRA,ARAP3,ETV6,CD276,ATP8A1,MARK4,MAN1A1,STAB1,SGMS1,DAB2,DIAPH2,MICAL2,ABCC5,AOX1,ETS1,DOCK4 |
4.643e-02 | -3.07 | protein homodimerization activity | molecular function | GO:0042803 | 714 | 5 | 18094 | 50 |
CEBPB,PLEK,GLDC,AOX1,MFSD1 |
4.653e-02 | -3.07 | ARL4C (ADP ribosylation factor like GTPase 4C) | protein interactions | 10123 | 134 | 2 | 19454 | 50 |
FLRT2,ABCC5 |
4.653e-02 | -3.07 | PHF10 (PHD finger protein 10) | protein interactions | 55274 | 134 | 2 | 19454 | 50 |
ETS1,ELF4 |
4.677e-02 | -3.06 | human chr7q31.1 | chromosome location | human chr7q31.1 | 25 | 1 | 26134 | 50 |
DOCK4 |
4.680e-02 | -3.06 | CORO1C (coronin 1C) | protein interactions | 23603 | 314 | 3 | 19454 | 50 |
GLDC,DISC1,FMNL1 |
4.680e-02 | -3.06 | HSF2BP (heat shock transcription factor 2 binding protein) | protein interactions | 11077 | 314 | 3 | 19454 | 50 |
HCK,ARHGAP45,BAZ2B |
4.693e-02 | -3.06 | xenobiotic metabolic process | biological process | GO:0006805 | 126 | 2 | 18204 | 50 |
ABCC5,AOX1 |
4.701e-02 | -3.06 | FCGR activation | REACTOME pathways | R-HSA-2029481 | 13 | 1 | 10285 | 38 |
HCK |
4.716e-02 | -3.05 | Myo1c (myosin IC) | protein interactions | 17913 | 135 | 2 | 19454 | 50 |
FCHO2,DAB2 |
4.725e-02 | -3.05 | myeloid cell differentiation | biological process | GO:0030099 | 295 | 3 | 18204 | 50 |
MEF2C,CEBPB,SH2B3 |
4.740e-02 | -3.05 | SPECTRNALPHA | prints domains | PR01887 | 11 | 1 | 5227 | 23 |
SH3KBP1 |
4.740e-02 | -3.05 | PAPAIN | prints domains | PR00705 | 11 | 1 | 5227 | 23 |
CTSV |
4.746e-02 | -3.05 | regulation of anatomical structure size | biological process | GO:0090066 | 498 | 4 | 18204 | 50 |
HCK,DOCK4,PLEK,DISC1 |
4.752e-02 | -3.05 | EGF_dom | interpro domains | IPR024731 | 18 | 1 | 18521 | 50 |
STAB1 |
4.757e-02 | -3.05 | binding | molecular function | GO:0005488 | 16422 | 49 | 18094 | 50 |
GLDC,CD276,HCK,SH3KBP1,DISC1,MFSD1,CEBPB,FNIP1,STAB1,SH2B3,PLEK,MARK4,RBM47,CD53,MLKL,ARAP3,RHBDF1,MEF2C,MYO1F,RGL1,TFEB,ELF4,CTSV,ARAP1,DAB2,ABCC5,AOX1,ADGRG3,RXRA,BLNK,MAN1A1,ETS1,ARHGAP45,FCHO2,CD68,DIAPH2,ETV6,DOCK4,CERT1,ATP8A1,BAZ2B,CSF3R,MICAL2,FMNL1,FERMT3,SRGN,FLRT2,ARHGEF1,ABCA1 |
4.771e-02 | -3.04 | lung-carcinoid-endocrine_tumour | COSMIC cancer mutations | lung-carcinoid-endocrine_tumour | 502 | 4 | 16828 | 46 |
MARK4,BAZ2B,HCK,MLKL |
4.774e-02 | -3.04 | RIMS2 (regulating synaptic membrane exocytosis 2) | protein interactions | 9699 | 19 | 1 | 19454 | 50 |
ABCA1 |
4.774e-02 | -3.04 | Capza1 (capping actin protein of muscle Z-line subunit alpha 1) | protein interactions | 12340 | 19 | 1 | 19454 | 50 |
SH3KBP1 |
4.774e-02 | -3.04 | ZNF197 (zinc finger protein 197) | protein interactions | 10168 | 19 | 1 | 19454 | 50 |
DISC1 |
4.774e-02 | -3.04 | RAP1BL (RAP1B like (pseudogene)) | protein interactions | 643752 | 19 | 1 | 19454 | 50 |
CD53 |
4.774e-02 | -3.04 | RIT2 (Ras like without CAAX 2) | protein interactions | 6014 | 19 | 1 | 19454 | 50 |
RGL1 |
4.774e-02 | -3.04 | CRYBB1 (crystallin beta B1) | protein interactions | 1414 | 19 | 1 | 19454 | 50 |
DISC1 |
4.774e-02 | -3.04 | PARVB (parvin beta) | protein interactions | 29780 | 19 | 1 | 19454 | 50 |
FERMT3 |
4.791e-02 | -3.04 | LGALS1 (galectin 1) | protein interactions | 3956 | 317 | 3 | 19454 | 50 |
CD68,CD276,HCK |
4.810e-02 | -3.03 | salivary_gland-carcinoma-acinic_cell_carcinoma | COSMIC cancer mutations | salivary_gland-carcinoma-acinic_cell_carcinoma | 18 | 1 | 16828 | 46 |
ETV6 |
4.827e-02 | -3.03 | regulation of protein binding | biological process | GO:0043393 | 128 | 2 | 18204 | 50 |
DAB2,DISC1 |
4.827e-02 | -3.03 | regulation of B cell activation | biological process | GO:0050864 | 128 | 2 | 18204 | 50 |
SH3KBP1,MEF2C |
4.832e-02 | -3.03 | heart formation | biological process | GO:0060914 | 18 | 1 | 18204 | 50 |
MEF2C |
4.832e-02 | -3.03 | retinoic acid receptor signaling pathway | biological process | GO:0048384 | 18 | 1 | 18204 | 50 |
RXRA |
4.832e-02 | -3.03 | negative regulation of platelet activation | biological process | GO:0010544 | 18 | 1 | 18204 | 50 |
SH2B3 |
4.832e-02 | -3.03 | positive regulation of cardiocyte differentiation | biological process | GO:1905209 | 18 | 1 | 18204 | 50 |
MEF2C |
4.832e-02 | -3.03 | ceramide transport | biological process | GO:0035627 | 18 | 1 | 18204 | 50 |
CERT1 |
4.832e-02 | -3.03 | regulation of clathrin-dependent endocytosis | biological process | GO:2000369 | 18 | 1 | 18204 | 50 |
DAB2 |
4.837e-02 | -3.03 | stomach-carcinoma-adenocarcinoma | COSMIC cancer mutations | stomach-carcinoma-adenocarcinoma | 15150 | 45 | 16828 | 46 |
FMNL1,CSF3R,CD68,SRGN,TFEB,SH3KBP1,RGL1,ARAP1,MFSD1,FERMT3,MLKL,SH2B3,ARHGEF1,BLNK,MYO1F,DISC1,FCHO2,FNIP1,RHBDF1,DOCK4,ETS1,AOX1,ABCC5,MICAL2,DAB2,DIAPH2,SGMS1,STAB1,MARK4,MAN1A1,ATP8A1,CD276,ETV6,ARAP3,RXRA,ELF4,RBM47,CD53,ABCA1,FLRT2,PLEK,HCK,BAZ2B,GLDC,MEF2C |
4.842e-02 | -3.03 | CLUH (clustered mitochondria homolog) | protein interactions | 23277 | 137 | 2 | 19454 | 50 |
ARHGEF1,CEBPB |
4.842e-02 | -3.03 | PUM2 (pumilio RNA binding family member 2) | protein interactions | 23369 | 137 | 2 | 19454 | 50 |
RBM47,GLDC |
4.844e-02 | -3.03 | EGF_3 | pfam domains | PF12947 | 18 | 1 | 17795 | 49 |
STAB1 |
4.859e-02 | -3.02 | gamma-tubulin complex | cellular component | GO:0000930 | 19 | 1 | 19108 | 50 |
MARK4 |
4.861e-02 | -3.02 | phosphatidylcholine transporter activity | molecular function | GO:0008525 | 18 | 1 | 18094 | 50 |
ABCA1 |
4.861e-02 | -3.02 | clathrin adaptor activity | molecular function | GO:0035615 | 18 | 1 | 18094 | 50 |
DAB2 |
4.861e-02 | -3.02 | lipoprotein particle receptor activity | molecular function | GO:0030228 | 18 | 1 | 18094 | 50 |
STAB1 |
4.865e-02 | -3.02 | UBXN6 (UBX domain protein 6) | protein interactions | 80700 | 319 | 3 | 19454 | 50 |
ARAP1,ARAP3,ARHGEF1 |
4.879e-02 | -3.02 | histone deacetylase binding | molecular function | GO:0042826 | 128 | 2 | 18094 | 50 |
CEBPB,MEF2C |
4.883e-02 | -3.02 | haematopoietic_neoplasm | COSMIC cancer mutations | haematopoietic_neoplasm | 11082 | 36 | 16828 | 46 |
SH3KBP1,DAB2,DIAPH2,RGL1,MICAL2,ABCC5,CSF3R,ETS1,DOCK4,AOX1,CD68,MFSD1,ATP8A1,ETV6,MAN1A1,MARK4,ARAP1,STAB1,SGMS1,BLNK,ARHGEF1,MYO1F,MLKL,SH2B3,ELF4,RXRA,FNIP1,GLDC,MEF2C,FCHO2,RHBDF1,HCK,FLRT2,PLEK,ABCA1,BAZ2B |
4.905e-02 | -3.01 | AKAP12 (A-kinase anchoring protein 12) | protein interactions | 9590 | 138 | 2 | 19454 | 50 |
HCK,SH3KBP1 |
4.905e-02 | -3.01 | NCOA1 (nuclear receptor coactivator 1) | protein interactions | 8648 | 138 | 2 | 19454 | 50 |
ETS1,RXRA |
4.940e-02 | -3.01 | ACTA1 (actin alpha 1, skeletal muscle) | protein interactions | 58 | 321 | 3 | 19454 | 50 |
MARK4,ARHGEF1,ETV6 |
4.951e-02 | -3.01 | regulation of lymphocyte activation | biological process | GO:0051249 | 505 | 4 | 18204 | 50 |
CEBPB,MEF2C,CD276,SH3KBP1 |
4.962e-02 | -3.00 | lymphocyte proliferation | biological process | GO:0046651 | 130 | 2 | 18204 | 50 |
MEF2C,ELF4 |
4.968e-02 | -3.00 | NEFM (neurofilament medium chain) | protein interactions | 4741 | 139 | 2 | 19454 | 50 |
DISC1,GLDC |
4.968e-02 | -3.00 | LARP1B (La ribonucleoprotein 1B) | protein interactions | 55132 | 139 | 2 | 19454 | 50 |
RBM47,GLDC |
4.968e-02 | -3.00 | IFT20 (intraflagellar transport 20) | protein interactions | 90410 | 139 | 2 | 19454 | 50 |
DISC1,CERT1 |
4.968e-02 | -3.00 | LHFPL5 (LHFPL tetraspan subfamily member 5) | protein interactions | 222662 | 139 | 2 | 19454 | 50 |
ADGRG3,CD53 |
4.969e-02 | -3.00 | START | smart domains | SM00234 | 13 | 1 | 9717 | 38 |
CERT1 |
4.969e-02 | -3.00 | Pept_C1 | smart domains | SM00645 | 13 | 1 | 9717 | 38 |
CTSV |
4.972e-02 | -3.00 | Transcriptional activation by NRF2 | WikiPathways | WP3 | 15 | 1 | 5310 | 18 |
CEBPB |
4.983e-02 | -3.00 | PK_Tyr_Ser-Thr | pfam domains | PF07714 | 130 | 2 | 17795 | 49 |
HCK,MLKL |